Interleukin-18 Variants and Methods of Use

JP2023550545A5Pending Publication Date: 2024-11-12SIMHA IYER-18 INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023551948
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-02
Filing Date
2021-11-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The clinical efficacy of interleukin-18 (IL-18) as an immunotherapeutic agent for cancer treatment is limited due to its instability and inhibition by IL-18 binding protein (IL-18BP).

Method used

Development of stabilized IL-18 polypeptides with specific mutations at cysteine residues (C38 and C68) to enhance stability and resistance to IL-18BP inhibition, including decoy-resistant (DR) and decoy-to-decoy (D2D) variants that maintain signaling activity while reducing binding to IL-18BP.

Benefits of technology

The stabilized IL-18 variants demonstrate enhanced stability, increased signaling activity, and improved efficacy in treating cancer and other diseases by stimulating immune cells, including T cells, NK cells, and myeloid cells, while overcoming IL-18BP inhibition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides compositions and methods comprising stabilized IL-18 polypeptides for use in therapeutic and non-therapeutic applications. In some cases, the stabilized IL-18 proteins provide IL-18 signaling activity even in the presence of inhibitory molecules, such as IL-18BP. Also provided are methods of administration and methods of producing the active polypeptides.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] cross reference

[0001] This application claims the benefit of US Provisional Application No. 63 / 108794, filed November 2, 2020, which is incorporated herein by reference in its entirety. [Background technology]

[0002]

[0002] Interleukin 18 (IL-18) is a pro-inflammatory cytokine that can stimulate T cells, NK cells, and myeloid cells. IL-18 has been proposed as an immunotherapeutic agent for the treatment of cancer due to its ability to stimulate anti-tumor immune cells. However, the clinical efficacy of IL-18 is limited.

[0003]

[0003] Therefore, there is a need for compositions and methods that provide effective IL-18 signaling activity to treat and prevent cancer and other diseases and disorders. The present disclosure addresses these needs. Inclusion by reference

[0004] All publications, patents, or patent applications mentioned herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application is specifically and individually intended to be incorporated by reference. incorporated herein by reference. Incorporating by referencing an array list

[0005] The sequence list is provided herein as a text file, "SMCH-003PRV_SeqList_ST25.txt", created on November 2, 2020 and 277KB in size. The contents of the text file are incorporated herein by reference in their entirety. [Summary of the invention] [Means to solve the problem]

[0004]

[0006] Compositions comprising variant (eg, stabilized) IL-18 polypeptides are provided. A stabilized IL-18 polypeptide contains a "stabilizing mutation" which is a mutation of two cysteine ​​residues (C38 and C68) compared to human wild-type IL-18 (SEQ ID NO: 30). IL-18 polypeptide. Surprisingly, mutations of these two amino acids were found to stabilize IL-18 more than all other possible cysteine ​​mutation combinations, see e.g. the Examples below. . In some cases, the mutation is a C to S substitution, and thus the stabilized IL-18 polypeptide is, in some cases, similar to human wild-type IL-18 (SEQ ID NO: 30). In comparison, it may contain mutations C38S and C68S (also referred to herein as "mutant pair C38S / C68S"). However, mutations in C68 can give rise to immunogenic epitopes in some cases. Thus, in some embodiments, the C68 mutation is a non-immunogenic substitution. In some such cases, the mutation is a C68 to G, A, V, D, E, or N mutation (in some cases, C68 to G, A, D, or N). be. Thus, in some such cases, the stabilized IL-18 polypeptides of interest may contain mutant pairs C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E , or including C38S / C68N. In some cases, the stabilized IL-18 polypeptide of interest comprises the mutation pair C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N. In some cases, the stabilized IL-18 polypeptide of interest comprises the mutation pair C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N. In some cases, the stabilized IL-18 polypeptide of interest comprises the mutation pair C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N.

[0005]

[0007] In some cases, the subject stabilized IL-18 polypeptide comprises the mutation pair C38S / C68D. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation pair C38S / C68G. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation pair C38S / C68A. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation pair C38S / C68N. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation pair C38S / C68S.

[0006]

[0008] In some cases, the stabilized IL-18 polypeptide of interest is a stabilized IL-18 variant polypeptide, i.e., has a stabilizing mutation (i.e., compared to human wild-type IL-18). IL-18 variant polypeptide containing mutations at positions C38 and C68). In some such cases, the stabilized IL-18 variant polypeptide is a stabilized "decoy-resistant" (DR) IL-18 variant; in other such cases, the stabilized The IL-18 variant polypeptides are stabilized "decoy-to-the-decoy" (D2D) IL-18 variants. In some embodiments, the stabilized IL-18 variant polypeptide has a binding affinity for IL-18BP of less than 0.6 nM.

[0007]

[0009] In some embodiments, a subject stabilized IL-18 polypeptide exhibits superior stability compared to an IL-18 polypeptide having a different sequence, and said superior stability is demonstrated in a stability assay. results in less dimer, multimer, aggregate, and / or degradation product formation after exposure to. In some embodiments, a subject stabilized IL-18 polypeptide has greater stability than a wild-type IL-18 polypeptide. In some embodiments, superior stability is measured by shelf life stability. In some embodiments, superior stability is achieved by subjecting a modified IL-18 polypeptide or a formulation disclosed herein containing a modified IL-18 polypeptide to freeze-thaw cycles. It is determined. In some embodiments, superior stability is determined by subjecting the stabilized IL-18 variant polypeptide to agitation.

[0008]

[0010] DR IL-18 variants bind to the IL-18 receptor (IL-18R), thereby inducing / enhancing / stimulating IL-18 signaling activity, but inhibiting IL-18 binding protein (IL-18BP). IL-18 is a variant / mutant of IL-18 that exhibits reduced binding [compared to the binding of WT IL-18 to IL-18BP] (slight to no binding in some cases). DR IL-18 variants are therefore IL-18R agonists that are resistant to inhibition by IL-18BP. Examples of human DR IL-18 variants include, but are not limited to, those set forth in SEQ ID NOs: 34-59, 73-91, and 191-193. Examples of mouse DR IL-18 variants include, but are not limited to, those set forth in SEQ ID NOs: 60-72.

[0009]

[0011] D2D IL-18 variants bind to IL-18BP but have reduced binding to IL-18R [compared to WT IL-18 binding to IL-18R] (from slight binding to A variant / mutant of IL-18 that exhibits no binding. Therefore, the D2D IL-18 variant binds to IL-18BP, thereby antagonizing the effect of IL-18BP on IL-18. Therefore, D2D IL-18 variants can be used to increase signaling by IL-18R as they act by inhibiting inhibitors. Examples of human D2D IL-18 variants include, but are not limited to, those set forth in SEQ ID NOs: 92-125. Examples of mouse D2D IL-18 variants include, but are not limited to, those set forth in SEQ ID NOs: 126-190.

[0010]

[0012] In some cases, stabilized DR IL-18 variant polypeptides are present at positions C38 (e.g., C38S) and C68 (e.g., C68S, C68G , C68A, C68V, C68D, C68E, or C68N) [e.g., C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N]. In addition, mutations at amino acid position M51 (e.g., M51E, M51R, M51K, M51T, M51D, or M51N), mutations at K53 (e.g., K53G, K53S, K53T, or K53R), mutations at Q56 (e.g., , Q56G, Q56R, Q56L, Q56E, Q56A, Q56V, or Q56K), mutations in D110 (e.g., D110S, D110N, D110G, D110K, D110H, D110Q, or D110E) and mutations in N111 (e.g., N111G, N111R , N111S, N111D, N111H, or N111Y). In some such cases, the stabilized IL-18 variant polypeptide further comprises a mutation at amino acid position S105 (e.g., S105D, S105A, S105N, S105R, S105D, or S105K); in some In some cases, it further includes a mutation at amino acid position P57 (eg, P57A, P57L, P57G, or P57K) and a mutation at M60 (eg, M60L, M60R, M60K, or M60Q).

[0011]

[0013] In some cases, the stabilized DR IL-18 variant polypeptides are C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D [relative to human wild type IL-18-SEQ ID NO: 30]; and a stabilizing pair of mutations selected from C38S / C68N, as well as mutations at amino acid position M51 (e.g., M51E, M51R, M51K, M51T, M51D, or M51N), mutations at K53 (e.g., K53G, K53S, K53T, or K53R), mutations in Q56 (e.g., Q56G, Q56R, Q56L, Q56E, Q56A, Q56V, or Q56K), mutations in D110 (e.g., D110S, D110N, D110G, D110K, D110H, D110Q, or D110E) and mutations of N111 (eg, N111G, N111R, N111S, N111D, N111H, or N111Y). In some such cases, the stabilized IL-18 variant polypeptide further comprises a mutation at amino acid position S105 (e.g., S105D, S105A, S105N, S105R, S105D, or S105K); in some In some cases, it further includes a mutation at amino acid position P57 (eg, P57A, P57L, P57G, or P57K) and a mutation at M60 (eg, M60L, M60R, M60K, or M60Q).

[0012]

[0014] In some cases, the stabilized DR IL-18 variant polypeptides are C38S / C68G, C38S / C68A, C38S / C68D, and C38S / C68N [relative to human wild-type IL-18-SEQ ID NO: 30]. Mutations at amino acid position M51 (e.g., M51E, M51R, M51K, M51T, M51D, or M51N), mutations at K53 (e.g., K53G, K53S, K53T, or K53R), mutations in Q56 (e.g., Q56G, Q56R, Q56L, Q56E, Q56A, Q56V, or Q56K), mutations in D110 (e.g., D110S, D110N, D110G, D110K, D110H, D110Q, or D110E), and N111 mutations (eg, N111G, N111R, N111S, N111D, N111H, or N111Y). In some such cases, the stabilized IL-18 variant polypeptide further comprises a mutation at amino acid position S105 (e.g., S105D, S105A, S105N, S105R, S105D, or S105K); in some In some cases, it further includes a mutation at amino acid position P57 (eg, P57A, P57L, P57G, or P57K) and a mutation at M60 (eg, M60L, M60R, M60K, or M60Q).

[0013]

[0015] In some cases, the stabilized DR IL-18 variant polypeptide comprises an amino acid sequence that has 85% or more identity to the amino acid sequence set forth in any one of SEQ ID NOs: 6 and 16-21. In some cases, the stabilized DR IL-18 variant polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 6 and 16-21.

[0014]

[0016] In some cases, the stabilized DR IL-18 variant polypeptide has 85% or more identity to the amino acid sequence set forth in any one of SEQ ID NOs: 6, 16, 17, 19, and 21. Contains amino acid sequence. In some cases, the stabilized DR IL-18 variant polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 6, 16, 17, 19, and 21.

[0015]

[0017] In some embodiments, stabilized IL-18 polypeptides (eg, stabilized DR IL-18 variants) are used for the treatment of a disease or disorder. In various embodiments, the disease or disorder is cancer, or an infectious disease such as a poxvirus encoding an IL-18BP ortholog, a metabolic disease or disorder (including obesity and diabetes), or macular degeneration (e.g., wet macular degeneration, e.g., wet age-related macular degeneration, e.g., IL-18 protein can be used as an anti-angiogenic agent; illustrative examples include, in some cases, stabilized IL-18 protein can weaken choroidal neovascularization). Accordingly, a stabilized IL-18 polypeptide (e.g., a stabilized DR IL-18 variant) may be administered to treat a disease or disorder, such as, but not limited to, cancer, or an infectious disease, metabolic disease or A method is provided comprising treating a disorder, or macular degeneration (eg, wet macular degeneration, eg, wet age-related macular degeneration).

[0016]

[0018] In some embodiments, the method comprises administering a composition comprising a stabilized IL-18 polypeptide (e.g., a stabilized DR IL-18 variant) to a subject in need thereof. . In some embodiments, the method comprises administering a composition comprising a stabilized IL-18 polypeptide (e.g., a stabilized DR IL-18 variant) and an additional agent to a subject in need thereof. including steps to In some such embodiments, the additional agent is an immunotherapeutic agent, e.g., a modified immune cell (e.g., a T cell, such as a chimeric antigen receptor T cell (CAR-T), an armed CAR-T cell) ; NK cells such as CAR-NK; tumor-infiltrating lymphocytes (TILs), TCR-T cells, etc.), viruses, antigens, vaccines, antibodies, immune checkpoint inhibitors, small molecules, chemotherapeutic agents, stem cells, etc. In some embodiments, a stabilized IL-18 polypeptide (e.g., a stabilized DR IL-18 variant) provides immunity before, during, or after infection with a bacterium, virus, or other pathogen. Used in methods to increase the activity of a system. In some embodiments, a stabilized IL-18 polypeptide (e.g., a stabilized DR IL-18 variant) can improve the number and / or activity of immune cells in vitro, in vivo, or ex vivo. For example, used in methods of increasing the number and / or activity of T cells, NK cells, and / or myeloid cells.

[0017]

[0019] The subject polypeptides can be administered in combination with, or as fusions with, immune checkpoint inhibitors and / or tumor opsonizing antibodies. The polypeptides of interest can be used for cell therapy, e.g., chimeric antigen receptor T cells (CAR-T cells), TCR-T cells, chimeric antigen receptor NK cells (CAR-NK cells), and tumor-infiltrating lymphocytes (TILs). May be administered in combination with therapy. Polypeptides of interest can also be administered as part of cell therapy, e.g., versions of cells, e.g., CAR-T cells, CAR-NK cells, TIL cells, etc., TRUCK cells ("T cells redirected for antigen -unrestricted cytokine-initiated killing").

[0018]

[0020] Also provided are methods of administering an IL-18 polypeptide to an individual, the method comprising administering an IL-18 polypeptide (e.g., wild-type IL-18 or a variant, e.g., stabilized DR, D2D, stabilized DR, or a stabilized D2D IL-18 variant) to the individual, the frequency of administration being no more than once a week.

[0019]

[0021] Also provided are methods and compositions for producing IL-18 polypeptides. Such methods include contacting an exogenously provided fusion protein with an exogenously provided SUMO (small ubiquitin-like modifier) ​​protease in a bacterial cell, wherein the fusion protein has a SUMO tag attached to its N-terminus. In the bacterial cell, SUMO protease cleaves the fusion protein, thus removing the SUMO tag from the polypeptide of interest. In some cases, the polypeptide of interest is an IL-18 polypeptide (e.g., wild-type human IL-18 protein or an IL-18 variant, e.g., stabilized, DR, D2D, stabilized DR, or stabilized D2D variants (see, eg, stabilized DR IL-18 variant polypeptides discussed above).

[0020]

[0022] IL-18 polypeptide (e.g., wild-type human IL-18 protein or IL-18 variant, e.g., stabilized, DR, D2D, stabilized DR, or stabilized D2D variant - e.g., stabilized Also provided are formulations comprising DR IL-18 variant polypeptides (see DR IL-18 variant polypeptides discussed above). In some cases, in addition to the IL-18 protein, the formulation contains buffers that maintain the pH (e.g., between 6.2 and 6.8, e.g. His / His-HCl), sugars (e.g. sucrose, e.g. 10%), chelating agents (e.g. EDTA, e.g. 0.05-1.5mM), agents that prevent oxidation (e.g. L-methionine, e.g. 4-6mM), and agents that prevent protein absorption (e.g. PS80, e.g. 0.01- Contains 0.03% w / v).

[0021]

[0023] The following detailed description of embodiments of the invention will be better understood when read in conjunction with the accompanying drawings. It is to be understood that the invention is not limited to the precise arrangement and instrumentality of the embodiments shown in the drawings. [Brief explanation of drawings]

[0022] [Figure 1A]

[0024] FIGS. 1A and 1B depict the results of exemplary experiments showing that the IL-18 pathway is a target for tumor immunotherapy. Figure 1A shows that the IL-18 pathway (including IL-18 and its receptor subunits) is activated and dysfunctional as seen in RNAseq expression analysis for cytokines and receptors in CD8+ TILs. provides a diagram showing that both tumor T cell programs are upregulated in the tumor T cell program. Genes are assigned "activated" and "dysfunctional" scores compared to naive T cells, as seen in the figure. Data points marked with diamonds and black letters indicate IL-18 cytokines, IL-18R1 (Rα), and IL-18RAP (Rβ). Data are adapted from Singer et al. (Singer, M. et al., 2016, Cell, 166:1500-1511, e1509). Figure 1B provides the results of infection with LCMV (left; CD4) or VSV-OVA (right; CD8). IL-18 receptor subunits IL-18Rα and IL-18Rβ are involved in gene expression programs associated with chronic antigen exposure, as seen after infection with LCMV (left; CD4) or VSV-OVA (right; CD8). Part of it. Data comes from the ImmGen database. [Figure 1B] FIGS. 1A and 1B depict the results of exemplary experiments showing that the IL-18 pathway is a target for tumor immunotherapy. Figure 1A shows that the IL-18 pathway (including IL-18 and its receptor subunits) is activated and dysfunctional as seen in RNAseq expression analysis for cytokines and receptors in CD8+ TILs. provides a diagram showing that both tumor T cell programs are upregulated in the tumor T cell program. Genes are assigned "activated" and "dysfunctional" scores compared to naive T cells, as seen in the figure. Data points marked with diamonds and black letters indicate IL-18 cytokines, IL-18R1 (Rα), and IL-18RAP (Rβ). Data are adapted from Singer et al. (Singer, M. et al., 2016, Cell, 166:1500-1511, e1509). Figure 1B provides the results of infection with LCMV (left; CD4) or VSV-OVA (right; CD8). IL-18 receptor subunits IL-18Rα and IL-18Rβ are involved in gene expression programs associated with chronic antigen exposure, as seen after infection with LCMV (left; CD4) or VSV-OVA (right; CD8). Part of it. Data comes from the ImmGen database.

Figure 2

[0025] Figures 2A-2C depict the results of exemplary experiments showing that IL-18BP has the characteristics of a "soluble immune checkpoint." Figure 2A shows how IL-18BP mediates interferon-gamma (IFN-gamma)-induced negative feedback of IL-18, similar to the immune checkpoint PD-L1. A schematic diagram of the IL-18 / IFN-γ / IL-18BP feedback loop is depicted. Black arrows indicate stimulation and gray circuits indicate inhibition. Figure 2B shows that IL-18BP is upregulated in gastric and breast cancer using data from the TCGA and Oncomine databases. Figure 2C shows that PD-1 and IL-18BP expression are strongly correlated in a large number of breast and gastric cancer samples (derived from the TCGA database). R=0.78 and 0.65, respectively. [Figure 3A]

[0026] Figures 3A-3C depict the results of exemplary experiments demonstrating the manipulation of human IL-18 variants for independence on IL-18BP using yeast display. Figure 3A provides a structure-guided library designed and introduced into a yeast display system to randomize residues on the IL-18:IL-18BP interface. Yeast clones were selected using magnetic and fluorescent cell sorting for binding to IL-18Rα and counterselected against IL-18BP. Figure 3B provides an overview of directed evolution to generate IL-18BP-resistant IL-18 variants. Positive selection conditions are hIL18Rα SA-beads and hIL18Rα. Counter-selection conditions are SA only, hIL-18BP, and nIL-18BP tetramer. Figure 3C provides flow cytometry analysis of yeast-displayed WT IL-18 (left) or variant after directed evolution (right). The Y-axis shows IL-18BP binding and the x-axis shows IL-18Rα binding. After five rounds of directed evolution, the remaining clones strongly selected IL-18Rα over IL-18BP. [Figure 3B] Figures 3A-3C depict the results of exemplary experiments demonstrating the manipulation of human IL-18 variants for independence on IL-18BP using yeast display. Figure 3A provides a structure-guided library designed and introduced into a yeast display system to randomize residues on the IL-18:IL-18BP interface. Yeast clones were selected using magnetic and fluorescent cell sorting for binding to IL-18Rα and counterselected against IL-18BP. Figure 3B provides an overview of directed evolution to generate IL-18BP-resistant IL-18 variants. Positive selection conditions are hIL18Rα SA-beads and hIL18Rα. Counter-selection conditions are SA only, hIL-18BP, and nIL-18BP tetramer. Figure 3C provides flow cytometry analysis of yeast-displayed WT IL-18 (left) or variant after directed evolution (right). The Y-axis shows IL-18BP binding and the x-axis shows IL-18Rα binding. After five rounds of directed evolution, the remaining clones strongly selected IL-18Rα over IL-18BP. [Figure 3C] Figures 3A-3C depict the results of exemplary experiments demonstrating the manipulation of human IL-18 variants for independence on IL-18BP using yeast display. Figure 3A provides a structure-guided library designed and introduced into a yeast display system to randomize residues on the IL-18:IL-18BP interface. Yeast clones were selected using magnetic and fluorescent cell sorting for binding to IL-18Rα and counterselected against IL-18BP. Figure 3B provides an overview of directed evolution to generate IL-18BP-resistant IL-18 variants. Positive selection conditions are hIL18Rα SA-beads and hIL18Rα. Counter-selection conditions are SA only, hIL-18BP, and nIL-18BP tetramer. Figure 3C provides flow cytometry analysis of yeast-displayed WT IL-18 (left) or variant after directed evolution (right). The Y-axis shows IL-18BP binding and the x-axis shows IL-18Rα binding. After five rounds of directed evolution, the remaining clones strongly selected IL-18Rα over IL-18BP. [Figure 4]

[0027] FIG. 4 depicts the results of an exemplary experiment outlining the sequence of a decoy-resistant human IL-18 (“DR-IL-18”, also referred to as “DR-18”) variant. The position of each mutation and the corresponding residue in the mature form of wild type human IL-18 is shown at the top of the table. SEQ ID NO: 38 to SEQ ID NO: 58 represent sequences obtained after selection using directed evolution. SEQ ID NO: 34 to SEQ ID NO: 37 are consensus sequences derived from the selected sequences. Shaded residues represent the five most conserved mutations observed. The sequence in the top row (“WT hIL-18”) is set forth as SEQ ID NO:30. [Figure 5]

[0028] Figures 5A and 5B depict the results of exemplary experiments showing biophysical characterization of human DR-IL-18 variants. Figure 5A provides binding isotherms for yeast displayed DR-hIL-18 variants. As shown, yeast-displayed DR-IL-18 variants SEQ ID NO: 34-37 and SEQ ID NO: 39 bind to hIL-18Rα with binding isotherms comparable to WT human IL-18 (left). Can be done. In contrast, very little binding is observed for the same variant and hIL-18BP (right). Figure 5B shows a representative surface plasmon resonance sensorgram between immobilized biotinylated hIL-18BP and DR-IL-18 variants. Recombinant hIL-18 (left) binds to IL-18BP with very high affinity, KD = 2.0 pM, whereas SEQ ID NO: 34 (right) shows greatly attenuated binding, with a much faster dissociation rate and KD =15.2nM. This data is summarized in Tables 6 and 7. [Figure 6]

[0029] Figures 6A and 6B depict the results of an exemplary experiment showing that human DR-IL-18 variants are not inhibited by IL-18BP. Figure 6A shows that recombinant IL-18BP inhibits biotinylated IL-18Rα binding to yeast-displayed WT IL-18, but not DR-IL-18 variants SEQ ID NO: 34-37 and SEQ ID NO: 39 is not affected (as shown in the figure on the left). In contrast, IL-18BP effectively neutralizes previously described IL-18 E42A, K89A and E42A / K89A (Kim et al., 2001, Proc. Natl. Acad. Sci., 98(6): 3304-3309) (shown in the right figure) [E42 and K89 of Kim et al. are E6 and K53 of SEQ ID NO: 30, respectively]. Biotinylated IL-18Rα was kept at a fixed concentration of 100 nM for all samples. Figure 6B shows that WT IL-18 and SEQ ID NO: 34, SEQ ID NO: 36, and SEQ ID NO: 37 stimulate IL-18 HEK-Blue reporter cells with comparable potency and efficacy, HEK Blue IL-18 Provides the results of the signaling assay (left). While wild-type IL-18 is very sensitive to application of recombinant IL-18BP in this assay (IC50=3nM), SEQ ID NO: 34 and SEQ ID NO: 36 show that even at 1 μM IL-18BP concentration, the recombinant Not inhibited by modified IL-18BP (right). hIL-18 was kept at a fixed concentration of 5 nM and SEQ ID NO: 34 and SEQ ID NO: 36 were kept at 2.5 μM. [Figure 7]

[0030] Figures 7A-7C depict the results of exemplary experiments demonstrating the manipulation of additional human IL-18 variants for independence against IL-18BP (version 2 variants) using yeast display. Figure 7A provides an overview of the positions in human IL-18 that were randomized in the version 2.0 library. A set of degenerate codons and encoded amino acids is given for each position. Figure 7B provides an overview of directed evolution to generate version 2.0 IL-18BP-resistant IL-18 variants. The positive selection conditions are hIL18Rα SA-beads and hIL18Rα, and the counter selection conditions are SA only, hIL-18BP, and hIL-18BP tetramer. Figure 7C provides flow cytometry analysis of the progress in creating version 2.0 DR-IL-18 variants. Yeast obtained after rounds 1, 4, and 6 were simultaneously stained with 250 nM IL-18BP streptavidin-PE tetramer or 100 nM IL-18Rα directly labeled with AlexaFluor647. The Y-axis shows IL-18BP binding and the x-axis shows IL-18Rα binding. After six rounds of directed evolution, the remaining clones strongly selected IL-18Rα over IL-18BP. [Figure 8]

[0031] FIG. 8 depicts the results of an exemplary experiment outlining the sequence of version 2.0 decoy-resistant human IL-18 (DR-IL-18) variants. The position of each mutation and the corresponding residue in the mature form of wild type human IL-18 is shown at the top of the table. Shaded rows indicate repetitive sequence variants obtained in both round 5 and round 6. The sequence in the top row (“WT hIL-18”) is set forth as SEQ ID NO:30. [Figure 9]

[0032] FIG. 9 depicts the results of an exemplary experiment showing biophysical characterization of version 2.0 human DR-IL-18 variants. Figure 9A shows that the yeast-displayed version 2.0 DR-IL-18 variant is able to bind hIL-18Rα with a binding isotherm comparable to WT human IL-18. Figure 9B shows, in contrast, that very little binding is observed for the same variant and hIL-18BP. Figure 9C provides thermal stability of version 2.0 DR-IL-18 variants assessed by staining with hIL-18Rα after heating yeast-displayed variants for 15 minutes over a range of temperatures. . Version 2.0 DR-IL-18 variant is more thermostable than WT IL-18 (Tm=47.6°C) and the first generation consensus sequence (Tm=50.9 and 40.2 for SEQ ID NO: 24 and SEQ ID NO: 35, respectively) It was sex. Figure 9D provides an overview of receptor binding properties and thermostability of second generation DR-IL-18 variants. NBD=No binding detected. N.D.=value not determined. [Figure 10A]

[0033] Figures 10A-10C depict the results of exemplary experiments demonstrating the manipulation of murine IL-18 variants for independence on IL-18BP using yeast display. Figure 10A provides an overview of directed evolution to generate IL-18BP-resistant murine IL-18 variants. Positive selection conditions are mIL18Rα SA-beads and mIL18Rα. Counter-selection conditions are mIL-18BP and mIL-18BP tetramer. FIG. 10B shows the results of flow cytometry analysis of yeast-displayed mouse IL-18 variants after five rounds of directed evolution. The Y-axis shows IL-18BP binding and the x-axis shows IL-18Rα binding. FIG. 10C provides an overview of the sequences of decoy-resistant murine IL-18 (DR-IL-18) variants. The sequence in the top row (“mIL-18”) is set forth as SEQ ID NO:31. The position of each mutation and the corresponding residue in the mature form of wild type murine IL-18 is indicated at the top of the table. SEQ ID NO: 62 to SEQ ID NO: 72 represent sequences obtained after selection using directed evolution. SEQ ID NO: 60 to SEQ ID NO: 61 are consensus sequences derived from the selected sequences. Shaded residues represent the five most conserved mutations observed. [Figure 10B] Figures 10A-10C depict the results of exemplary experiments demonstrating the manipulation of murine IL-18 variants for independence on IL-18BP using yeast display. Figure 10A provides an overview of directed evolution to generate IL-18BP-resistant murine IL-18 variants. Positive selection conditions are mIL18Rα SA-beads and mIL18Rα. Counter-selection conditions are mIL-18BP and mIL-18BP tetramer. FIG. 10B shows the results of flow cytometry analysis of yeast-displayed mouse IL-18 variants after five rounds of directed evolution. The Y-axis shows IL-18BP binding and the x-axis shows IL-18Rα binding. FIG. 10C provides an overview of the sequences of decoy-resistant murine IL-18 (DR-IL-18) variants. The sequence in the top row (“mIL-18”) is set forth as SEQ ID NO:31. The position of each mutation and the corresponding residue in the mature form of wild type murine IL-18 is indicated at the top of the table. SEQ ID NO: 62 to SEQ ID NO: 72 represent sequences obtained after selection using directed evolution. SEQ ID NO: 60 to SEQ ID NO: 61 are consensus sequences derived from the selected sequences. Shaded residues represent the five most conserved mutations observed. [Figure 10C] Figures 10A-10C depict the results of exemplary experiments demonstrating the manipulation of murine IL-18 variants for independence on IL-18BP using yeast display. Figure 10A provides an overview of directed evolution to generate IL-18BP-resistant murine IL-18 variants. Positive selection conditions are mIL18Rα SA-beads and mIL18Rα. Counter-selection conditions are mIL-18BP and mIL-18BP tetramer. FIG. 10B shows the results of flow cytometry analysis of yeast-displayed mouse IL-18 variants after five rounds of directed evolution. The Y-axis shows IL-18BP binding and the x-axis shows IL-18Rα binding. FIG. 10C provides an overview of the sequences of decoy-resistant murine IL-18 (DR-IL-18) variants. The sequence in the top row (“mIL-18”) is set forth as SEQ ID NO:31. The position of each mutation and the corresponding residue in the mature form of wild type murine IL-18 is indicated at the top of the table. SEQ ID NO: 62 to SEQ ID NO: 72 represent sequences obtained after selection using directed evolution. SEQ ID NO: 60 to SEQ ID NO: 61 are consensus sequences derived from the selected sequences. Shaded residues represent the five most conserved mutations observed. [Figure 11]

[0034] FIGS. 11A and 11B depict the results of exemplary experiments showing biophysical characterization of murine DR-IL-18 variants. Figure 11A shows that yeast-displayed DR-IL-18 variants SEQ ID NO: 70, SEQ ID NO: 67, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 60, and SEQ ID NO: 61 are equivalent to WT mouse IL-18. Binding isotherm shows that it can bind to mIL-18Rα (left). In contrast, very little binding is observed for the same variant and mIL-18BP (right). FIG. 11B provides measurements of IL-18BP binding using representative surface plasmon resonance sensorgrams between immobilized biotinylated mIL-18BP and mouse DR-IL-18 variants. Recombinant mIL-18 (left) binds mIL-18BP with high affinity, KD=0.8 pM, whereas SEQ ID NO: 61 (right) shows greatly reduced binding with KD higher than 10 μM. This data is summarized in Tables 8 and 9. [Figure 12A]

[0035] Figures 12A-12D depict the results of exemplary experiments showing the pharmacodynamics of DR-IL-18 administered to mice. Figure 12A is a schematic diagram of the study design. Mice were administered vehicle (PBS), mIL-18 (1 mg / kg), or the DR-IL-18 variant SEQ ID NO: 61 (1 mg / kg) once daily for seven total doses (depicted as syringes). kg) was administered. Blood samples were taken 5 hours after injection, 2 days before the experiment, and on days 0, 3, and 6. Figure 12B shows peripheral blood cell counts of CD4, CD8, NK cells, and monocytes at days 0, 3, and 6. Both IL-18 and SEQ ID NO: 61 expanded NK cells and monocytes to similar extents by day 3. For each time point (day), the bar on the left is PBS, the bar in the middle is IL-18, and the bar on the right is SEQ ID NO: 61. Figure 12C shows peripheral CD4, CD8, and CD69 expression on NK cells. SEQ ID NO: 61, but not IL-18, stimulated CD69 expression on CD4 and CD8 cells. Both IL-18 and SEQ ID NO: 61 increased CD69 on NK cells, but SEQ ID NO: 61 treatment caused an apparent sustained CD69 expression at day 6 compared to IL-18; Returned to baseline CD69 level. For each time point (day), the bar on the left is PBS, the bar in the middle is IL-18, and the bar on the right is SEQ ID NO: 61. Figure 12D provides serum cytokine levels for interferon-g (IFN-g), MIP-1b, and G-CSF. SEQ ID NO: 61 treatment resulted in higher levels of IFN-g, MIP-1b, and G-CSF than mIL-18 treatment. [Figure 12B] Figures 12A-12D depict the results of exemplary experiments showing the pharmacodynamics of DR-IL-18 administered to mice. Figure 12A is a schematic diagram of the study design. Mice were administered vehicle (PBS), mIL-18 (1 mg / kg), or the DR-IL-18 variant SEQ ID NO: 61 (1 mg / kg) once daily for seven total doses (depicted as syringes). kg) was administered. Blood samples were taken 5 hours after injection, 2 days before the experiment, and on days 0, 3, and 6. Figure 12B shows peripheral blood cell counts of CD4, CD8, NK cells, and monocytes at days 0, 3, and 6. Both IL-18 and SEQ ID NO: 61 expanded NK cells and monocytes to similar extents by day 3. For each time point (day), the bar on the left is PBS, the bar in the middle is IL-18, and the bar on the right is SEQ ID NO: 61. Figure 12C shows peripheral CD4, CD8, and CD69 expression on NK cells. SEQ ID NO: 61, but not IL-18, stimulated CD69 expression on CD4 and CD8 cells. Both IL-18 and SEQ ID NO: 61 increased CD69 on NK cells, but SEQ ID NO: 61 treatment caused an apparent sustained CD69 expression at day 6 compared to IL-18; Returned to baseline CD69 level. For each time point (day), the bar on the left is PBS, the bar in the middle is IL-18, and the bar on the right is SEQ ID NO: 61. Figure 12D provides serum cytokine levels for interferon-g (IFN-g), MIP-1b, and G-CSF. SEQ ID NO: 61 treatment resulted in higher levels of IFN-g, MIP-1b, and G-CSF than mIL-18 treatment. [Figure 12C] Figures 12A-12D depict the results of exemplary experiments showing the pharmacodynamics of DR-IL-18 administered to mice. Figure 12A is a schematic diagram of the study design. Mice were administered vehicle (PBS), mIL-18 (1 mg / kg), or the DR-IL-18 variant SEQ ID NO: 61 (1 mg / kg) once daily for seven total doses (depicted as syringes). kg) was administered. Blood samples were taken 5 hours after injection, 2 days before the experiment, and on days 0, 3, and 6. Figure 12B shows peripheral blood cell counts of CD4, CD8, NK cells, and monocytes at days 0, 3, and 6. Both IL-18 and SEQ ID NO: 61 expanded NK cells and monocytes to similar extents by day 3. For each time point (day), the bar on the left is PBS, the bar in the middle is IL-18, and the bar on the right is SEQ ID NO: 61. Figure 12C shows peripheral CD4, CD8, and CD69 expression on NK cells. SEQ ID NO: 61, but not IL-18, stimulated CD69 expression on CD4 and CD8 cells. Both IL-18 and SEQ ID NO: 61 increased CD69 on NK cells, but SEQ ID NO: 61 treatment caused an apparent sustained CD69 expression at day 6 compared to IL-18; Returned to baseline CD69 level. For each time point (day), the bar on the left is PBS, the bar in the middle is IL-18, and the bar on the right is SEQ ID NO: 61. Figure 12D provides serum cytokine levels for interferon-g (IFN-g), MIP-1b, and G-CSF. SEQ ID NO: 61 treatment resulted in higher levels of IFN-g, MIP-1b, and G-CSF than mIL-18 treatment. [Figure 12D] Figures 12A-12D depict the results of exemplary experiments showing the pharmacodynamics of DR-IL-18 administered to mice. Figure 12A is a schematic diagram of the study design. Mice were administered vehicle (PBS), mIL-18 (1 mg / kg), or the DR-IL-18 variant SEQ ID NO: 61 (1 mg / kg) once daily for seven total doses (depicted as syringes). kg) was administered. Blood samples were taken 5 hours after injection, 2 days before the experiment, and on days 0, 3, and 6. Figure 12B shows peripheral blood cell counts of CD4, CD8, NK cells, and monocytes at days 0, 3, and 6. Both IL-18 and SEQ ID NO: 61 expanded NK cells and monocytes to similar extents by day 3. For each time point (day), the bar on the left is PBS, the bar in the middle is IL-18, and the bar on the right is SEQ ID NO: 61. Figure 12C shows peripheral CD4, CD8, and CD69 expression on NK cells. SEQ ID NO: 61, but not IL-18, stimulated CD69 expression on CD4 and CD8 cells. Both IL-18 and SEQ ID NO: 61 increased CD69 on NK cells, but SEQ ID NO: 61 treatment caused an apparent sustained CD69 expression at day 6 compared to IL-18; Returned to baseline CD69 level. For each time point (day), the bar on the left is PBS, the bar in the middle is IL-18, and the bar on the right is SEQ ID NO: 61. Figure 12D provides serum cytokine levels for interferon-g (IFN-g), MIP-1b, and G-CSF. SEQ ID NO: 61 treatment resulted in higher levels of IFN-g, MIP-1b, and G-CSF than mIL-18 treatment. [Figure 13]

[0036] FIG. 13 depicts the results of an exemplary experiment showing that DR-IL-18 treatment reduces body fat composition in mice. Fat mass and lean mass composition measured every 3 days in mice treated with 0.01, 0.1, or 1 mg / kg of DR-IL-18 variant SEQ ID NO: 61 or 1 mg / kg of WT mIL-18 did. SEQ ID NO: 61 treatment resulted in a significant reduction in body fat as a percentage of total body weight (top panel). This was evidenced by a decrease or stabilization of fat mass (left panel), consistent with an increase in lean mass (right panel). Vehicle-treated and mIL-18-treated mice showed increased fat mass and stable lean mass over the same treatment period. [Figure 14A]

[0037] Figures 14A-14B depict the results of exemplary experiments showing that DR-IL-18 is an effective immunotherapeutic agent in melanoma models. Figure 14A shows saline (control), WT IL-18 (0.32 mg / kg), DR-IL-18 variant SEQ ID NO: 61 (0.32 mg / kg), anti-PD1 (8 mg / kg), IL-18 FIG. 7 provides tumor growth spider plots for mice bearing Yummer1.7 melanoma tumors treated twice weekly with +anti-PD1, or SEQ ID NO: 61+anti-PD-1. Figure 14B provides survival curves from the same group as in Figure 14A. As shown in Figure 14B, SEQ ID NO: 61 was effective as monotherapy and synergized with anti-PD1 in this model. [Figure 14B] Figures 14A-14B depict the results of exemplary experiments showing that DR-IL-18 is an effective immunotherapeutic agent in melanoma models. Figure 14A shows saline (control), WT IL-18 (0.32 mg / kg), DR-IL-18 variant SEQ ID NO: 61 (0.32 mg / kg), anti-PD1 (8 mg / kg), IL-18 FIG. 7 provides tumor growth spider plots for mice bearing Yummer1.7 melanoma tumors treated twice weekly with +anti-PD1, or SEQ ID NO: 61+anti-PD-1. Figure 14B provides survival curves from the same group as in Figure 14A. As shown in Figure 14B, SEQ ID NO: 61 was effective as monotherapy and synergized with anti-PD1 in this model. [Figure 15]

[0038] 15A and 15B depict the results of an exemplary experiment showing that the efficacy of DR-IL-18 in the melanoma model of FIG. 14 is dependent on CD4 and CD8 lymphocytes and interferon gamma. Figure 15A shows DR combined with saline (control) or the DR-IL-18 variant SEQ ID NO: 61 (0.32 mg / kg) alone or with depletion of antibodies against CD8, CD4, interferon gamma, or NK1.1. - Provides tumor growth spider plots for mice bearing Yummer1.7 melanoma tumors treated with IL-18 variant SEQ ID NO: 61 (0.32 mg / kg). Figure 15B provides survival curves from the same group as in Figure 15A. [Figure 16]

[0039] FIG. 16 depicts the results of an exemplary experiment showing dose-dependent efficacy of DR-IL-18 in the MC38 tumor model. MC38 colons treated every 3 days with PBS (control), 1.0 mg / kg WT IL-18, 1.0 mg / kg SEQ ID NO: 61, 0.1 mg / kg SEQ ID NO: 61, or 0.01 mg / kg SEQ ID NO: 61 Figure 2 is a tumor growth spider plot from a mouse bearing a cancer tumor. WT IL-18 was not effective at 1 mg / kg, while SEQ ID NO: 61 showed partial efficacy at 0.1 mg / kg and maximum efficacy at 1.0 mg / kg. [Figure 17]

[0040] FIG. 17 depicts the results of an exemplary experiment demonstrating the efficacy of DR-IL-18, alone or in combination with the immune checkpoint inhibitor anti-PD1, in the MC38 tumor model. PBS (control), 0.32 mg / kg WT IL-18, 0.32 mg / kg DR-IL-18 variant SEQ ID NO: 61, 5 mg / kg anti-PD1, combination of anti-PD and WT IL-18; Tumor growth spider plots from mice bearing MC38 colon cancer tumors treated with a combination of anti-PD1 and SEQ ID NO: 61 are shown. All drugs were administered intraperitoneally twice weekly for a maximum of 6 total doses. [Figure 18A]

[0041] Figures 18A and 18B depict the results of exemplary experiments investigating the anti-tumor mechanism of DR-IL-18 in mice bearing MC38 tumors. Figure 18A provides the results of tumor immunophenotyping experiments from mice treated with saline, WT IL-18, or the DR-IL-18 variant SEQ ID NO: 61 twice weekly for 4 doses. DR-IL-18 treatment increases the number of CD8 and NK cells per mg of tumor (top left two panels) and the expression of activation markers granzyme B and KLRG1 on CD8 and NK cells (top right 2 panels). DR-IL-18 treatment did not improve the CD8:Treg ratio compared to saline treatment, whereas WT IL-18 made the ratio less favorable. However, DR-IL-18 treatment increased the ratio of CD8 cells to inhibitory myeloid populations, including tumor-associated macrophages (TAMs) and monocytes and granulocytic myeloid-derived suppressor cells (mMDSCs and gMDSCs). Figure 18B provides Serum Luminex cytokine measurements from the same mice as Figure 18A taken 24 hours after the fourth treatment dose. DR-IL-18 exhibits a dramatically altered secondary cytokine release profile from treatment with WT IL-18, significantly increasing interferon-gamma, IL-7, and IL-15 levels by more than 100-fold let [Figure 18B] Figures 18A and 18B depict the results of exemplary experiments investigating the anti-tumor mechanism of DR-IL-18 in mice bearing MC38 tumors. Figure 18A provides the results of tumor immunophenotyping experiments from mice treated with saline, WT IL-18, or the DR-IL-18 variant SEQ ID NO: 61 twice weekly for 4 doses. DR-IL-18 treatment increases the number of CD8 and NK cells per mg of tumor (top left two panels) and the expression of activation markers granzyme B and KLRG1 on CD8 and NK cells (top right 2 panels). DR-IL-18 treatment did not improve the CD8:Treg ratio compared to saline treatment, whereas WT IL-18 made the ratio less favorable. However, DR-IL-18 treatment increased the ratio of CD8 cells to inhibitory myeloid populations, including tumor-associated macrophages (TAMs) and monocytes and granulocytic myeloid-derived suppressor cells (mMDSCs and gMDSCs). Figure 18B provides Serum Luminex cytokine measurements from the same mice as Figure 18A taken 24 hours after the fourth treatment dose. DR-IL-18 exhibits a dramatically altered secondary cytokine release profile from treatment with WT IL-18, significantly increasing interferon-gamma, IL-7, and IL-15 levels by more than 100-fold let [Figure 19]

[0042] Figures 19A-19C depict the results of exemplary experiments demonstrating the ability of DR-IL-18 to effectively treat tumors that are refractory to immune checkpoint inhibitors due to loss of surface MHC class I expression. Figure 19A shows tumor growth spider plots from mice bearing B2m-deficient Yummer1.7 tumors treated with saline, anti-PD1+anti-CTLA4, or the DR-IL-18 variant SEQ ID NO:61. Figure 19B contains a diagram showing survival rate versus days after engraftment. DR-IL-18 showed strong efficacy on tumor growth and survival, curing 60% of treated mice in this model that was completely resistant even to combined treatment with anti-CTLA4+anti-PD1. This efficacy is NK cell dependent, as administration of DR-IL-18 together with anti-NK1.1 (which depletes NK cells) abolishes the therapeutic effect of SEQ ID NO: 61. Figure 19C provides a plot comparing interferon-gamma production and Ki67 levels in tumors. NK cells isolated from B2m-deficient Yummer1.7 are dysfunctional and exhibit reduced proliferation (Ki67 staining) and function (interferon-gamma secretion). However, treatment with DR-IL-18 reverses this phenotype to allow robust proliferation and cytokine secretion. [Figure 20]

[0043] Figures 20A-20C depict exemplary experiments demonstrating the manipulation of human IL-18 variants (or "decoy-to-decoy", D2D) as IL-18BP antagonists using yeast display. These variants bind IL-18BP but not the signal, thereby abrogating the effect of IL-18BP on endogenous IL-18. Figure 20A is a summary of the positions in human IL-18 that were randomized in the D2D library. A set of degenerate codons and encoded amino acids is given for each position. FIG. 20B provides an overview of directed evolution to generate D2D IL-18 variants that bind and neutralize IL-18BP but do not signal through IL-18R. The positive selection condition is mIL18BP. Counter selection conditions are nIL18Rα, hIL18Rb, and mIL18Rα. (FIG. 20C) Flow cytometry analysis of progress in generating D2D hIL-18 variants. Yeast obtained after rounds 1-4 were stained with 1 nM mouse IL-18BP (left panel), 1 nM human IL-18BP (middle panel), or 1 μM IL-18Rα + 1 μM IL18Rβ. Selected variants exhibit enhanced IL-18BP binding over selection rounds without increasing IL18Rα or IL18Rβ binding. [Figure 21]

[0044] Figure 21 depicts the results of an exemplary experiment outlining the sequences of D2D human IL-18 variants. The position of each mutation and the corresponding residue in the mature form of wild type human IL-18 is shown at the top of the table. The sequence in the top row (“WT hIL-18”) is set forth as SEQ ID NO:30. [Figure 22]

[0045] Figures 22A-22C depict the results of exemplary experiments showing biophysical characterization of human decoy-to-decoy (D2D) IL-28 variants. Figure 22A shows that the yeast-displayed D2D IL-8 variants SEQ ID NO: 120, SEQ ID NO: 101, SEQ ID NO: 94, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 123, SEQ ID NO: 124, and SEQ ID NO: 125 are WT It shows that it can bind to hIL-18RBP with a binding isotherm equivalent to that of human IL-18. Figure 22B, in contrast, shows that very little binding is observed for the same variant and hIL-18Rα. Figure 22C provides an overview of receptor binding properties of D2D IL-18 variants. NBD=No binding detected. [Figure 23]

[0046] Figure 23 depicts the results of an exemplary experiment outlining the sequences of D2D murine IL-18 variants. The position of each mutation and the corresponding residue in the mature form of wild type murine IL-18 is indicated at the top of the table. The top row sequence (“WT mIL-18”) is set forth as SEQ ID NO:31. [Figure 24]

[0047] Figure 24 depicts the results of biophysical affinity measurements (sensorgrams) of second generation DR-IL-18 variants for binding to IL-18Rα and IL-18BP using surface plasmon resonance (SPR). do. Top row: Representative sensorgrams of the indicated IL-18 variants (soluble analytes) with respect to hIL-18Rα (immobilized ligand). Bottom row: Representative sensorgrams of the indicated IL-18 variants (hIL-18BP) in humans. The x-axis is time (seconds) and the y-axis is response units (RU). The curve is the observed data over time for different concentrations (starting at 1 nM and 2-fold dilution) overlaid with a best-fit curve assuming a 1:1 Langmuir binding model. [Figure 25]

[0048] Figures 25A and 25B depict data demonstrating the efficacy of DR-IL-18 against the CT26 colorectal tumor model. 250,000 CT26 cells were implanted subcutaneously and treatment started on day 7 when tumors reached an average size of approximately 60 mm3. WT IL-18 and SEQ ID NO: 61 were administered at 0.32 mg / kg twice weekly for a total of 5 doses. Anti-PD1 was given at 10 mg / kg on the same schedule. Figure 25A shows animals treated with saline (PBS) in black lines (circles), WT IL-18 in dark gray (squares), and DR-IL-18 (SEQ ID NO: 61) in gray (triangles). Spider plot overlay showing tumor growth shown. Only treatment with DR-IL-18, but not WT IL-18, resulted in tumor growth inhibition and tumor disappearance in a subset of animals. Figure 25B contains survival curves for mice treated with anti-PD-1, WT IL-18, and DR-IL-18 (SEQ ID NO: 61). The number of complete responses is shown in parentheses. DR-IL-18, but not WT IL-18, resulted in prolonged survival and tumor disappearance in 40% of mice, an improvement over the checkpoint inhibitor anti-PD-1. [Figure 26]

[0049] Figures 26A and 26B depict data showing the efficacy of DR-IL-18 in the 4T1 breast cancer model and the B16-F10 melanoma model. Figure 26A shows 4T1 tumors implanted in BALB / C mice after treatment with saline (PBS; black), WT IL-18 (dark gray), or the DR-IL-18 variant SEQ ID NO: 61 (gray). Tumor growth curves are shown. Figure 26B shows B16 transplanted into C57BL / 6 mice after treatment with saline (PBS; black), WT IL-18 / TA99 (dark grey), or the DR-IL-18 variant SEQ ID NO: 61 (gray). - Shows the tumor growth curve of F10 tumor. In both models, only DR-IL-18, but not WT IL-18, resulted in tumor growth inhibition. Treatments were administered after tumors exceeded a mean volume of 50 mm3, as indicated by the box marked "t". [Figure 27]

[0050] Figures 27A and 27B depict data that extends the data of Figures 19A-19C. Data are depicted demonstrating the efficacy of DR-IL-18 in treating additional MHC class I-deficient tumor models that are resistant to immune checkpoint inhibitors. Figure 27A provides a diagram of tumor volume versus days post implantation for mice implanted with B2m-deficient MC38 cells prepared using CRISPR / Cas9-mediated deletion as described for B2m-deficient YUMMER cells. . B2m- / -MC38 cells were implanted subcutaneously and treatment started on day 7 when tumors reached an average size of approximately 65 mm3. SEQ ID NO: 61 was administered at 0.32 mg / kg twice weekly for 5 doses. Anti-PD1 and anti-CTLA4 were given at 8 mg / kg on the same schedule. Figure 27B shows a diagram of tumor volume versus days post implantation for mice implanted with RMA / S cells. RMA / S is a variant of the RMA lymphoma lineage that contains a spontaneous mutation in tapasin. The result is a defect in antigen content and therefore a reduction in MHC class I surface expression. It is congenic with C57BL / 6 and is refractory to immune checkpoint inhibitors. Mice were implanted subcutaneously with 1,000,000 RMA / S cells and treatment started on day 7. SEQ ID NO: 61 was administered at 0.32 mg / kg twice a week. Anti-PD1 was given at 8 mg / kg on the same schedule. In both studies, only treatment with the DR-18 variant SEQ ID NO: 61 showed antitumor efficacy in the form of tumor growth inhibition (B2m- / -MC38) or tumor disappearance (RMA / S). [Figure 28]

[0051] Figure 28 depicts data demonstrating the effectiveness of DR-IL-18 in enhancing anti-tumor antibody-dependent cell-mediated cytotoxicity (ADCC). Ex vivo cytotoxicity studies used CFSE-labeled Raji (B-cell lymphoma) cells and isolated human peripheral blood mononuclear cells (PBMCs). PBMCs and labeled Raji cells were incubated together for 25 hours at an effector:target (E:T) ratio of 1:10. Human DR-IL-18 variant hCS-1 (1 μM), rituximab (10 μg / mL), or a combination of both drugs were applied to samples as indicated. Cytotoxicity was measured by flow cytometry and calculated as the fraction of CFSE cells that became DAPI positive. DR-18 stimulated significant tumor cell killing as a single agent and significantly enhanced killing by the therapeutic antibody rituximab. *p<0.05 by two-way ANOVA with Tukey's correction for multiple comparisons. [Figure 29A]

[0052] Figures 29A and 29B depict data demonstrating the antiviral efficacy of the DR-18 variant, SEQ ID NO: 61, for the treatment of viral infections (eg, in this case, in the treatment of systemic vaccinia virus infections). Figure 29A shows the experimental design scheme. C57BL / 6 mice were infected intraperitoneally (IP) with 10 PFU of vaccinia virus (VACV) and administered IP with 1 mg / kg of WT mIL-18 or SEQ ID NO: 61. Mice were sacrificed and virus titers were measured in blood and ovaries by RT-PCR on day 3 post-infection. Figure 29B shows quantification of VACV viral copies in the ovaries and blood of treated mice 3 days post-infection. Treatment with SEQ ID NO: 61 showed a significant reduction in virus titer, whereas WT IL-18 was not effective. *p<0.05, **p<0.01, ***p<0.001. [Figure 29B] Figures 29A and 29B depict data demonstrating the antiviral efficacy of the DR-18 variant, SEQ ID NO: 61, for the treatment of viral infections (eg, in this case, in the treatment of systemic vaccinia virus infections). Figure 29A shows the experimental design scheme. C57BL / 6 mice were infected intraperitoneally (IP) with 10 PFU of vaccinia virus (VACV) and administered IP with 1 mg / kg of WT mIL-18 or SEQ ID NO: 61. Mice were sacrificed and virus titers were measured in blood and ovaries by RT-PCR on day 3 post-infection. Figure 29B shows quantification of VACV viral copies in the ovaries and blood of treated mice 3 days post-infection. Treatment with SEQ ID NO: 61 showed a significant reduction in virus titer, whereas WT IL-18 was not effective. *p<0.05, **p<0.01, ***p<0.001. [Figure 30]

[0053] Figure 30 depicts data showing that second generation human DR-IL-18 variants are active. (FIG. 30) WT IL-18 and human SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, and SEQ ID NO: 87 stimulate IL-18 HEK-Blue reporter cells. Human SEQ ID NO: 89, SEQ ID NO: 90, and SEQ ID NO: 91 exhibit enhanced efficacy compared to WT hIL-18, while SEQ ID NO: 87 has comparable efficacy to WT hIL-18. Thus, the data indicate that all tested second generation human DR-IL-18 variants actively signal through IL-18R. [Figure 31]

[0054] Figure 31 depicts IL-18 variants with mutations at various cysteine ​​positions that were prepared and then run on an SDS / PAGE gel (visualized using Spyro-Ruby staining). R=reduced sample; N=non-reduced sample; MW=molecular weight. The numbers at the bottom refer to the sequence numbers (see Table 13). [Figure 32]

[0055] Figure 32 depicts SDS / PAGE gel analysis of various C38S / C68 mutants that remove potential T cell epitopes on C68S. R = reduced sample. NR=non-reduced sample. [Figure 33]

[0056] Figure 33 depicts size exclusion chromatography data from storage stability studies on various C38S / C68 mutants that eliminate potential T cell epitopes on C68S. [Figure 34]

[0057] Figure 34 depicts dose response data using the HEK-Blue reporter cell line. All variants showed increased potency compared to WT IL-18 and potency similar to the parent variant, SEQ ID NO: 89. [Figure 35]

[0058] Figure 35 depicts size exclusion chromatography data comparing SEQ ID NO: 19 and SEQ ID NO: 89 from freeze-thaw studies. [Figure 36]

[0059] Figure 36 depicts size exclusion chromatography data comparing SEQ ID NO: 19 and SEQ ID NO: 89 from a stirring study. [Figure 37]

[0060] Figures 37A and 37B show the results of surface plasmon resonance experiments to test the affinity of SEQ ID NO: 19 and wild-type human IL-18 for human and cynomolgus IL-18Rα (Figure 37A) and IL-18BP (Figure 37B). Describe. [Figure 38]

[0061] Figure 38 depicts the results of the IL-18BP resistance assay. Although WT hIL-18 was strongly inhibited by the addition of IL-18BP, SEQ ID NO: 19 retained strong signaling ability at all concentrations of IL-18BP. [Figure 39]

[0062] Figure 39 depicts tumor growth data in mice from a dosing experiment (using the murine DR IL-18 variant SEQ ID NO: 61). [Figure 40]

[0063] Figure 40 depicts tumor growth data in mice from additional dosing experiments (using the murine DR IL-18 variant SEQ ID NO: 61). [Figure 41]

[0064] Figures 41A and 41B depict tolerance experiments in primates (Cynomolgus macques) using the DR IL-18 variant (in this case SEQ ID NO: 89). [Figure 42]

[0065] Figures 42A and 42B show the production and purification of an IL-18 polypeptide (SEQ ID NO: 89, in this case DR IL-18) using a cell-free SUMO protease that cleaves and removes the N-terminal SUMO tag of the IL-18 protein. Describe. [Figure 43A]

[0066] Figures 43A and 43B depict results from monitoring SUMO protease cleavage by RP-HPLC. [Figure 43B] Figures 43A and 43B depict results from monitoring SUMO protease cleavage by RP-HPLC. [Figure 44]

[0067] Figure 44 shows how an IL-18 polypeptide (in this case, DR IL -18, SEQ ID NO: 19). [Figure 45]

[0068] Figure 45 depicts RP-HPLC data derived from monitoring SUMO protease cleavage reactions inside bacterial cells. [Figure 46]

[0069] Figure 46 depicts a schematic diagram of a yeast (eg, Pichia pastoris) secretion system that produces IL-18 variants. [Figure 47]

[0070] Figure 47 depicts a representative reducing SDS-PAGE gel showing expression of DR-18 (IL-18 variants - in this case SEQ ID NO: 89 and SEQ ID NO: 87). [Figure 48]

[0071] Figure 48 depicts a two chromatography step process (and associated data) that facilitated tag-free purification of IL-18 from a yeast secretory expression system (in this case, Pichia pastoris). [Form for carrying out the invention]

[0023]

[0072] Variant (eg, stabilized) IL-18 polypeptides and methods of their use (eg, to treat a disease or disorder) are provided. The subject stabilized IL-18 polypeptides contain mutations of two cysteine ​​residues (C38 and C68) compared to human wild-type IL-18 (SEQ ID NO: 30). In some cases, the mutation is a C to S substitution, and thus the stabilized IL-18 polypeptide may in some cases include the mutations C38S and C68S. In some cases, the stabilized IL-18 polypeptides of interest include mutant pairs C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N( For example, in some cases, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N; in some cases, C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N; and in some cases, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N).

[0024]

[0073] In some cases, the stabilized IL-18 polypeptide of interest is a stabilized IL-18 variant polypeptide (e.g., a stabilized "decoy resistant" (DR) IL-18 variant or a stabilized is a “decoy-to-decoy” (D2D) IL-18 variant), i.e., an IL-18 variant that additionally contains mutations at positions C38 and C68 compared to human wild-type IL-18.

[0025]

[0074] An IL-18 polypeptide (e.g., wild-type IL-18 or a variant such as a stabilized, DR, D2D, stabilized DR, or stabilized D2D IL-18 variant) is administered to an individual ( (eg, subcutaneously), wherein the frequency of administration is no more than once a week. Also provided are methods of producing / making polypeptides. Some such methods include contacting an exogenously provided fusion protein inside a cell (e.g., a bacterial cell) with a SUMO protease, where the fusion protein is N-terminally fused to a SUMO tag. containing the protein of interest, whereby the SUMO protease cleaves the fusion protein and removes the SUMO tag from the protein of interest.

[0026]

[0075] Before describing the present invention in more detail, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. Additionally, the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting, as the scope of the disclosure will be limited only by the appended claims. It should also be understood that this is not the case.

[0027]

[0076] If a range of values ​​is provided, each intervening value between the upper and lower limits of that range, rounded to two decimal places, unless the text clearly indicates otherwise; and It is understood that any other stated or intervening values ​​within the stated range are encompassed by the invention. The upper and lower limits of these smaller ranges, which may independently be included in the smaller ranges, are also encompassed by the invention, subject to any specifically excluded limit in the stated range. be. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0028]

[0077] Certain ranges are presented herein with numerical values ​​preceded by the term "about." The term "about" is used herein to provide verbatim support for the exact number that it precedes, as well as for a number that is close to or approximately the number that it precedes. . In determining whether a number is near or approximately a number specifically stated, an unstated number that is near or approximately the number specifically stated, in the context in which it is presented. may be a number that provides a substantial equivalent of the number set forth in .

[0029]

[0078] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, representative exemplary methods and materials are now described. .

[0030]

[0079] All publications and patents cited herein are herein incorporated by reference and cited as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. The publications herein are incorporated by reference to disclose and describe the methods and / or materials in connection with the publications herein. Citation of a publication is not for its disclosure prior to the filing date and shall not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Additionally, the publication dates provided may differ from the actual publication dates, which may need to be independently confirmed.

[0031]

[0080] As used in this specification and the appended claims, the singular forms "a," "an," and "the" are intended to include plural referents unless the text clearly dictates otherwise. ing. Furthermore, it is recognized that the claims can be drafted to exclude any optional element. As such, this description should be used as a preferential basis for the use of exclusive terms such as ``merely'', ``only'', etc. in conjunction with the description of claim elements or the use of ``negative'' limitations. Intended to be helpful.

[0032]

[0081] As will be apparent to those skilled in the art upon reading this disclosure, each individual embodiment described and illustrated herein may incorporate several other embodiments without departing from the scope or spirit of the invention. Having separate components and features that can be easily separated from or combined with any other feature. Any of the methods described can be performed in the order of events described or in any other order that is logically possible.

[0033]

[0082] Although the apparatus and method have been or will be described for purposes of grammatical fluidity as well as a functional description, the claims do not, unless expressly formulated under 35 U.S.C. § 112. Although the construction of a "means" or "step" limitation should not necessarily be construed as limiting in any way, the meaning of the definition provided by the claims under the principles underlying the enactment of equivalents and the full scope of equivalents and, if the claims are expressly formulated under 35 U.S.C. § 112, the full statutory equivalents under 35 U.S.C. § 112. It should be explicitly understood that this should be done. definition

[0083] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In describing and claiming the invention, the following terminology will be used.

[0034]

[0084] It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0035]

[0085] The articles "a" and "an" are used herein to refer to one or more (ie, at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.

[0036]

[0086] "About" as used herein when referring to a measurable value, such as an amount, duration of time, etc., means ±40% or ± from the specified value, such that such change is appropriate. Meant to include non-limiting variations of 20% or ±10%, ±5%, ±1%, or ±0.1%.

[0037]

[0087] The term "abnormal" when used in the context of organisms, tissues, cells, or their components refers to organisms in which these organisms, tissues, cells, or their components exhibit "normal" (expected) respective characteristics. , tissue, cell, or component thereof, in at least one observable or detectable characteristic (eg, age, treatment, time of day, etc.). Characteristics that are normal or expected for one cell or tissue type may be abnormal for a different cell or tissue type.

[0038]

[0088] The term "antibody" as used herein refers to an immunoglobulin molecule that is capable of specifically binding to a particular epitope on an antigen. Antibodies may be intact immunoglobulins derived from natural or recombinant sources, and may be immunoreactive portions of intact immunoglobulins. Antibodies in the present invention include, for example, polyclonal antibodies, monoclonal antibodies, intracellular antibodies ("intrabodies"), Fv, Fab and F(ab)2, as well as single chain antibodies (scFv), heavy chain antibodies, such as camel antibodies. may exist in a variety of forms, including synthetic, chimeric, and humanized antibodies (Harlow et al., 1999, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426).

[0039]

[0089] As used herein, "antibody heavy chain" refers to the larger of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformation.

[0040]

[0090] As used herein, "antibody light chain" refers to the smaller of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformation. Kappa and lambda light chains refer to the two major antibody light chain isotypes.

[0041]

[0091] As used herein, the term "synthetic antibody" refers to an antibody produced using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage as described herein. means. The term also refers to antibodies produced by the synthesis of a DNA molecule encoding the antibody, where the DNA molecule expresses the antibody protein, or the amino acid sequence that specifies the antibody, and where the DNA or amino acid sequence is available and well known in the art. Should be taken to mean antibodies obtained using certain synthetic DNA or amino acid sequencing techniques.

[0042]

[0092] As used herein, "immunoassay" refers to any binding assay that uses antibodies that can specifically bind to a target molecule to detect and quantify the target molecule.

[0043]

[0093] For example, with respect to IL-18 variant polypeptides, the term "specifically binds" as used herein refers to IL-18 that recognizes and binds to a particular molecule, such as IL-18R or IL-18BP. -18 variant polypeptide. As an example, wild type IL-18 can be said to specifically bind to both IL-18R and IL-18BP. In some cases, the IL-18 variant polypeptide has substantially reduced binding to IL-18BP. For example, an IL-18 variant polypeptide that specifically binds to a receptor from a species may also bind to that receptor from one or more species. However, such cross-species reactivity does not in itself reclassify the IL-18 variant polypeptide as specific. In another example, an IL-18 variant polypeptide that specifically binds a receptor can also bind different allelic forms of the receptor. However, such cross-reactivity does not in itself reclassify the IL-18 variant polypeptide as specific. In some instances, the terms "specific binding" or "specifically binds" can be used to refer to the interaction of an antibody, protein, or peptide with a chemical species, and that , depend on the presence of a specific structure (e.g., an antigenic determinant or epitope) on a chemical species; e.g., if an IL-18 variant polypeptide recognizes a specific protein structure rather than the entire protein, this means to combine with. Similarly, for example, in the context of an antibody "targeted" to a particular antigen, the term "target" is used to refer to a specific binding partner of a given molecule. For example, a drug (e.g., an antibody) that "targets" a particular protein / antigen is one that "targets" that protein / antigen in the sense that it binds preferentially to that particular protein / antigen over other proteins / antigens. specifically binds to.

[0044]

[0094] As used herein, the term "applicator" refers to a device, including, but not limited to, a hypodermic syringe, pipette, iontophoresis device, patch, etc., for administering the compositions of the present invention to a subject. means any device containing

[0045]

[0095] As used herein, the term "coding sequence" means a sequence of a nucleic acid or its complement, or one thereof, that can be transcribed and / or translated to produce an mRNA and / or polypeptide or fragment thereof. means part. The coding sequence includes exons in the genomic DNA or immature primary RNA transcripts that are linked together by the cell's biochemical machinery to provide the mature mRNA. The antisense strand is the complement of such a nucleic acid and the coding sequence can be deduced therefrom. In contrast, as used herein, the term "non-coding sequence" refers to sequences that are not translated into amino acids in vivo or that the tRNA does not interact with to place or attempt to place amino acids. Refers to the sequence of a nucleic acid or its complement, or a portion thereof. Non-coding sequences include both intronic sequences in genomic DNA or immature primary RNA transcripts and gene-related sequences such as promoters, enhancers, silencers, etc.

[0046]

[0096] As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (ie, sequences of nucleotides) that are related by the base pairing rules. For example, the sequence "A-G-T" is complementary to the sequence "T-C-A." Complementarity may be "partial" if only some of the bases of the nucleic acids match according to the base pairing rules. Alternatively, there may be "perfect" or "total" complementarity between nucleic acids. The degree of complementarity between nucleic acid strands has a significant effect on the efficiency and strength of hybridization between nucleic acid strands. This is particularly important in amplification reactions as well as detection methods that rely on binding between nucleic acids.

[0047]

[0097] A "disease" is a health condition in an animal in which the animal is unable to maintain homeostasis and the animal's health continues to deteriorate if the disease is not improved. In contrast, a "disorder" in an animal is a state of health in which the animal is able to maintain homeostasis, but the animal's state of health is less favorable than it would have been in the absence of the disorder. It is. Even if left untreated, the disorder does not necessarily cause further decline in the animal's health status.

[0048]

[0098] As used herein, "effective amount" means an amount that provides a therapeutic, prophylactic, or other desired benefit.

[0049]

[0099] "Coding" means other polymers in biological processes that have either a defined sequence of nucleotides (i.e. guide RNA, rRNA, tRNA and mRNA) or a defined sequence of amino acids and biological properties resulting therefrom. and refers to the unique properties of a particular sequence of nucleotides in a polynucleotide, such as a gene, cDNA, or mRNA, that serves as a template for the synthesis of macromolecules. Thus, a gene encodes a protein if transcription and translation of the mRNA corresponding to the gene results in the protein in a cell or other biological system. A protein or its gene or cDNA can be referred to as encoding other products.

[0050]

[0100] As used herein, the term "fragment" as applied to a nucleic acid refers to a subsequence of a larger nucleic acid. A "fragment" of a nucleic acid is at least about 15 nucleotides in length; for example, at least about 50 nucleotides to about 100 nucleotides; at least about 100 to about 500 nucleotides; at least about 500 to about 1000 nucleotides; at least about 1000 nucleotides to about 1500 nucleotides; It may be from 1500 nucleotides to about 2500 nucleotides; or about 2500 nucleotides (and any integer value therebetween). As used herein, the term "fragment" applied to a protein, polypeptide or peptide refers to a subsequence of a larger protein, polypeptide or peptide. A "fragment" of a protein, polypeptide, or peptide is at least about 5 amino acids long; for example, at least about 10 amino acids long; at least about 20 amino acids long; at least about 50 amino acids long; at least about 100 amino acids long; at least about 200 amino acids long. ; or at least about 300 amino acids in length (and any integer value therebetween).

[0051]

[0101] The term "gene" refers to a nucleic acid (eg, DNA) sequence that contains the coding sequences necessary for the production of a polypeptide, precursor, or RNA (eg, mRNA). A polypeptide is defined by a full-length coding sequence or by a fragment of the coding sequence so long as the desired activity or functional property (e.g., enzymatic activity, receptor binding, signal transduction, immunogenicity, etc.) of the full-length or fragment is retained. It may be coded by any part. The term also refers to the coding region of a structural gene and a distance of approximately 2 kb or more on either end such that the gene corresponds to the length of the full-length mRNA and 5' regulatory sequences that influence the transcriptional properties of the gene. Sequences located near the coding region at both the ' and 3' ends are also included. Sequences located 5' to the coding region and present on the mRNA are referred to as 5' untranslated sequences. 5' untranslated sequences usually contain regulatory sequences. Sequences located 3' or downstream of the coding region and present on the mRNA are referred to as 3' untranslated sequences. The term "gene" encompasses both cDNA and genomic forms of genes. A genomic form or clone of a gene contains a coding region interrupted with non-coding sequences called "introns" or "intervening regions" or "intervening sequences." Introns are segments of genes that are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or "spliced ​​out" from the nuclear or primary transcript; therefore, introns are not present in messenger RNA (mRNA) transcripts. During translation, mRNA functions to specify the sequence or order of amino acids in the nascent polypeptide.

[0052]

[0102] As used herein in the context of two or more nucleic acid or polypeptide sequences, "homologous," "identical," or "identity" refers to specific means having a percentage of residues. To optimally align two sequences, to compare two sequences over a specific region, to determine the number of positions where the same residue is present in both sequences to obtain the number of matched positions , the percentage can be calculated by dividing the number of matched positions by the total number of positions in a particular region and multiplying the result by 100 to obtain the percentage of sequence identity. If the two sequences are of different lengths or the alignment results in one or more staggered ends and the particular region of comparison contains only a single sequence, then the residues of the single sequence are calculated is included in the denominator, not the numerator. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered equivalent. Identity can be performed manually or by using computer sequence algorithms such as BLAST or BLAST 2.0.

[0053]

[0103] As used herein, the term "instructional materials" refers to the use of the present invention in a kit for identifying or ameliorating or treating various diseases or disorders described herein. Includes publications, records, diagrams, or any other medium of representation that can be used to convey the usefulness of nucleic acids, peptides, polypeptides, and / or compounds. Optionally or alternatively, the instructional material may describe one or more methods of identifying or alleviating a disease or disorder in a subject's cells or tissues. Kit instructional materials are, for example, affixed to or shipped together with containers containing the nucleic acids, polypeptides, and / or compounds of the invention. be able to. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient will use the instructional material and the compound together.

[0054]

[0104] "Isolated" means altered or removed from its natural state. For example, a nucleic acid or polypeptide that occurs naturally in a living animal is not "isolated," but the same nucleic acid or polypeptide that is partially or completely separated from coexisting material in its natural state is " isolated. An isolated nucleic acid or protein may exist in substantially purified form or may exist in a non-natural environment such as, for example, a host cell.

[0055]

[0105] As used herein, the terms "purify" and "purified" in the context of a protein refer to, for example, a degree of purity that allows for effective use of the protein in vitro, ex vivo, or in vivo. refers to the level of For a protein that is useful for a given application, it is free from contaminants, other proteins, and / or should be substantially free of chemicals. Such applications include the preparation of therapeutic compositions, administration of proteins in therapeutic compositions, and other methods disclosed herein. Preferably, as referred to herein, a "purified" protein is one produced by any method (i.e., by direct purification from a natural source, recombinantly, or synthetically). and the protein is at least about 75% by weight of the total protein in a given composition, 80% by weight of the total protein in a given composition, more preferably, of the total protein in a given composition. At least about 85%, more preferably at least about 90%, more preferably at least about 91%, more preferably at least about 92%, more preferably at least about 93%, more preferably at least about 94% by weight. , more preferably at least about 95%, more preferably at least about 96%, more preferably at least about 97%, more preferably at least about 98%, more preferably at least about 99%, by weight. A protein that has been purified from other protein components. As an example, a purified polypeptide can be removed from other components with which it would normally be associated in its naturally occurring state (e.g., when a protein is a naturally occurring protein) and when it is inside a cell. A polypeptide that is separated from components with which it may be associated while in the body or in the extracellular environment. For example, in some cases the protein can be purified from a cell lysate (eg, from a lysate of bacterial cells in which the protein was expressed exogenously). As another example, the protein can be purified from the extracellular medium, eg, from the culture medium in which the cell (eg, yeast cell) has secreted the protein.

[0056]

[0106] "Isolated nucleic acid" means a nucleic acid segment or fragment that is separated from the sequences that flank it in its naturally occurring state, e.g., the sequences that normally flank the fragment, e.g., in the genome in which it naturally occurs. refers to a DNA fragment extracted from the sequence adjacent to the fragment. The term also applies to nucleic acids that have been substantially purified from other components naturally associated with the nucleic acids, such as RNA or DNA, or from the proteins that naturally accompany them in cells. Thus, the term refers to ( Includes recombinant DNA, present, for example, as cDNA or genomic or cDNA fragments produced by PCR or restriction enzyme digestion. It also includes recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequences.

[0057]

[0107] As used herein, the term "label" refers to a detectable compound or composition that is conjugated directly or indirectly to a probe to produce a "labeled" probe. The label may itself be detectable (e.g., a radioisotope or fluorescent label) or, in the case of an enzymatic label, a chemical modification of the substrate compound or composition that is detectable (e.g., avidin-biotin ) may be used as a catalyst. In some examples, primers can be labeled to detect PCR products.

[0058]

[0108] As used herein, the term "modulating" refers to the activity and / or level of an mRNA, polypeptide or response compared to and / or A detectable increase in the activity and / or level of the mRNA, polypeptide, or response in the subject compared to an otherwise identical but activity and / or level of the mRNA, polypeptide, or response in an untreated subject. or mean to mediate a decrease. This term refers to mediating a beneficial therapeutic, prophylactic, or other desired response in a subject, e.g., a human, by activating, inhibiting, and / or otherwise influencing natural signals or responses. includes doing. As used herein, a "mutation", "mutant" or "variant" refers to a nucleic acid relative to a reference sequence (which may be the naturally occurring normal / "wild type" sequence). or changes in the amino acid sequence, including translocations, deletions, insertions, and substitutions / point mutations. As used herein, "mutant" or "variant" refers to any nucleic acid or protein that contains a mutation.

[0059]

[0109] "Nucleic acid" refers to polynucleotides and includes polyribonucleotides and polydeoxyribonucleotides. Nucleic acids according to the invention may include pyrimidine and purine bases, preferably cytosine, thymine, and uracil, respectively, and any polymers or oligomers of adenine and guanine (incorporated herein in their entirety for all purposes). , Albert L. Lehninger, Principles of Biochemistry, 793-800 (Worth Pub. 1982)). Indeed, the present invention contemplates any deoxyribonucleotide, ribonucleotide or peptide nucleic acid moiety, and any chemical variant thereof, such as methylated, hydroxymethylated or glucosylated forms of these bases. Polymers or oligomers may be heterogeneous or homogeneous in composition and may be isolated from naturally occurring sources or produced artificially or synthetically. Additionally, the nucleic acid may be DNA or RNA, or a mixture thereof, permanently or transiently in single-stranded or double-stranded form, including homoduplex, heteroduplex, and hybrid states. may exist.

[0060]

[0110] An "oligonucleotide" or "polynucleotide" is a nucleic acid ranging in length from at least 2, preferably at least 8, 15 or 25 nucleotides, but up to 50, 100, 1000, or 5000 nucleotides in length; Alternatively, it may be a compound that specifically hybridizes to a polynucleotide. Polynucleotides include sequences of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or mimetics thereof, which can be isolated from natural sources, recombinantly produced, or artificially synthesized. A further example of a polynucleotide of the invention may be a peptide nucleic acid (PNA) (see US Pat. No. 6,156,501, incorporated by reference in its entirety). The present invention also encompasses situations where non-traditional base pairing exists, such as Hoogsteen-type base pairing, which has been identified in certain tRNA molecules and is assumed to exist in a triple helix. "Polynucleotide" and "oligonucleotide" are used interchangeably in this disclosure. As used herein, if a nucleotide sequence is represented by a DNA sequence (e.g., A, T, G, and C), this means a corresponding RNA sequence (e.g., A, U, It will be understood that this also includes G, C).

[0061]

[0111] The terms "individual," "subject," "host" and "patient" are used interchangeably herein to refer to any mammalian subject, particularly a human, for whom diagnosis, treatment, or therapy is desired.

[0062]

[0112] As used herein, the terms "peptide," "polypeptide," and "protein" are used interchangeably and refer to compounds that include amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that a protein or peptide sequence may contain. A polypeptide includes any peptide or protein that contains two or more amino acids linked together by peptide bonds. As used herein, the term generally refers to short chains, also referred to as peptides, oligopeptides and oligomers, as commonly used in the art, for example, to proteins, which exist in many types. refers to both a longer chain called "Polypeptide" refers to, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. including. Polypeptides include natural peptides, recombinant peptides, synthetic peptides, mutant polypeptides, variant polypeptides, or combinations thereof.

[0063]

[0113] As used herein, "polynucleotide" refers to cDNA, RNA, DNA / RNA hybrids, antisense RNA, ribozymes, genomic DNA, synthetic forms, and mixed polymers, both sense and antisense strands. may be chemically or biochemically modified to represent non-natural or derivatized, synthetic, or semi-synthetic nucleotide bases. Also contemplated are modifications to wild-type or synthetic genes, such as, but not limited to, deletions, insertions, substitutions of one or more nucleotides, or fusions with other polynucleotide sequences.

[0064]

[0114] As used herein, "sample" or "biological sample" refers to biological material isolated from a subject. A biological sample may contain any biological material suitable for detecting mRNA, polypeptides or other markers of a physiological or pathological process in a subject, including fluids, tissues, cells obtained from an individual. may contain cellular and / or non-cellular materials.

[0065]

[0115] As used herein, the term "therapy" or "therapeutic regimen" refers to activities undertaken to prevent, treat, or modify a disease or disorder, such as pharmacological, surgical, dietary refers to a course of treatment intended to reduce or eliminate at least one sign or symptom of a disease or disorder using surgical and / or other techniques. A treatment regimen may include prescribed dosages of one or more compounds or surgical procedures. Although therapy will most often be beneficial and reduce or eliminate at least one sign or symptom of a disorder or disease condition, in some instances the effects of therapy may be undesirable or cause side effects. will have. The effectiveness of therapy will also be influenced by the physiological state of the subject, such as age, sex, genetics, weight, other disease states, etc.

[0066]

[0116] The term "therapeutically effective amount" means the intended biological, physiological, clinical or medical effect of a cell, tissue, organ, system, or subject as sought by a researcher, veterinarian, physician, or other clinician. refers to the amount of a compound or composition that elicits a specific response. The term "therapeutically effective amount" includes an amount of a compound or composition that, when administered, is sufficient to treat one or more signs or symptoms of the disorder or disease being treated. A therapeutically effective amount will vary depending on the compound or composition, the disease and its severity, and the age, weight, etc. of the subject being treated.

[0067]

[0117] As used herein, the term "treating" a disease or disorder means reducing the frequency or severity of at least one sign or symptom of the disease or disorder experienced by a subject. As used herein, the terms "treatment," "treating," "treating," and the like generally refer to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic in terms of completely or partially preventing the disease or its symptoms and / or partially or completely stabilizing or curing the disease and / or the adverse effects caused by the disease. May be therapeutic from the point of view. The term "treatment" includes any treatment of a disease in a mammal, particularly a human, and includes (a) the treatment of a disease and / or condition in a subject who may be predisposed to the disease or condition but has not yet been diagnosed with the disease or condition; (b) inhibiting the disease and / or symptoms, e.g. slowing down or halting their development (e.g. stopping tumor growth, inhibiting tumor growth; (c) alleviating disease symptoms, i.e. causing regression of the disease and / or symptoms (e.g. reducing tumor size); (e.g. causing cancer cells, reducing the number of cancer cells present). Those who require treatment include those who are already suffering (e.g., those with cancer, infections, metabolic disorders, macular degeneration, etc.) and those for whom prevention is desirable (e.g., those with (e.g., those with high susceptibility to cancer, those with high possibility of infection, those suspected of having cancer, those suspected of carrying infection, those with high susceptibility to metabolic diseases, those with high susceptibility to macular degeneration, etc.) Can be mentioned.

[0068]

[0118] As used herein, the term "wild type" refers to a gene or gene product that is isolated from a naturally occurring source or that has a naturally occurring sequence (e.g., a naturally occurring amino acid sequence) A wild-type protein having a .sup.2 (a) can be isolated from a natural source or from a synthetic source and would still be considered a wild-type protein). In contrast, the terms "altered," "variant," or "mutant" refer to alterations (i.e., altered characteristics) in sequence and / or functional properties when compared to a wild-type gene or gene product. Refers to a gene or gene product that has

[0069]

[0119] Ranges: Throughout this disclosure, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and is not to be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have all possible subranges specifically disclosed as well as individual numerical values ​​within that range. For example, a description of a range such as 1 to 6 is not specifically disclosed such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, 2 to 5, 2 to 6, etc. and the individual numbers within that range, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the width of the range. Compositions and methods

[0120] As summarized above, in some embodiments, the compositions and methods of the present disclosure provide IL-18 with mutations at amino acid positions C38 and C68 compared to wild-type IL-18 (SEQ ID NO: 30). Contains 18 polypeptides. Such variants are referred to herein as "stabilized" IL-18 variants.

[0070]

[0121] In some embodiments, the compositions and methods of the present disclosure include an IL-18 variant polypeptide that is mutated compared to wild-type IL-18, such that one of IL-18's natural binding partners is binds but cannot bind to the other (or has reduced binding to the other). For example, wild-type IL-18 inhibits IL-18R (which signals through the receptor) and IL-18BP (which inhibits IL-18 by preventing it from binding to IL-18R). combine with both. In some cases, the IL-18 variant polypeptides discussed herein are “decoy-resistant IL-18” (“DR IL-18”) variants; such variants do not bind to IL-18R. However, their binding to IL-18BP is reduced (and in some cases, they do not bind to it). In other cases, the IL-18 variant polypeptides discussed herein are “decoy-to-decoy IL-18” (“D2D IL-18”) variants; such variants binds, but has reduced binding to (and in some cases no binding to) IL-18R. As shown in this disclosure, IL-18 variant polypeptides can exhibit binding affinity for IL-18Rα comparable to wild-type IL-18, but lower binding affinity for IL-18BP compared to wild-type IL-18. Binding affinity is also shown.

[0071]

[0122] In some cases, there is overlap between the terms used to describe the various variants. For example, a DR IL-18 variant or a D2D IL-18 variant may contain mutations at C38 and C68, in which case the IL-18 variant would be a "stabilized" variant. Therefore, the term "stabilized" refers to stabilized wild-type IL-18 (WT IL-18 with C38 and C68 mutations) as well as DR IL-18 and D2D IL-18 with C38 and C68 mutations. Encompasses stabilized variant proteins such as variants. Similarly, the term "DR IL-18" variant encompasses such variants with and without C38 / C68 mutations, and the term "D2D IL-18" variants include those with C38 / C68 mutations. and includes such variants that do not have. Therefore, the term "stabilized DR IL-18" variant can be used when discussing DR IL-18 variants with C38 / C68 mutations, and the term "stabilized D2D IL-18" variant can be used when discussing D2D IL-18 variants with C38 / C68 mutations.

[0072]

[0123] As such, the following discusses various embodiments of "stabilized" IL-18 proteins (various C38 / C68 mutants). This description applies equally to any type of IL-18 protein (eg, wild type, DR IL-18 variant, D2D IL-18 variant, etc.). Mutations in C38 / C68 are discussed first, followed by DR IL-18 and D2D IL-18 variants. All of the variants discussed can be used in any of the methods described herein.

[0073]

[0124] Stabilized IL-18 polypeptides contain "stabilizing mutations" that are mutations of two cysteine ​​residues (C38 and C68) compared to human wild-type IL-18 (SEQ ID NO: 30) IL-18 polypeptide. Surprisingly, mutations of these two amino acids were found to stabilize IL-18 better than all other possible combinations of cysteine ​​mutations. See, for example, the Examples below. In some cases, the mutation is a C to S substitution, and thus the stabilized IL-18 polypeptide is, in some cases, compared to human wild-type IL-18 (SEQ ID NO: 30). Mutations C38S and C68S (also referred to herein as "mutant pair C38S / C68S") may be included. In some cases, the IL-18 polypeptide of interest has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more, 95% or more) to human wild-type IL-18 (SEQ ID NO: 30). % or more, 97% or more, 98% or more, or 98.5% or more sequence identity), and contains mutations at amino acid positions C38 and C68 with respect to SEQ ID NO: 30. In some cases, the IL-18 polypeptide of interest has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more, 98% or more) to human wild-type IL-18 (SEQ ID NO: 30). % or more, or 98.5% or more sequence identity), and contains mutations at amino acid positions C38 and C68 with respect to SEQ ID NO: 30. Examples of such variant proteins include those set forth as SEQ ID NO: 6 and SEQ ID NO: 16-21, which sequences make them DR IL-18 variants (see below). Additional mutations are also included, such SEQ ID NO: 6 and SEQ ID NO: 16-21 are examples of stabilized DR IL-18 variants.

[0074]

[0125] In some cases, the mutation is a C to S substitution, and thus the stabilized IL-18 polypeptide is, in some cases, compared to human wild-type IL-18 (SEQ ID NO: 30). Mutations C38S and C68S (also referred to herein as "C38S / C68S") may be included. Mutations at C68 can lead to immunogenic epitopes in some cases. Thus, in some embodiments, the mutation at C68 is a non-immunogenic substitution. In some such cases, the mutation is a mutation of C68 to G, A, V, D, E, or N (in some cases, a mutation of C68 to G, A, D, or N ). Thus, in some such cases, the stabilized IL-18 polypeptide of interest may be mutated C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or Including C38S / C68N. In some cases, the stabilized IL-18 polypeptide of interest comprises the mutations C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N. In some cases, the stabilized IL-18 polypeptide of interest comprises the mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N. In some cases, the stabilized IL-18 polypeptide of interest comprises mutations C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation C38S / C68D. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation C38S / C68G. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation C38S / C68A. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation C38S / C68A. In some cases, the subject stabilized IL-18 polypeptide comprises the mutation C38S / C68N.

[0075]

[0126] Thus, in some embodiments, a subject IL-18 polypeptide has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more) to human wild-type IL-18 (SEQ ID NO: 30). % or more, 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity), and the mutation C38S / C68S, C38S / C68G, C38S / C68A with respect to SEQ ID NO: 30 , C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N. In some embodiments, the subject IL-18 polypeptide has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68G, C38S / C68A, C38S / C68V, C38S to SEQ ID NO: 30. / C68D, C38S / C68E, or C38S / C68N. In some embodiments, the subject IL-18 polypeptide has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S to SEQ ID NO: 30. / C68D or C38S / C68N included. In some embodiments, the subject IL-18 polypeptide has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68G, C38S / C68A, C38S / C68D, or Including C38S / C68N. In some embodiments, the subject IL-18 polypeptide has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68D with respect to SEQ ID NO:30. In some embodiments, the subject IL-18 polypeptide has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity), and contains the mutation C38S / C68G to SEQ ID NO:30. In some embodiments, the subject IL-18 polypeptide has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68A to SEQ ID NO:30. In some embodiments, the subject IL-18 polypeptide has 80% or more sequence identity (e.g., 85% or more, 90% or more, 92% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68N to SEQ ID NO:30.

[0076]

[0127] In some embodiments, the subject IL-18 polypeptide has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S to SEQ ID NO: 30. / C68E or C38S / C68N included. In some embodiments, the subject IL-18 polypeptide has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 98% or more, or 98.5% or more sequence identity) with respect to SEQ ID NO: 30, the mutation C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or Including C38S / C68N. In some embodiments, the subject IL-18 polypeptide has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N to SEQ ID NO: 30. include. In some embodiments, the subject IL-18 polypeptide has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 98% or more, or 98.5% or more sequence identity) and contains mutations C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N to SEQ ID NO:30. In some embodiments, the subject IL-18 polypeptide has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68D with respect to SEQ ID NO: 30. In some embodiments, the subject IL-18 polypeptide has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68G with respect to SEQ ID NO: 30. In some embodiments, the subject IL-18 polypeptide has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68A to SEQ ID NO:30. In some embodiments, the subject IL-18 polypeptide has 90% or more sequence identity (e.g., 92% or more, 95% or more, 97% or more) to human wild-type IL-18 (SEQ ID NO: 30). , 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68N to SEQ ID NO: 30. Stabilized DR IL-18 or D2D IL-18 variant

[0128] In some cases, the stabilized IL-18 polypeptide of interest is a stabilized IL-18 variant polypeptide, i.e., has stabilizing mutations (i.e., C38 and C38 compared to human wild-type IL-18). This is an IL-18 variant polypeptide containing a mutation at position C68). In some such cases, the stabilized IL-18 variant polypeptide is a stabilized "decoy-resistant" (DR) IL-18 variant; in other such cases, the stabilized IL-18 variant polypeptide is a stabilized "decoy-resistant" (DR) IL-18 variant; The -18 variant polypeptide is a stabilized "decoy-to-decoy" (D2D) IL-18 variant. Examples of human DR IL-18 variants include, but are not limited to, those set forth in SEQ ID NOs: 34-59, 73-91, and 191-193; Examples include, but are not limited to, those set forth in SEQ ID NOS: 92-125; see also the Examples below. DR-IL18 variants are described in detail below, and any such variant may contain a C38 / C68 mutation as described herein to be a stabilized DR-IL18. good.

[0077]

[0129] In some cases, the stabilized DR IL-18 variants of interest are mutated, except that C38 and C68 are mutated (e.g., C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N - in some cases, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N - in some cases, C38S / C68S , C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N - in some cases, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N - in some cases, C38S / C68D- C38S / C68G (in some cases, C38S / C68A-in some cases, C38S / C68N), containing the amino acid sequence set forth in SEQ ID NO: 89. Examples of stabilized DR IL-18 variants include those set forth as SEQ ID NO: 6 and SEQ ID NO: 16-21 (these include the C38 of the DR-18 variant set forth as SEQ ID NO: 89). / C68 mutant version). One skilled in the art can readily produce equivalent stabilized variants for any desired IL-18 variant (see, e.g., Examples below) (e.g., SEQ ID NO: 34). Any of the human DR-IL variants set forth as ~59, 73-91, and 191-193, such as any of the human D2D IL-18 variants set forth as SEQ ID NOs: 87-91, or SEQ ID NOs: 92-125. mosquito).

[0078]

[0130] Thus, in some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59; 73 to 91, and 191 to 193 or any one of SEQ ID NOs. 87 to 91 or SEQ ID NO. 89] (e.g., 85% or more, 90% or more, 92 % or more, 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity), and mutations C38S / C68S, C38S / C68G, C38S / C68A with respect to SEQ ID NO: 30. , C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NOs. 87 to 91 or SEQ ID NO. 89] of 80% or more (e.g., 85% or more, 90% or more, 92% or more) , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68G, C38S / C68A, C38S / C68V, C38S to SEQ ID NO: 30. / C68D, C38S / C68E, or C38S / C68N. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NOs. 87 to 91 or SEQ ID NO. 89] of 80% or more (e.g., 85% or more, 90% or more, 92% or more) , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S to SEQ ID NO: 30. / C68D or C38S / C68N included. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NOs. 87 to 91 or SEQ ID NO. 89] of 80% or more (e.g., 85% or more, 90% or more, 92% or more) , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68G, C38S / C68A, C38S / C68D, or Including C38S / C68N. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NOs. 87 to 91 or SEQ ID NO. 89] of 80% or more (e.g., 85% or more, 90% or more, 92% or more) , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68D with respect to SEQ ID NO:30.

[0079]

[0131] In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NOs. 87 to 91 or SEQ ID NO. 89] of 80% or more (e.g., 85% or more, 90% or more, 92% or more) , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity), and contains the mutation C38S / C68G to SEQ ID NO:30. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NOs. 87 to 91 or SEQ ID NO. 89] of 80% or more (e.g., 85% or more, 90% or more, 92% or more) , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68A to SEQ ID NO:30.

[0080]

[0132] In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NOs. 87 to 91 or SEQ ID NO. 89] of 80% or more (e.g., 85% or more, 90% or more, 92% or more) , 95% or more, 97% or more, 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68N to SEQ ID NO:30. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NO: 87 to 91 or SEQ ID NO: 89] of 90% or more (e.g., 92% or more, 95% or more, 97% or more) , 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S to SEQ ID NO: 30. / C68E or C38S / C68N included. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NO: 87 to 91 or SEQ ID NO: 89] of 90% or more (e.g., 92% or more, 95% or more, 97% or more) , 98% or more, or 98.5% or more sequence identity) with respect to SEQ ID NO: 30, the mutation C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or Including C38S / C68N.

[0081]

[0133] In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NO: 87 to 91 or SEQ ID NO: 89] of 90% or more (e.g., 92% or more, 95% or more, 97% or more) , 98% or more, or 98.5% or more sequence identity) with mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N to SEQ ID NO: 30. include. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NO: 87 to 91 or SEQ ID NO: 89] of 90% or more (e.g., 92% or more, 95% or more, 97% or more) , 98% or more, or 98.5% or more sequence identity) and contains mutations C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N to SEQ ID NO:30. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NO: 87 to 91 or SEQ ID NO: 89] of 90% or more (e.g., 92% or more, 95% or more, 97% or more) , 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68D with respect to SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NO: 87 to 91 or SEQ ID NO: 89] of 90% or more (e.g., 92% or more, 95% or more, 97% or more) , 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68G with respect to SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NO: 87 to 91 or SEQ ID NO: 89] of 90% or more (e.g., 92% or more, 95% or more, 97% or more) , 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68A to SEQ ID NO:30. In some embodiments, the IL-18 polypeptide of interest is human wild-type IL-18 (SEQ ID NO: 30) [or any one of SEQ ID NOs: 6 and 16-21 or SEQ ID NOs: 34-59, 73- 91, and any one of 191 to 193 or any one of SEQ ID NO: 87 to 91 or SEQ ID NO: 89] of 90% or more (e.g., 92% or more, 95% or more, 97% or more) , 98% or more, or 98.5% or more sequence identity) and contains the mutation C38S / C68N to SEQ ID NO: 30.

[0082]

[0134] In some embodiments, the IL-18 variant polypeptide is a DR IL-18 variant (ie, it binds IL-18R and exhibits reduced binding to IL-18BP). In some embodiments, the DR IL-18 variant has a binding affinity for IL-18BP of 95% or less (e.g., 90% or less, 80% or less, 70% or less, 60% or less, IL-18BP with a binding affinity of ≤50%, ≤40%, ≤30%, ≤20%, ≤10%, ≤5%, ≤2%, ≤1%, ≤0.05%, or ≤0.001%). join to. In some embodiments, the DR IL-18 variant has a binding affinity for IL-18BP of 10% or less (e.g., 5% or less, 2% or less, 1% or less, 0.05% or less, or less than 0.001%).

[0083]

[0135] In some embodiments, the DR IL-18 variant of interest has a K for IL-18BP that is greater than or equal to 10 nM. D (higher K D means lower binding affinity). In some embodiments, the DR-IL-18 variant polypeptide of interest has a K of 20 nM or more (e.g., 50 nM or more, 100 nM or more, 500 nM or more, or 1 μM or more) D has.

[0084]

[0136] IL-18 polypeptides (e.g., DR IL-18 polypeptides containing mutations at positions C38 and C68 compared to human wild-type IL-18) are IL-18 polypeptides with different sequences (e.g., wild-type may exhibit enhanced stability compared to an IL-18 sequence (or an IL-18 sequence lacking the C38 and C68 mutations but otherwise containing the same sequence as the subject IL-18 polypeptide).

[0085]

[0137] In some embodiments, the stability of an IL-18 polypeptide disclosed herein (e.g., DR IL-18) can be determined by freezing the polypeptide or a formulation disclosed herein containing the polypeptide. Thawing cycles, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least It can be evaluated by subjecting it to 8, at least 9, at least 10, at least 15, or at least 20 freeze-thaw cycles. A freeze-thaw cycle involves freezing a polypeptide or a formulation containing a polypeptide (e.g., to about -20°C or -80°C) and thawing the polypeptide or formulation (e.g., to about 20°C, 23°C, 25°C). or 37°C).

[0086]

[0138] In some embodiments, the stability of an IL-18 polypeptide disclosed herein (e.g., DR IL-18) can be determined by stirring the polypeptide or a formulation disclosed herein containing the polypeptide. It can be evaluated by multiplying by . Agitation may include, for example, incubating the polypeptide or formulation while stirring at about 100 rpm, about 150 rpm, about 200 rpm, or about 250 rpm (e.g., about 20°C, about 23°C, about 25°C, about 30°C, about 37°C, or at about 40°C). The sample can be tested, for example, after about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 1 week, or about 2 weeks after incubation at the temperature and agitation rate. .

[0087]

[0139] By comparing the size of the main peak of IL-18 measured by size exclusion chromatography before and after the stability assays disclosed herein (e.g., before and after freeze-thaw cycles and / or agitation), IL-18 The stability of 18 polypeptides (eg, DR IL-18) can be assessed. In some embodiments, after exposure to stability assay conditions, the main peak is at least about 80%, at least about 85%, at least about 90%, at least about 91% of the size of the main peak before exposure to assay conditions. %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 95.5%, at least about 96%, at least about 96.5%, at least about 97%, at least about 97.5%, at least about 98 %, at least about 98.5%, at least about 99%, at least about 99.1%, at least about 99.1%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8 %, at least about 99.9%, at least about 99.95%, at least about 99.99%, or about 100%.

[0088]

[0140] In some embodiments, retention of the main peak after exposure to stability assay conditions is associated with IL-18 polypeptides having different sequences (e.g., wild-type IL-18 sequence, or lacking the C38 and C68 mutations). , otherwise containing the same sequence as the subject IL-18 polypeptide), at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, or at least about 50% higher.

[0089]

[0141] The stability of IL-18 polypeptides (e.g., DR IL-18) was determined before and after the stability assays disclosed herein (e.g., before and after freeze-thaw cycles and / or agitation). can be assessed by determining the presence and size of one or more peaks measured by size exclusion chromatography that indicate the formation of bodies, aggregates, or degradation products. In some embodiments, after exposure of an IL-18 polypeptide (e.g., DR IL-18 in a formulation disclosed herein) to stability assay conditions, a peak indicative of dimer formation is detected. not detected or substantially undetected. In some embodiments, no peaks indicative of multimer formation are detected after exposure of an IL-18 polypeptide (e.g., DR IL-18 in a formulation disclosed herein) to stability assay conditions. or virtually undetectable. In some embodiments, no peaks indicative of aggregate formation are detected after exposure of an IL-18 polypeptide (e.g., DR IL-18 in a formulation disclosed herein) to stability assay conditions. or virtually undetectable. In some embodiments, no peaks indicative of the formation of degradation products are detected after exposure of an IL-18 polypeptide (e.g., DR IL-18 in a formulation disclosed herein) to stability assay conditions. or virtually undetectable.

[0090]

[0142] In some embodiments, the stability of an IL-18 polypeptide (e.g., DR IL-18 in a formulation disclosed herein) after exposure to assay conditions is determined by, e.g., size exclusion chromatography. If the IL-18 polypeptide has a different sequence (e.g., the wild-type IL-18 sequence, or lacks mutations at C38 and C68, but otherwise contains the same sequence as the IL-18 polypeptide of interest) IL-18 sequence), the IL-18 polypeptide comprises at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7 %, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 20%, at least about 25 %, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% less dimer, multimer, Indicates aggregate and / or degradation product formation.

[0091]

[0143] In some embodiments, the disclosed DR IL-18 variants are at least about 100 μM, at least about 10 μM, at least about 1 μM, at least about 900 nM, at least about 800 nM, at least about 700 nM, at least about 600 nM, at least about 500 nM, at least about 400nM, at least about 300nM, at least about 200nM, at least about 150nM, at least about 100nM, at least about 90nM, at least about 80nM, at least about 70nM, at least about 60nM, at least about 50nM, at least about 40nM, at least about 30nM, at least about 20nM, or at least about 10 nM to IL-18BP D has. In some embodiments, the disclosed DR IL-18 variants do not bind to IL-18BP, substantially do not bind to IL-18BP, or do not bind to IL-18BP below the limit of detection in the assays disclosed herein. Binds to IL-18BP.

[0092]

[0144] The DR IL-18 variants disclosed herein can exhibit binding to human IL-18R, e.g., bind to human IL-18R with comparable affinity to wild-type human IL-18. or can bind human IL-18R with higher affinity than wild-type human IL-18. In some embodiments, the DR IL-18 variants disclosed herein bind human IL-18R with an affinity that is at least comparable to wild-type human IL-18 for human IL-18R.

[0093]

[0145] In some embodiments, the DR IL-18 variants disclosed herein are, for example, less than about 100 μM, less than about 10 μM, less than about 1 μM, less than about 900 nM, less than about 800 nM, less than about 700 nM. lower, lower than about 600nM, lower than about 500nM, lower than about 400nM, lower than about 300nM, lower than about 200nM, lower than about 150nM, lower than about 100nM, lower than about 90nM, lower than about 80nM, about 70nM lower, lower than about 60nM, lower than about 50nM, lower than about 40nM, lower than about 30nM, lower than about 20nM, lower than about 10nM, lower than about 5nM, lower than about 4nM, lower than about 3nM, about 2nM K lower or lower than about 1nM D and binds to human IL-18Rα or human IL-18R.

[0094]

[0146] In some embodiments, the DR IL-18 variants disclosed herein are, for example, about 1 pM to about 1 μM, about 1 pM to about 500 nM, about 1 pM to about 400 nM, about 1 pM to about 300 nM, about 1 pM to Approximately 200nM, approximately 1pM to approximately 100nM, approximately 1pM to approximately 50nM, approximately 100pM to approximately 1μM, approximately 100pM to approximately 500nM, approximately 100pM to approximately 400nM, approximately 100pM to approximately 300nM, approximately 100pM to approximately 200nM, approximately 100pM to approximately 100nM , about 100pM to about 50nM, about 1nM to about 1μM, about 1nM to about 500nM, about 1nM to about 400nM, about 1nM to about 300nM, about 1nM to about 200nM, about 1nM to about 100nM, about 1nM to about 75nM, about K of 1nM to about 50nM, about 1nM to about 40nM, about 1nM to about 30nM, or about 1nM to about 10nM D binds to human IL-18Rα or human IL-18R.

[0095]

[0147] In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 2 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18 ( Note that an increase in dissociation constant ratio means a relative decrease in IL-18BP binding compared to IL-18R binding). In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 20 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 200 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 2000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 20,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 200,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 2,000,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 20000000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18.

[0096]

[0148] In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 3 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 30 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 300 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 3000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 30,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 300,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 3,000,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 30000000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18.

[0097]

[0149] In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 10 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 100 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 1000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 10,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 100,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 1,000,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 10,000,000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18. In some embodiments, the DR IL-18 variant has an IL-18BP / IL-18R dissociation constant ratio that is at least about 100000000 times higher than the IL-18BP / IL-18R dissociation constant ratio of wild-type IL-18.

[0098]

[0150] In some embodiments, the DR IL-18 variant of interest has greater than 3 nM (e.g., 5 nM or more, 10 nM or more, 50 nM or more, 100 nM or more, 500 nM or more, 750 nM or more, or 1 μM or more) inhibition to IL-18BP. It has a constant (Ki). In some embodiments, the DR-IL-18 variant polypeptide of interest has a Ki to IL-18BP that is 500 nM or greater. In some embodiments, the DR-IL-18 variant polypeptide of interest has a Ki to IL-18BP that is 1 μM or greater.

[0099]

[0151] In some embodiments, a subject IL-18 variant polypeptide (DR-IL-18) that binds to IL-15 18R and exhibits decreased binding to IL-18BP is greater than 200 nM (e.g., 500 nM or more , 750 nM or higher, or 1 μM or higher) to IL-18BP. In some embodiments, the DR-IL-18 variant polypeptide of interest has a Ki to IL-18BP that is 1 μM or greater.

[0100]

[0152] In some embodiments, a subject IL-18 variant polypeptide (DR-IL-18) that binds to IL-18R and exhibits substantially reduced binding to IL-18BP is have an inhibition constant (Ki) to IL-18BP that is at least two-fold higher than the Ki to IL-18BP (i.e., the Ki of the IL-18 variant polypeptide of interest to IL-18BP is at least two times higher than the Ki to IL-18BP) at least twice compared to the Ki to IL-18BP). For example, in some cases, the DR-IL-18 variant polypeptide of interest is at least 5-fold higher than the Ki of wild-type IL-18 to IL-18BP (e.g., at least 10-fold, at least 50-fold, at least 100 times, at least 200 times, at least 500 times, or at least 1000 times higher) to IL-18BP.

[0101]

[0153] In some embodiments, a subject IL-18 variant polypeptide (DR-IL-18) that binds to IL-18R and exhibits substantially reduced binding to IL-18BP is have an EC50 to IL-18BP that is at least 2-fold higher than the EC50 to IL-18BP of the subject IL-18 variant polypeptide (i.e., the EC50 of the subject IL-18 variant polypeptide to IL-18BP is higher than the EC50 of WT IL-18 to IL-18BP is at least twice as large as the EC50 of For example, in some cases, the DR-IL-18 variant polypeptide of interest is at least 5-fold higher than the EC50 of wild-type IL-18 to IL-18BP (e.g., at least 10-fold, at least 50-fold, at least EC50 to IL-18BP (100-fold, at least 200-fold, at least 500-fold, or at least 1000-fold higher).

[0102]

[0154] In any of the above cases, the DR IL-18 variant may include any combination of C38 / C68 mutations presented above (e.g., in some cases C38S / C68S, C38S / C68G, C38S / C68A , C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N; In some cases, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N; C38S / C68D; In some cases, C38S / C68G; In some cases, C38S / C68A; In some cases In some cases, C38S / C68N; in some cases C38S / C68S).

[0103]

[0155] Similarly, DR IL-18 variants may contain C38 / C68 mutations in any combination presented above (e.g., in some cases, C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N; in some cases, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N ;In some cases, C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N;In some cases, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N ;C38S / C68D; in some cases, C38S / C68G; in some cases, C38S / C68A; in some cases, C38S / C68N; in some cases, C38S / C68S).

[0104]

[0156] In some embodiments, the DR-IL-18 variants include Y1, L5, K8, M51, K53, S55, Q56, P57, G59, M60, E77, Q103, S105, D110, N111, M113, V153, and at least one mutation (eg, at least 2, at least 3, at least 4, at least 5, or at least 6 mutations) at an amino acid position selected from the group consisting of N155. In various embodiments, the human IL-18 variant polypeptides include Y1, L5, K8, M51, K53, S55, Q56, P57, G59, M60, E77, Q103, S105, D110, N111, M113, V153, and Contains at least four mutations at amino acid positions selected from the group consisting of N155. In various embodiments, the human IL-18 variant polypeptides include Y1, L5, K8, M51, K53, S55, Q56, P57, G59, M60, E77, Q103, S105, D110, N111, M113, V153, and Contains at least six mutations at amino acid positions selected from the group consisting of N155. In various embodiments, the human IL-18 variant polypeptide is selected from the group consisting of Y1, L5, K8, S55, Q56, P57, G59, E77, Q103, S105, D110, N111, M113, V153, and N155. at least one mutation (eg, at least 2, at least 3, at least 4, at least 5, or at least 6 mutations) at a given amino acid position. In some embodiments, the human IL-18 variant polypeptide is Y1H, Y1R, L5H, L5I, L5Y, K8Q, K8R, M51T, M51K, M51D, M51N, M51E, M51R, K53R, K53G, K53S, K53T, S55K, S55R, Q56E, Q56A, Q56R, Q56V, Q56G, Q56K, Q56L, P57L, P57G, P57A, P57K, G59T, G59A, M60K, M60Q, M60R, M60L, E77D, Q103E, Q103K, Q103P, Q103 A, Q103R, S105R, S105D, S105K, S105N, S105A, D110H, D110K, D110N, D110Q, D110E, D110S, D110G, N111H, N111Y, N111D, N111R, N111S, N111G, M113V, M113R, M1 13T, M113K, V153I, V153T, V153A, at least one mutation (eg, at least 2, at least 3, at least 4, at least 5, or at least 6 mutations) at an amino acid position selected from the group consisting of N155K, and N155H.

[0105]

[0157] In some embodiments, the DR IL-18 variant polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 34-59, 73-91, and 191-193. In some embodiments, the DR IL-18 variant polypeptide has 80% or more sequence identity (e.g., , 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, or 100%). In some embodiments, the DR IL-18 variant polypeptide has 85% or more sequence identity (e.g., , 90% or more, 95% or more, 98% or more, 99% or more, or 100%). In some embodiments, the DR IL-18 variant polypeptide has 90% or more sequence identity (e.g., , 95% or more, 98% or more, 99% or more, or 100%).

[0106]

[0158] In some cases, the subject DR-IL-18 variant has at least one mutation (e.g., , at least 2, at least 3, or at least 4 mutations). In some cases, the subject DR-IL-18 variant comprises at least three mutations at amino acid positions selected from the group consisting of M51, M60, S105, D110, and N111 relative to SEQ ID NO: 30. . In some cases, the subject DR-IL-18 variant has at least one mutation (e.g., , at least 2, at least 3, or at least 4 mutations); M51 is T, K, D, E, R, or N; M60 is K, Q, L, or R; S105 is R, D, K, A, or N; D110 is H, K, N, Q, E, N, S, or G; N111 is H, D, Y, R, S, or G be. In some cases, the DR-IL-18 variant of interest has at least three mutations (e.g., , at least 2, at least 3, or at least 4 mutations); M51 is T, K, D, E, R, or N; M60 is K, Q, L, or R; S105 is R, D, K, A, or N; D110 is H, K, N, Q, E, N, S, or G; N111 is H, D, Y, R, S, or G be. In some cases, the subject DR-IL-18 variant has at least one mutation (e.g., , at least 2, at least 3, or at least 4 mutations); M51 is T or K; M60 is K or L; S105 is D, N, or A; D110 is K; N, S, or G; N111 is H, Y, G, or R.

[0107]

[0159] In some cases, the DR-IL-18 variant of interest comprises mutations at amino acid positions M51, M60, S105, D110, and N111 relative to SEQ ID NO:30. For example, in some cases, the DR-IL-18 variant of interest contains mutations at amino acid positions M51, M60, S105, D110, and N111 relative to SEQ ID NO: 30, where M51 is T, K, D , E, R, or N; M60 is K, Q, L, or R; S105 is R, D, K, A, or N; D110 is H, K, N, Q, E, N, S, or G; N111 is H, D, Y, R, S, or G; In some cases, the DR-IL-18 variant of interest contains mutations at amino acid positions M51, M60, S105, D110, and N111 relative to SEQ ID NO: 30, where M51 is T or K; M60 is K or L; S105 is D, N, or A; D110 is K, N, S, or G; N111 is H, Y, G, or R. In other words, in some cases, the DR-IL-18 variant of interest has mutations {M51T or M51K};{M60K or M60L};{S105D, S105N, S105A};{D110K} relative to SEQ ID NO:30. , D110N, D110S, or D110G}; and {N111H, N111Y, N111R, or N111G}.

[0108]

[0160] In some cases, the DR-IL-18 variant of interest has at least one mutation (e.g., , at least 2, at least 3, or at least 4 mutations). In some cases, the DR-IL-18 variant of interest comprises at least three mutations at amino acid positions selected from the group consisting of M51, K53, Q56, S105, and N111 relative to SEQ ID NO:30. . In some cases, the DR-IL-18 variant of interest has at least one mutation (e.g., , at least 2, at least 3, or at least 4 mutations); M51 is E, R, or K; K53 is G, S, or T; Q56 is E, A, R, V , G, K, or L; S105 is N, S, K, or G; N111 is R, S, G, or D. In some cases, the DR-IL-18 variant of interest comprises at least three mutations at amino acid positions selected from the group consisting of M51, K53, Q56, S105, and N111 relative to SEQ ID NO:30. , M51 is E, R, or K; K53 is G, S, or T; Q56 is E, A, R, V, G, K, or L; S105 is N, S, K, or G; N111 is R, S, G, or D. In some cases, the DR-IL-18 variant of interest has at least one mutation (e.g., , at least 2, at least 3, or at least 4 mutations); M51 is K; K53 is G or S; Q56 is G, R, or L; S105 is S, N, or G; N111 is G or R.

[0109]

[0161] In some cases, the DR-IL-18 variant of interest comprises mutations at amino acid positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO:30. For example, in some cases, the subject DR-IL-18 variant contains mutations at amino acid positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30, where M51 is E, R, or K; K53 is G, S, or T; Q56 is E, A, R, V, G, K, or L; D110 is S, N, G, or K; N111 is R , S, G, or D. In some cases, the DR-IL-18 variant of interest contains mutations at amino acid positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30, where M51 is a K; K53 is a G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R. In other words, in some cases, the DR-IL-18 variant of interest has mutations {M51K};{K53G or K53S};{Q56G, Q56R, or Q56L};{D110S}, relative to SEQ ID NO:30; D110N, or D110G}; and {N111R, or N111G}.

[0110]

[0162] In some cases, in addition to the mutations in the previous paragraph, DR-IL-18 variants also contain mutations at positions P57 and M60, and in some cases at S105 as well. For example, in some cases, P57 is A, K, G or L; M60 is L or R - in some such cases, S105 is A, N, or D. In some cases, P57 is A (i.e., P57A), M60 is L (i.e., M60L), and in some such cases, S105 is A, N, or D ( In some cases, S105D).

[0111]

[0163] In some cases, the DR-IL-18 variant of interest has 85% or more sequence identity (e.g., 90% or more, 92% or more, 93% or more) to the wild-type human IL-18 amino acid sequence set forth in SEQ ID NO: 30. % or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more). Thus, in some cases, the DR-IL-18 of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92 % or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); and (ii) wild-type IL-18 (e.g. , human IL-18) (e.g., at least 2, at least 3, at least 4, at least 5, or at least 6 mutations) (e.g., all the mutations listed above) (see combinations of).

[0112]

[0164] In some cases, the DR-IL-18 variant of interest has 85% or more sequence identity (e.g. , 90% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more). Thus, in some cases, the DR-IL-18 variant of interest has (i) 85% or more of the amino acid sequence set forth in any one of SEQ ID NOs: 34-59, 73-91, and 191-193; have sequence identity (e.g., 90% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); and (ii) at least one mutation (e.g., at least 2, at least 3, at least 4, at least 5, or at least 6 mutations compared to wild-type IL-18 (e.g., human IL-18) (mutations), including amino acid sequences.

[0113]

[0165] In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); At least one mutation ( for example, at least 2, at least 3, at least 4, at least 5, or at least 6 mutations). In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); At least four mutations at amino acid positions selected from the group consisting of L5, K8, M51, K53, S55, Q56, P57, G59, M60, E77, Q103, S105, D110, N111, M113, V153, and N155. Contains an amino acid sequence. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); At least six mutations at amino acid positions selected from the group consisting of L5, K8, M51, K53, S55, Q56, P57, G59, M60, E77, Q103, S105, D110, N111, M113, V153, and N155. Contains an amino acid sequence. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); At least one mutation (e.g., at least two at least 3, at least 4, at least 5, or at least 6 mutations).

[0114]

[0166] In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; Includes an amino acid sequence that includes at least one mutation (eg, at least two, at least three, or at least four mutations) at an amino acid position selected from the group consisting of M60, S105, D110, and N111. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; An amino acid sequence comprising at least three mutations at amino acid positions selected from the group consisting of M60, S105, D110, and N111. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; at least one mutation (e.g., at least two, at least three, or at least four mutations) at an amino acid position selected from the group consisting of M60, S105, D110, and N111, and M51 is T, K, D, E, R, or N; M60 is K, Q, L, or R; S105 is R, D, K, A, or N; D110 is H, K, N, Q, E , N, S, or G; N111 includes an amino acid sequence where N111 is H, D, Y, R, S, or G. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; comprising at least three mutations at amino acid positions selected from the group consisting of M60, S105, D110, and N111, where M51 is T, K, D, E, R, or N; M60 is K, Q, L , or R; S105 is R, D, K, A, or N; D110 is H, K, N, Q, E, N, S, or G; N111 is H, D, Y, Contains an amino acid sequence that is R, S, or G. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% and (ii) have a sequence identity of 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; and (ii) to SEQ ID NO: 30. at least one mutation (e.g., at least two, at least three, or at least four mutations) at an amino acid position selected from the group consisting of M51, M60, S105, D110, and N111, where M51 is T or K; M60 is K or L; S105 is D, N, or A; D110 is K, N, S, or G; N111 is H, Y, G, or R. including.

[0115]

[0167] In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% and (ii) position M51 with respect to SEQ ID NO: 30. , including mutations at positions M60, S105, D110, and N111. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% and (ii) position M51 with respect to SEQ ID NO: 30. , containing mutations at positions M60, S105, D110, and N111, where M51 is T, K, D, E, R, or N; M60 is K, Q, L, or R; S105 is R, D, K, A, or N; D110 is H, K, N, Q, E, N, S, or G; N111 is H, D, Y, R, S, or G Contains a certain amino acid sequence.

[0116]

[0168] In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% and (ii) position M51 with respect to SEQ ID NO: 30. , containing mutations at positions M60, S105, D110, and N111, where M51 is T or K; M60 is K or L; S105 is D, N, or A; D110 is K; N, S, or G; N111 includes an amino acid sequence that is H, Y, G, or R.

[0117]

[0169] In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; Includes an amino acid sequence that includes at least one mutation (eg, at least 2, at least 3, or at least 4 mutations) at a position selected from the group consisting of K53, Q56, D110, and N111. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; An amino acid sequence comprising at least three mutations at positions selected from the group consisting of K53, Q56, D110, and N111. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; at least one mutation (e.g., at least 2, at least 3, or at least 4 mutations) at a position selected from the group consisting of K53, Q56, D110, and N111, and M51 is E, R, or K53 is G, S, or T; Q56 is E, A, R, V, G, K, or L; D110 is N, S, K, or G; N111 is R , S, G, or D. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; comprising at least three mutations at positions selected from the group consisting of K53, Q56, D110, and N111, where M51 is E, R, or K; K53 is G, S, or T; Q56 is E; D110 is N, S, K, or G; N111 is R, S, G, or D. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; at least one mutation (e.g., at least two, at least three, or at least four mutations) at a position selected from the group consisting of K53, Q56, D110, and N111; is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R.

[0118]

[0170] In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% and (ii) position M51 with respect to SEQ ID NO: 30. , including mutations at positions K53, Q56, D110, and N111. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% and (ii) position M51 with respect to SEQ ID NO: 30. , containing mutations at positions K53, Q56, D110, and N111; M51 is E, R, or K; K53 is G, S, or T; Q56 is E, A, R, V , G, K, or L; D110 is N, S, K, or G; N111 is R, S, G, or D. In some cases, the DR-IL-18 variant of interest has (i) 85% or more sequence identity (e.g., 90% or more, 92% and (ii) position M51 with respect to SEQ ID NO: 30. , containing mutations at positions K53, Q56, D110, and N111, where M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R;

[0119]

[0171] In some cases, in addition to the mutations in the previous paragraph, DR-IL-18 variants also contain mutations at positions P57 and M60, and in some cases S105 as well. For example, in some cases, P57 is A, K, G or L; M60 is L or R - in some such cases, S105 is A, N, or D. In some cases, P57 is A (i.e., P57A), M60 is L (i.e., M60L), and in some such cases, S105 is A, N, or D ( In some cases, S105D).

[0120]

[0172] Examples of murine IL-18 variant polypeptides (in this case, DR IL-18 variants) include, but are not limited to, mCS1 (SEQ ID NO: 60), mCS2 (SEQ ID NO: 61), mC1 (SEQ ID NO: 62), mA12 (SEQ ID NO: 62), No. 63), mE8 (SEQ ID No. 64), mC10 (SEQ ID No. 65), mB7 (SEQ ID No. 66), mB1 (SEQ ID No. 67), mD1 (SEQ ID No. 68), mH7 (SEQ ID No. 69), mA7 (SEQ ID No. 70), mE1 (SEQ ID NO: 71) and mH3 (SEQ ID NO: 72).

[0121]

[0173] As mentioned above, any IL-18 variant herein can be "stabilized" relative to SEQ ID NO: 30 by further mutating C38 and C68. As in the illustrative examples, in some cases, a subject stabilized DR-IL-18 variant is (i) 85% or more similar to the wild-type human IL-18 amino acid sequence set forth in SEQ ID NO: 30; (e.g., 90% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more). ;(ii) SEQ ID NO: 30 [or any one of SEQ ID NOs: 6 and 16-21 or any one of SEQ ID NOs: 34-59, 73-91, and 191-193, or SEQ ID NOs: 87-91 or the sequence No. 89] contains mutations at positions M51, K53, Q56, D110, and N111; and (iii) contains mutations at positions C38 and C68 (e.g. C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N - In some cases, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D , C38S / C68E, or C38S / C68N - in some cases, C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N - in some cases, C38S / C68G, C38S / C68A , C38S / C68D, or C38S / C68N - in some cases, C38S / C68D - in some cases, C38S / C68G - in some cases, C38S / C68A - in some cases C38S / C68N), Contains amino acid sequence. In some cases, the DR-IL-18 variant of interest is (i) SEQ ID NO: 30 [or any one of SEQ ID NO: 6 and 16-21 or SEQ ID NO: 34-59, 73-91, and 191- Sequence identity of 85% or more (for example, 90% or more, 92 (ii) position M51 with respect to SEQ ID NO: 30. , containing mutations at positions K53, Q56, D110, and N111; M51 is E, R, or K; K53 is G, S, or T; Q56 is E, A, R, V, G, K, or L; D110 is N, S, K, or G; N111 is R, S, G, or D; and (iii) mutations at positions C38 and C68. Including (e.g. C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N - in some cases, C38S / C68G, C38S / C68A, C38S / C68V , C38S / C68D, C38S / C68E, or C38S / C68N - in some cases, C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N - in some cases, C38S / C68G , C38S / C68A, C38S / C68D, or C38S / C68N - In some cases, C38S / C68D - In some cases, C38S / C68G - In some cases, C38S / C68A - In some cases, C38S / C68N), including the amino acid sequence. In some cases, the DR-IL-18 variant of interest is (i) SEQ ID NO: 30 [or any one of SEQ ID NO: 6 and 16-21 or SEQ ID NO: 34-59, 73-91, and 191- Sequence identity of 85% or more (for example, 90% or more, 92 (ii) position M51 with respect to SEQ ID NO: 30. , containing mutations at positions K53, Q56, D110, and N111; M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N , or G; N111 is G or R; and (iii) contains mutations at positions C38 and C68 (e.g., C38S / C68S, C38S / C68G, C38S / C68A, 8S / C68V, C38S / C68D , C38S / C68E, or C38S / C68N - in some cases, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or C38S / C68N - in some cases, C38S / C68S , C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N - In some cases, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N - In some cases, C38S / C68D - in some cases C38S / C68G - in some cases C38S / C68A - in some cases C38S / C68N), comprising the amino acid sequence.

[0122]

[0174] In some cases, in addition to the mutations in the previous paragraph, DR-IL-18 variants also contain mutations at positions P57 and M60, and in some cases at position S105 as well. For example, in some cases, P57 is A, K, G or L; M60 is L or R - in some such cases, S105 is A, N, or D. In some cases, P57 is A (i.e., P57A), M60 is L (i.e., M60L), and in some such cases, S105 is A, N, or D ( In some cases, S105D).

[0123]

[0175] In some cases, the DR-IL-18 variants of interest include (i) (relative to SEQ ID NO: 30) mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S; / C68E, or C38S / C68N; (ii) 90% or more sequence identity with the wild type human IL-18 amino acid sequence set forth in SEQ ID NO: 30 (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); (iii) position M51, position K53, position Q56, position D110 with respect to SEQ ID NO: 30; and contains a mutation at position N111. In some such cases, the variant further includes mutations at positions P57, M60. In some such cases, the variant further comprises a mutation at position S105.

[0124]

[0176] In some cases, the DR-IL-18 variants of interest include (i) (relative to SEQ ID NO: 30) mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S; / C68E, or C38S / C68N; (ii) 90% or more sequence identity with the wild type human IL-18 amino acid sequence set forth in SEQ ID NO: 30 (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); (iii) position M51, position K53, position Q56, position D110 with respect to SEQ ID NO: 30; and contains a mutation at position N111; M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or It is R. In some such cases, the variant further comprises a mutation at the position where P57 is A, K, G or L; M60 is L or R. In some such cases, the variant further comprises a mutation at position S105, where S105 is A, N, or D.

[0125]

[0177] In some cases, the DR-IL-18 variant of interest is (i) (relative to SEQ ID NO: 30) mutated C38S / C68G, 20C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or (ii) 90% or more sequence identity with the wild type human IL-18 amino acid sequence set forth in SEQ ID NO: 30 (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); (iii) at position M51, K53, Q56, D110, and N111 with respect to SEQ ID NO: 30 Contains mutations. In some such cases, the variant further includes mutations at positions P57 and M60. In some such cases, the variant further comprises a mutation at position S105.

[0126]

[0178] In some cases, the DR-IL-18 variant of interest is (i) (relative to SEQ ID NO: 30) mutated C38S / C68G, C38S / C68A, C38S / C68V, C38S / C68D, C38S / C68E, or (ii) 90% or more sequence identity with the wild type human IL-18 amino acid sequence set forth in SEQ ID NO: 30 (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); (iii) at position M51, K53, Q56, D110, and N111 with respect to SEQ ID NO: 30 M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R. In some such cases, the variant further comprises a mutation at the position where P57 is A, K, G or L; M60 is L or R. In some such cases, the variant further comprises a mutation at position S105, where S105 is A, N, or D.

[0127]

[0179] In some cases, the DR-IL-18 variant of interest has (i) mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N (relative to SEQ ID NO: 30); (ii) 90% or more sequence identity with the wild type human IL-18 amino acid sequence set forth in SEQ ID NO: 30 (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 with respect to SEQ ID NO: 30 . In some such cases, the variant further includes mutations at positions P57 and M60. In some such cases, the variant further comprises a mutation at position S105.

[0128]

[0180] In some cases, the DR-IL-18 variant of interest has (i) mutations C38S / C68S, C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N (relative to SEQ ID NO: 30); (ii) 90% or more sequence identity with the wild type human IL-18 amino acid sequence set forth in SEQ ID NO: 30 (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity); (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 with respect to SEQ ID NO: 30 , M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R. In some such cases, the variant further comprises a mutation at the position where P57 is A, K, G or L; M60 is L or R. In some such cases, the variant further comprises a mutation at position S105, where S105 is A, N, or D.

[0129]

[0181] In some cases, the DR-IL-18 variant of interest (i) comprises the mutations C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N (relative to SEQ ID NO: 30); (ii) ) 90% or more sequence identity with the wild-type human IL-18 amino acid sequence set forth in SEQ ID NO: 30 (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 with respect to SEQ ID NO: 30. In some such cases, the variant further includes mutations at positions P57 and M60. In some such cases, the variant further comprises a mutation at position S105.

[0130]

[0182] In some cases, the DR-IL-18 variant of interest (i) comprises the mutations C38S / C68G, C38S / C68A, C38S / C68D, or C38S / C68N (relative to SEQ ID NO: 30); (ii) ) 90% or more sequence identity with the wild-type human IL-18 amino acid sequence set forth in SEQ ID NO: 30 (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 with respect to SEQ ID NO: 30, and M51 is K K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R. In some such cases, the variant further comprises a mutation at the position where P57 is A, K, G or L; M60 is L or R. In some such cases, the variant further comprises a mutation at position S105, where S105 is A, N, or D.

[0131]

[0183] In some cases, the DR-IL-18 variant of interest (i) comprises the mutation C38S / C68D (relative to SEQ ID NO: 30); (ii) wild-type human IL-18 as set forth in SEQ ID NO: 30; 90% or more sequence identity with the amino acid sequence (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity) (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30. In some such cases, the variant further includes mutations at positions P57 and M60. In some such cases, the variant further comprises a mutation at position S105.

[0132]

[0184] In some cases, the DR-IL-18 variant of interest (i) comprises the mutation C38S / C68D (relative to SEQ ID NO: 30); (ii) wild-type human IL-18 as set forth in SEQ ID NO: 30; 90% or more sequence identity with the amino acid sequence (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity) (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30, where M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R. In some such cases, the variant further comprises a mutation at the position where P57 is A, K, G or L; M60 is L or R. In some such cases, the variant further comprises a mutation at position S105, where S105 is A, N, or D.

[0133]

[0185] In some cases, the DR-IL-18 variant of interest (i) comprises the mutation C38S / C68G (relative to SEQ ID NO: 30); (ii) wild-type human IL-18 as set forth in SEQ ID NO: 30; 90% or more sequence identity with the amino acid sequence (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity) (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30. In some such cases, the variant further includes mutations at positions P57 and M60. In some such cases, the variant further comprises a mutation at position S105.

[0134]

[0186] In some cases, the DR-IL-18 variant of interest (i) comprises the mutation C38S / C68G (relative to SEQ ID NO: 30); (ii) wild-type human IL-18 as set forth in SEQ ID NO: 30; 90% or more sequence identity with the amino acid sequence (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity) (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30, where M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R. In some such cases, the variant further comprises a mutation at the position where P57 is A, K, G or L; M60 is L or R. In some such cases, the variant further comprises a mutation at position S105, where S105 is A, N, or D.

[0135]

[0187] In some cases, the DR-IL-18 variant of interest (i) comprises the mutation C38S / C68A (relative to SEQ ID NO: 30); (ii) wild-type human IL-18 as set forth in SEQ ID NO: 30; 90% or more sequence identity with the amino acid sequence (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity) (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30. In some such cases, the variant further includes mutations at positions P57 and M60. In some such cases, the variant further comprises a mutation at position S105.

[0136]

[0188] In some cases, the DR-IL-18 variant of interest (i) comprises the mutation C38S / C68A (relative to SEQ ID NO: 30); (ii) wild-type human IL-18 as set forth in SEQ ID NO: 30; 90% or more sequence identity with the amino acid sequence (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity) (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30, where M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R. In some such cases, the variant further comprises a mutation at the position where P57 is A, K, G or L; M60 is L or R. In some such cases, the variant further comprises a mutation at position S105, where S105 is A, N, or D.

[0137]

[0189] In some cases, the DR-IL-18 variant of interest (i) comprises the mutation C38S / C68N (relative to SEQ ID NO: 30); (ii) wild-type human IL-18 as set forth in SEQ ID NO: 30; 90% or more sequence identity with the amino acid sequence (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity) (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30. In some such cases, the variant further includes mutations at positions P57 and M60. In some such cases, the variant further comprises a mutation at position S105.

[0138]

[0190] In some cases, the DR-IL-18 variant of interest (i) comprises the mutation C38S / C68N (relative to SEQ ID NO: 30); (ii) wild-type human IL-18 as set forth in SEQ ID NO: 30; 90% or more sequence identity with the amino acid sequence (e.g., 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity) (iii) Contains mutations at positions M51, K53, Q56, D110, and N111 relative to SEQ ID NO: 30, where M51 is K; K53 is G or S; Q56 is G, R, or L; D110 is S, N, or G; N111 is G or R. In some such cases, the variant further comprises a mutation at the position where P57 is A, K, G or L; M60 is L or R. In some such cases, the variant further comprises a mutation at position S105, where S105 is A, N, or D.

[0139]

[0191] In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) comprises residue 78 (e.g., compared to SEQ ID NO: 30, 89, and / or 19). Contains no cysteine. In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) comprises residues N78 (e.g., compared to SEQ ID NO: 30, 89, and / or 19). does not contain any mutations.

[0140]

[0192] In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) comprises residue 121 (e.g., compared to SEQ ID NO: 30, 89, and / or 19). Contains no cysteine. In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) comprises residues E121 (e.g., compared to SEQ ID NO: 30, 89, and / or 19). does not contain any mutations.

[0141]

[0193] In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) has residues 144 Contains no cysteine. In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) comprises residue L144 (e.g., compared to SEQ ID NO: 30, 89, and / or 19). does not contain any mutations.

[0142]

[0194] In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) has residues 157 Contains no cysteine. In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) comprises residues D157 (e.g., compared to SEQ ID NO: 30, 89, and / or 19). does not contain any mutations.

[0143]

[0195] In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) comprises residue 78 (e.g., compared to SEQ ID NO: 30, 89, and / or 19). , does not contain cysteine ​​at residue 121, residue 144, or residue 157. In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18) comprises residues N78 (e.g., compared to SEQ ID NO: 30, 89, and / or 19). , contains no mutations at residue E121, residue L144, or residue D157.

[0144]

[0196] IL-18 polypeptides of the present disclosure (e.g., DR IL-18) can include mutations to C38 and C68 as disclosed herein, adding non-natural cysteine ​​residues to the polypeptide sequence. Any mutations that introduce groups can be absent. For example, in some embodiments, the IL-18 polypeptide (e.g., DR IL-18) contains cysteine ​​only at positions 76 and / or 127 (compared to SEQ ID NO: 30, 89, or 19). do. In some embodiments, the IL-18 polypeptide (e.g., DR IL-18) contains any cysteine ​​except for positions 76 and / or 127 (compared to SEQ ID NO: 30, 89, or 19). do not. The lack of non-natural cysteine ​​residues may, for example, affect the stability and / or or can negatively affect biological activity and thus contribute to the advantageous properties of the IL-18 polypeptides of the present disclosure.

[0145]

[0197] IL-18 polypeptides of the present disclosure (eg, DR IL-18) can lack or substantially lack surface-exposed or solvent-exposed cysteine ​​residues. The lack of surface-exposed or solvent-exposed cysteine ​​residues may result in, for example, surface- or intermolecular disulfide bonds, dimers, aggregation, etc. can negatively affect the stability and / or biological activity of IL-18, thereby contributing to the advantageous properties of the IL-18 polypeptides of the present disclosure. IL-18 polypeptides of the present disclosure (e.g., DR IL-18) may be surface-exposed or solvent-exposed, e.g., as determined by structural modeling or assays that detect free thiols (e.g., Ellman titration). may lack or substantially lack cysteine ​​residues. IL-18 polypeptides of the present disclosure (eg, DR IL-18) can lack or substantially lack free or surface-exposed thiols.

[0146]

[0198] IL-18 polypeptides disclosed herein (eg, DR IL-18) can be characterized by their molecular weight. For example, an IL-18 polypeptide can have a molecular weight of about 18 kDa. In some embodiments, the IL-18 polypeptides disclosed herein are about 13kDa, about 14kDa, about 15kDa, about 16kDa, about 17kDa, about 18kDa, about 19kDa, about 20kDa, about 21kDa, about 22kDa , or has a molecular weight of approximately 23 kDa. In some embodiments, the IL-18 polypeptides disclosed herein are at least about 10 kDa, at least about 11 kDa, at least about 12 kDa, at least about 13 kDa, at least about 14 kDa, at least about 15 kDa, at least about 16 kDa, at least It has a molecular weight of about 17 kDa, at least about 18 kDa, at least about 19 kDa, or at least about 20 kDa. In some embodiments, the IL-18 polypeptides disclosed herein are up to about 17 kDa, up to about 18 kDa, up to about 19 kDa, up to about 20 kDa, up to about 21 kDa, up to about 22 kDa, up to about 23 kDa, up to It has a molecular weight of about 24 kDa, up to about 25 kDa, up to about 30 kDa, up to about 40 kDa, up to about 50 kDa, or up to about 100 kDa. In some embodiments, the IL-18 polypeptides disclosed herein have a molecular weight of about 18.15153 kDa, about 18.1515 kDa, about 18.152 kDa, about 18.15 kDa, about 18.2 kDa, or about 18 kDa.

[0147]

[0199] The IL-18 polypeptides disclosed herein (e.g., DR IL-18) may include, for example, about 130, about 135, about 140, about 145, about 150, about 151, about 152 pieces, about 153 pieces, about 154 pieces, about 155 pieces, about 156 pieces, about 157 pieces, about 158 ​​pieces, about 159 pieces, about 160 pieces, about 161 pieces, about 162 pieces, about 163 pieces, about 1645 pieces, It may contain about 165, about 170, about 175, about 180, about 185, or about 190 amino acids.

[0148]

[0200] In some embodiments, the IL-18 polypeptides disclosed herein (e.g., DR IL-18) have at least about 130, at least about 135, at least about 140, at least about 145, at least about 150, at least about 151, at least about 152, at least about 153, at least about 154, at least about 155, at least about 156, at least about 157, at least about 158, at least about 159, at least Contains about 160 amino acids. In some embodiments, the IL-18 polypeptides disclosed herein (e.g., DR IL-18) have up to about 155, up to about 156, up to about 157, up to about 158, up to Approximately 159 pieces, maximum of approximately 160 pieces, maximum of approximately 161 pieces, maximum of approximately 162 pieces, maximum of approximately 163 pieces, maximum of approximately 1645 pieces, maximum of approximately 165 pieces, maximum of approximately 170 pieces, maximum of approximately 175 pieces, maximum of approximately 180 pieces, maximum Contains about 185 or up to about 190 amino acids. In some embodiments, the IL-18 polypeptides disclosed herein (e.g., DR IL-18) have about 150 to 170, about 152 to about 162, about 155 to about 159, about Contains 156 to about 158 ​​or 157 amino acids.

[0149]

[0201] The IL-18 polypeptides disclosed herein (e.g., DR IL-18, such as DR IL-18 in the formulations of the present disclosure) exhibit biological activity or potency that can be measured by assays for biological activity. It can have levels. A non-limiting example of an assay that can be used to measure the level of potency or biological activity of an IL-18 polypeptide disclosed herein is the IL-18 HEK-Blue potency assay. HEK-Blue IL-18 cells are engineered to detect bioactive IL-18 by monitoring activation of NFκβ and AP-1 pathways. These reporter cells were generated by stable transfection of HEK293-derived cells with genes encoding IL-18Rα and IL-18Rβ. Responses to human TNF-α and IL-1β are also blocked, and cells respond specifically to IL-18. These cells express a secreted placental alkaline phosphatase (SEAP) reporter gene under the control of an IFN-β minimal promoter fused to five NFκβ and five AP-1 binding sites. Binding of bioactive IL-18 to the heterodimeric IL-18 receptor on the surface of HEK-Blue IL-18 cells drives a signaling cascade that results in the production of SEAP, which can be quantified by colorimetric assays. do.

[0150]

[0202] The biological activity or potency of the IL-18 polypeptides disclosed herein (e.g., DR IL-18, such as DR IL-18 in the formulations of the present disclosure) is determined by reference, e.g., wild-type IL-18, or It can be compared to a reference standard of the same IL-18 polypeptide previously produced and characterized. In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18, such as DR IL-18 in a formulation of the present disclosure) is at least 5% of the reference value, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% has a biological activity or efficacy (eg, EC50) of at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. In some embodiments, the IL-18 polypeptides disclosed herein (e.g., DR IL-18, such as DR IL-18 in the formulations of the present disclosure) are up to 105% of the reference value, up to 110%, max 115%, max 120%, max 125%, max 130%, max 135%, max 140%, max 145%, max 150%, max 155%, max 160%, max 165%, max 170% , up to 175%, up to 180%, up to 185%, up to 190%, up to 195%, up to 200%, up to 250%, or up to 300%. In some embodiments, an IL-18 polypeptide disclosed herein (e.g., DR IL-18, such as DR IL-18 in a formulation of the present disclosure) is about 30% to about 500%, about 30% to about 250%, about 30% to about 200%, about 30% to about 175%, about 30% to about 150%, about 30% to about 140%, about 30% to about 130% , about 30% to about 120%, about 30% to about 110%, about 30% to about 105%, about 50% to about 500%, about 50% to about 250%, about 50% to about 200%, about 50% to approximately 175%, approximately 50% to approximately 150%, approximately 50% to approximately 140%, approximately 50% to approximately 130%, approximately 50% to approximately 120%, approximately 50% to approximately 110%, approximately 50% ~105%, 60%~500%, 60%~260%, 60%~200%, 60%~175%, 60%~160%, 60%~260% 140%, about 60% to about 130%, about 60% to about 120%, about 60% to about 110%, about 60% to about 105%, about 70% to about 500%, about 70% to about 250% , about 70% to about 200%, about 70% to about 175%, about 70% to about 150%, about 70% to about 140%, about 70% to about 130%, about 70% to about 120%, about 70% to approximately 110%, approximately 70% to approximately 105%, approximately 90% to approximately 500%, approximately 90% to approximately 250%, approximately 90% to approximately 200%, approximately 90% to approximately 175%, approximately 90% ~about 150%, about 90% to about 140%, about 90% to about 130%, about 90% to about 120%, about 90% to about 110%, or about 90% to about 105%, biological activity or have efficacy (e.g. EC50). In some embodiments, the biological activity or efficacy (eg, EC50) is at least 60% and up to 140% of the reference value.

[0151]

[0203] In some embodiments, the IL-18 polypeptides disclosed herein (e.g., DR IL-18, such as DR IL-18 in the formulations of the present disclosure) are, e.g., IL-18 HEK-Blue at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%, at least more than the biological activity of human wild-type IL-18 as determined by a potency assay. 97.5%, at least 100%, at least 102.5%, at least 105%, at least 110%, at least 115%, at least 120%, at least 125%, at least 130%, at least 140%, at least 150%, or at least 200%, at least 3 have a biological activity or potency (eg, EC50) that is at least 4 times, at least 5 times, at least 6 times, at least 8 times, at least 9 times, or at least 10 times more potent.

[0152]

[0204] In some embodiments, the IL-18 polypeptides disclosed herein are less than about 100 μM, less than about 10 μM, less than about 1 μM, e.g., as determined by an IL-18 HEK-Blue potency assay. lower, less than about 900nM, less than about 800nM, less than about 700nM, less than about 600nM, less than about 500nM, less than about 400nM, less than about 300nM, less than about 200nM, less than about 100nM, less than about 50nM lower, less than about 30 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 900 pM, less than about 800 pM, less than about 700 pM lower, lower than about 600 pM, lower than about 500 pM, lower than about 400 pM, lower than about 300 pM, lower than about 200 pM, lower than about 100 pM, lower than about 50 pM, lower than about 10 pM, or lower than about 1 pM, the EC50 show.

[0153]

[0205] In some embodiments, the IL-18 polypeptides disclosed herein are about 1 pM to about 1 μM, about 1 pM to about 500 nM, about 1pM to about 400nM, about 1pM to about 300nM, about 1pM to about 200nM, about 1pM to about 100nM, about 1pM to about 50nM, about 1pM to about 10pM, about 10pM to about 1μM, about 10pM to about 500nM, about 10pM Approximately 400nM, approximately 10pM to approximately 300nM, approximately 10pM to approximately 200nM, approximately 10pM to approximately 100nM, approximately 10pM to approximately 50nM, approximately 50pM to approximately 1μM, approximately 50pM to approximately 500nM, approximately 50pM to approximately 400nM, approximately 50pM to approximately 300nM , about 50 pM to about 200 nM, about 50 pM to about 100 nM, about 100 pM to about 1 μM, about 100 pM to about 500 nM, about 100 pM to about 400 nM, about 100 pM to about 300 nM, or about 100 pM to about 200 nM.

[0154] nucleic acid

[0206] Also provided herein are nucleic acids encoding any of the proteins described herein (eg, IL-18 proteins with mutations at C38 and C68). Such nucleic acids can take any convenient form (eg, a PCR product, a viral vector, a plasmid, a cosmid, a vector such as a minicircle). In some cases, the nucleotide sequence encoding the IL-18 protein of interest is operably linked to (under the control of) a promoter (e.g., functional in prokaryotic cells or, in some cases, , functional in eukaryotic cells such as yeast or immune cells such as T cells, NK cells, TILs, etc.).

[0155]

[0207] Also provided herein are cells comprising such nucleic acids and / or comprising an IL-18 protein of interest (eg, a stabilized protein). In some cases, the cell is a prokaryotic cell, such as a bacterial cell (e.g., for propagating a nucleic acid or producing a protein of interest); in some cases, the cell is a eukaryotic cell, e.g., yeast cells (e.g., to produce a protein of interest); in some cases, the cells are immune cells, e.g. T cells (e.g., CAR-T cells, e.g. TRUCK cells), TILs, TCR-T cells ( T cells with an engineered TCR, e.g. engineered to bind a target antigen with increased affinity compared to the natural TCR), or NK cells (e.g. CAR-NK cells), e.g. Such cells can be engineered to express (eg, secrete) an IL-18 protein of interest (eg, a stabilized protein such as SEQ ID NO: 19).

[0156] cytokine inhibitor

[0208] In some embodiments, compositions of the present disclosure include an inhibitor of one or more cytokines. In some embodiments, the inhibitor of one or more cytokines is a chemical compound, protein, peptide, peptidomimetic, antibody, ribozyme, small Includes molecular chemical compounds, or antisense nucleic acid molecules (eg, siRNA, miRNA, etc.). In some embodiments, the inhibitor inhibits IL-17, IL-5, or IL-3 expression, activity, or both. In some embodiments, cytokine inhibitors reduce toxicity. In some embodiments, the cytokine inhibitor is an administered IL-18 variant polypeptide (e.g., stabilized IL-18 variant, DR IL-18 variant, D2D IL-18 variant, stabilized DR IL-18 variants, and stabilized D2D IL-18 variants).

[0157] treatment

[0209] In various embodiments, the present disclosure provides methods for stimulating signaling activity through, e.g., at least one IL-18R, in a cell, tissue, organ, system, or subject in need thereof. Compositions comprising activators of IL-18 activity (e.g., stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants, stabilized DR IL-18 variants, and D2D IL-18 variant). In various embodiments, the activators of IL-18 active compositions and methods of treatment of the invention increase the amount of IL-18R signaling, the amount of immune cell activity, or both. In various embodiments, diseases or disorders for which increased IL-18R signaling may improve therapeutic outcomes include, but are not limited to, cancer, infectious diseases, macular degeneration, and metabolic diseases or disorders.

[0158]

[0210] Various IL-18 polypeptides (e.g., IL-18 polypeptides with C38 / C68 mutations) are discussed above, and any of the proteins discussed above can be used in the methods discussed herein. Therefore, it will not be repeated here. For example, in some cases stabilized IL-18 polypeptides (e.g. stabilized IL-18 variant polypeptides, e.g. stabilized DR IL-18 variants and stabilized D2D IL-18 variants) ), for example, in diseases or disorders such as cancer or infections (e.g., cancers that are resistant to immune checkpoint inhibitors, cancers that are associated with tumors that have reduced or no expression of MHC class I, high levels of cancers associated with IL-18BP (e.g., circulating or expressed by tumors), cancers associated with tumors in which IL-18R is expressed on infiltrating T cells or NK cells, metabolic diseases or disorders; It is used to treat infectious diseases, viral infections such as HIV, etc.

[0159]

[0211] In some cases, the administered polypeptide is a wild-type IL-18 polypeptide (eg, wild-type human IL-18 protein). In some cases, the administered polypeptide is a stabilized IL-18 polypeptide of interest (eg, one containing amino acid mutations at positions C38 and C68 relative to SEQ ID NO: 30). In some cases, the administered polypeptide is an IL-18 variant polypeptide, such as a DR IL-18 variant or a D2D IL-18 variant. In some cases, the administered polypeptide is a stabilized IL-18 variant polypeptide (e.g., a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant - e.g., as described above). (See Stabilized DR IL-18 Variant Polypeptides Discussed).

[0160] Fusion / conjugation

[0212] In some embodiments, an IL-18 polypeptide of the present disclosure (e.g., a stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g. , SEQ ID NO: 19) can be conjugated to another molecule (e.g. fused to another protein), i.e. the IL-18 variant polypeptide can be fused in frame with the second polypeptide (fusion partner). . In some embodiments, the second polypeptide (fusion partner) can increase the overall size of the fusion protein, eg, the fusion protein will not be rapidly cleared from circulation. In some cases, an IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., SEQ ID NO: 19 ) is not fused to a second polypeptide.

[0161]

[0213] In some embodiments, the second polypeptide (fusion partner of the IL-18 variant polypeptide or fragment thereof) is part or all of an immunoglobulin Fc region (ie, an antibody Fc sequence). In other embodiments, the second polypeptide is any material that is substantially similar to Fc, e.g., provides increased size, multimerization domains, and / or additional binding or interaction with Ig molecules. is a preferred polypeptide. In some embodiments, the second polypeptide is part or all of human serum albumin (HSA). In some embodiments, the second polypeptide is part or all of an antibody, antibody fragment, camel antibody, or "nanobody" or other affinity reagent that binds or interacts with HSA. These fusion proteins can facilitate purification, multimerization, and exhibit increased half-life in vivo. Fusion proteins with disulfide-linked multimeric structures may also be more effective at binding and neutralizing other molecules in some cases.

[0162]

[0214] When fused to a heterologous polypeptide, a portion corresponding to an IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (eg, SEQ ID NO: 19) may be referred to as the "IL-18 variant polypeptide portion" of the IL-18 variant polypeptide of interest.

[0163]

[0215] In some cases, the second polypeptide is a marker sequence (eg, an affinity tag), eg, a peptide that facilitates purification of the fused polypeptide. For example, the marker amino acid sequence can be a hexa-histidine peptide, such as a tag provided in the pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311), many of which are commercially available. obtain. For example, hexahistidine provides convenient purification of fusion proteins, as described in Gentz ​​et al., Proc. Natl. Acad. Sci. USA 86:821-824, 1989. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from influenza hemagglutinin protein. Wilson et al., Cell 37:767, 1984. The addition of peptide moieties to facilitate manipulation of polypeptides is a common technique well known in the art. A subject IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., SEQ ID NO: 19) can be modified For example, it can be conjugated / conjugated to a wide variety of other oligopeptides, proteins, and / or non-protein moieties for various purposes. For example, it is modified post-translationally by prenylation, acetylation, amidation, carboxylation, glycosylation, PEGylation (covalent attachment of polyethylene glycol (PEG) polymer chains), and the like. Such modifications may include alterations in glycosylation, e.g., by exposure of the polypeptide to enzymes that affect glycosylation, such as mammalian glycosylation or deglycosylation enzymes, during its synthesis and processing, or by further They may also include those created by altering the glycosylation pattern of a polypeptide during a processing step. In some embodiments, the subject IL-18 variant polypeptide has one or more phosphorylated amino acid residues, such as phosphotyrosine, phosphoserine, or phosphothreonine.

[0164]

[0216] In some embodiments, the IL-18 polypeptides disclosed herein are glycosylated. In some embodiments, the IL-18 polypeptides disclosed herein are not glycosylated.

[0165]

[0217] In some embodiments, an IL-18 polypeptide disclosed herein is conjugated to a water-soluble polymer. In some embodiments, the IL-18 polypeptides disclosed herein are pegylated. In some embodiments, the IL-18 polypeptides disclosed herein are polyethylene glycol homopolymers, polyethylene glycol copolymers, polypropylene glycol homopolymers, poly(N-vinylpyrrolidone), poly(vinyl alcohol), (ethylene glycol-co-propylene glycol), poly(N-2-(hydroxypropyl)methacrylamide), poly(sialic acid), poly(N-acryloyl morpholino), or dextran.

[0166]

[0218] In some embodiments, the IL-18 polypeptides disclosed herein are not conjugated to a water-soluble polymer. In some embodiments, the IL-18 polypeptides disclosed herein are not pegylated. In some embodiments, the IL-18 polypeptides disclosed herein are polyethylene glycol homopolymers, polyethylene glycol copolymers, polypropylene glycol homopolymers, poly(N-vinylpyrrolidone), poly(vinyl alcohol), (ethylene glycol-co-propylene glycol), poly(N-2-(hydroxypropyl)methacrylamide), poly(sialic acid), poly(N-acryloyl morpholino), or dextran.

[0167]

[0219] In some other embodiments, an IL-18 polypeptide of the present disclosure (e.g., a stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (eg, SEQ ID NO: 19) includes reagents that have been further modified to improve their resistance to proteolytic degradation or to optimize their solubility properties or to make them more suitable as therapeutic agents. For example, variants of the present disclosure further include analogs containing residues other than naturally occurring L-amino acids, such as D-amino acids or non-naturally occurring synthetic amino acids. D-amino acids may be substituted for some or all amino acid residues.

[0168] Co-administration and multispecific IL-18 variant polypeptides

[0220] In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence No. 19) is administered with further drugs. The terms “co-administration,” “co-administer,” and “in combination with” mean simultaneously, concurrently, or without a specific time limit. Includes administration of two or more therapeutic agents (eg, the subject's stabilized IL-18) either sequentially. In some embodiments, the agents are simultaneously present within the cell or within the subject, or exert a biological or therapeutic effect at the same time. In some embodiments, the therapeutic agents are within the same composition or unit dosage form. In other embodiments, the therapeutic agents are in separate compositions or unit dosage forms. In certain embodiments, the first agent is administered within minutes (e.g., minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, etc.) prior to administration of the second therapeutic agent. concurrently with the administration of the second therapeutic agent (24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before); or following administration of a second therapeutic agent (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 hours).

[0169]

[0221] In some cases, a subject IL-18 polypeptide (e.g., stabilized IL-18, e.g. stabilized DR IL-18 variant or stabilized IL-18 variant) (e.g., formulated as a pharmaceutical composition) (eg, SEQ ID NO: 19) is co-administered with a cancer therapeutic, a therapeutic to treat an infection, or an antibody against cancer. Such administration may include simultaneous (ie, at the same time), prior to, or subsequent administration of the drug / antibody with respect to administration of one or more agents of the present disclosure. Those skilled in the art will have no difficulty determining the appropriate timing, sequence and dosage of administration of the particular drugs and compositions of this disclosure.

[0170]

[0222] In some embodiments, treatment involves combining the IL-18 polypeptide of interest (e.g., a stable stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g. SEQ ID NO:19) . One example class of cytotoxic agents that can be used is chemotherapeutic agents. Exemplary chemotherapeutic agents include, but are not limited to, aldesleukin, altretamine, amifostine, asparaginase, bleomycin, capecitabine, carboplatin, carmustine, cladribine, cisapride, cisplatin, cyclophosphamide, cytarabine, dacarbazine (DTIC), Tinomycin, docetaxel, doxorubicin, dronabinol, duocarmycin, etoposide, filgrastim, fludarabine, fluorouracil, gemcitabine, granisetron, hydroxyurea, idarubicin, ifosfamide, interferon alfa, irinotecan, lansoprazole, levamisole, leucovorin, megestrol, mesna , methotrexate, metoclopramide, mitomycin, mitotane, mitoxantrone, omeprazole, ondansetron, paclitaxel (Taxol(TM)), pilocarpine, prochloroperazine, rituximab, saproin, tamoxifen, taxol, topotecan hydrochloride , including trastuzumab, vinblastine, vincristine and vinorelbine tartrate.

[0171]

[0223] A subject IL-18 polypeptide (e.g., a stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., SEQ ID NO: 19) has an active The drug is optionally formulated with, but is not necessarily, formulated with one or more agents that enhance or otherwise increase the therapeutic effect. In some embodiments, the treatment is directed to the IL-18 polypeptide of interest (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (eg, SEQ ID NO: 19) and an agent that opsonizes the target cells (co-administration). Accordingly, herein, (a) an IL-18 polypeptide of interest (e.g., a stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (eg, SEQ ID NO: 19); and (b) compositions (and methods of using the compositions) comprising an agent that opsonizes a target cell. In some cases, the agent that opsonizes the target cells is rituximab. In some cases, the agent that opsonizes the target cells is cetuximab.

[0172]

[0224] An "agent that opsonizes a target cell" (an "opsonizing agent") is capable of binding to a target cell (e.g., a cancer cell, a cell with an intracellular pathogen, etc.) and is capable of opsonizing a target cell (e.g., Any agent that marks target cells for phagocytosis and / or antibody-dependent cell-mediated cytotoxicity (ADCC). For example, any antibody that has an FC region and is capable of binding to a target cell (eg, a cancer cell, such as a tumor cell) is considered an agent that opsonizes the target cell. In some cases, the agent that opsonizes the target cell is an antibody that binds to the target cell (eg, an anti-tumor antibody, an anti-cancer antibody, an anti-infectious antibody, etc.).

[0173]

[0225] For example, antibodies selective for tumor cell markers, radiation, surgery, and / or hormone deprivation, see Kwon et al., Proc. Natl. Acad. Sci U.S.A., 96:15074-9, 1999.

[0174]

[0226] Angiogenesis inhibitors may also be combined with the methods of the invention. Many antibodies are currently in clinical use for the treatment of cancer, and others are in various stages of clinical development. For example, there are many antigens and corresponding monoclonal antibodies for the treatment of B cell malignancies. One target antigen is CD20. Rituximab is a chimeric, unconjugated monoclonal antibody directed against the CD20 antigen. CD20 has an important functional role in B cell activation, proliferation, and differentiation. The CD52 antigen is targeted by the monoclonal antibody alemtuzumab, which is indicated for the treatment of chronic lymphocytic leukemia. CD22 is targeted by many antibodies and its efficacy in combination with toxins has recently been demonstrated in chemotherapy-resistant hairy cell leukemia. Two new monoclonal antibodies targeting CD20, tositumomab and ibritumomab, have been submitted to the Food and Drug Administration (FDA). These antibodies are conjugated with radioactive isotopes. Alemtuzumab (Campath) is used in the treatment of chronic lymphocytic leukemia; gemtuzumab (Mylotarg) is found for use in the treatment of acute myeloid leukemia; ibritumomab (Zavalin) is used in the treatment of non-Hodgkin's lymphoma. Panitumomab (Vectibix) finds use in the treatment of colon cancer.

[0175]

[0227] Monoclonal antibodies useful in the methods of the present disclosure for use in solid tumors include, but are not limited to, edrecolomab and trastuzumab (Herceptin). Edrecolomab targets the 17-1A antigen found in colon and rectal cancer and is approved for use in Europe for these indications. Traszumab targets the HER-2 / neu antigen. Cetuximab (Erbitux) is also of interest for use in the methods of the present disclosure. The antibody binds to the EGF receptor (EGFR) and is used in the treatment of solid tumors, including colon cancer and squamous cell carcinoma of the head and neck (SCCHN).

[0176]

[0228] The subject IL-18 polypeptide (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant, etc.) can be administered to any of the above agents (e.g., agents such as antibodies that opsonize target cells). Thus, in some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) Used in combination therapy (co-administered) with one or more opsonizing agents selective for cancer cells, e.g. tumor cells. In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, such as the stabilized DR IL-18 variant or the stabilized D2D IL-18 variant) is (binds EGFR), panitumumab (binds EGFR), rituximab (binds CD20), trastuzumab (binds HER2), pertuzumab (binds HER2), alemtuzumab (binds CD52), brentuximab ( used in combination therapy (co-administered) with one or more of the following: tositumomab, ibritumomab, gemtuzumab, ibritumomab, and edrecolomab (which binds to 17-1A), or combinations thereof.

[0177]

[0229] In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence No. 19) is a cancer cell opsonizing agent (e.g., CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD37, CD38, CD44, CD45, CD47, CD51, CD52, CD56, CD62L, CD70, CD74, CD79, CD80, CD96, CD97, CD99, CD123, CD134, CD138, CD152(CTLA-4), CD200, CD213A2, CD221, CD248, CD276(B7H3), B7H4, CD279(PD-1), CD274(PD-L1) ), CD319, SIRPa, EGFR, EPCAM, 17-1A, HER1, HER2, HER3, CD117, C-Met, HGFR, PDGFRA, AXL, TWEAKR, PTHR2, HAVCR2(TIM3), GD2 ganglioside, MUC1, mucin CanAg, mesothelin , endoglin, Lewis-Y antigen, CEA, CEACAM1, CEACAM5, CA-125, PSMA, BAFF, FGFR2, TAG-72, gelatinase B, glypican 3, nectin-4, BCMA, CSF1R, SLAMF7, integrin αvβ3, TYRP1, GPNMB, CLDN18.2, FOLR1, CCR4, CXCR4, MICA, C242 antigen, DLL3, DLL4, EGFL7, vimentin, fibronectin extra domain-B, TROP-2, LRRC15, FAP, SLITRK6, NOTCH2, NOTCH3, tenascin-3, STEAP1 , or NRP1, or any combination thereof).

[0178]

[0230] In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence Number 19) is CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD47, SIRPA, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279(PD-1), CD274( PD-L1), EGFR, 17-1A, HER2, CD117, C-Met, PTHR2, and HAVCR2 (TIM3).

[0179]

[0231] In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence No. 19) is used in combination therapy (co-administered) with conventional immunomodulators (eg immune checkpoint inhibitors or immune agonists). As mentioned above, examples of targets for immune checkpoint inhibitors include, but are not limited to: PD-L1, PD1, CTLA4, TIM3, TIGIT, LAG3, B7H3, B7H4, VISTA, BTLA, CD47, SIRP alpha, CD48. , CD155, CD160, TREM2, IDO1, adenosine 2A receptor, aryl hydrocarbon receptor, KIR, and LILRB2. Thus, examples of immune checkpoint inhibitors include proteins such as: PD-L1, PD1, CTLA4, TIM3, TIGIT, LAG3, B7H3, B7H4, VISTA, BTLA, CD47, SIRP alpha, CD48, CD155, CD160, TREM2, Includes agents (eg, antibodies) that inhibit IDO1, adenosine 2A receptor, aryl hydrocarbon receptor, KIR, and LILRB2. In some cases, the stabilized variant IL-18 polypeptide (e.g., DR-IL-18 variant, D2D-IL-18 variant) (e.g., SEQ ID NO: 19) of interest is PD-L1, PD1, CTLA4, TIM3, TIGIT, LAG3, B7H3, B7H4, VISTA, BTLA, CD47, SIRP alpha, CD48, CD155, CD160, TREM2, IDO1, adenosine 2A receptor, aryl hydrocarbon receptor, KIR, LILRB2, or any of these co-administered with an immune checkpoint inhibitor (eg, an antibody) that inhibits the combination of

[0180]

[0232] In some cases, a subject stabilized IL-18 variant polypeptide (e.g., DR-IL-18 variant, D2D-IL-18 variant) (e.g., SEQ ID NO: 19) is co-administered with an immune agonist. Ru. Examples of immune agonists include proteins such as tumor necrosis factor receptor superfamily (TNFRSF) proteins (e.g., GITR, 41BB, OX40, CD27, CD40, HVEM); immunoglobulin superfamily (IgSF) proteins (e.g., CD28, ICOS); , CD226, NKG2D); TLRs (e.g., TLR2, TLR4, TLR5, TLR7, TLR9); nucleic acid sensors (e.g., STING, cGAS, RIG-I (DDX58)); . Examples of immune agonists also include, but are not limited to, inflammasome activators (agonists); T cell engagers (e.g., multispecific agents that cross-link CD3 and / or CD28 with tumor antigens, e.g., BiTE); and Cytokines or cytokine variants (e.g., IL-2, IL-7, IL-10, IL-12, IL-15, IL-21, IL-23, IL-27, IL-33, TNF, TL1A, IFNA, IFNB , IFNG).

[0181]

[0233] Thus, in some cases, a stabilized IL-18 variant polypeptide (e.g., DR-IL-18 variant, D2D-IL-18 variant) (e.g., SEQ ID NO: 19) of interest is an immune agonist, e.g. , agents (e.g., antibodies) that agonize tumor necrosis factor receptor superfamily (TNFRSF) proteins (e.g., GITR, 41BB, OX40, CD27, CD40, HVEM); immunoglobulin superfamily (IgSF) proteins (e.g., CD28, Agents (e.g., antibodies) that agonize TLRs (e.g., TLR2, TLR4, TLR5, TLR7, TLR9); Nucleic acid sensors (e.g., STING, cGAS, RIG-I (DDX58)); ); inflammasome activators; T cell engagers (e.g. multispecific agents that cross-link CD3 and / or CD28 with tumor antigens, e.g. BiTE); cytokines or cytokine variants (e.g. IL-2 or any combination thereof co-administered with

[0182]

[0234] In some cases, the stabilized IL-18 variant polypeptide (e.g., DR-IL-18 variant, D2D-IL-18 variant) (e.g., SEQ ID NO: 19) of interest is a TGF beta antagonist, e.g. TGF beta antibody; co-administered with interferons such as interferon alpha, interferon beta, or interferon gamma; TNF; TRAIL; lymphotoxin; LIGHT / TNSF14, etc.

[0183]

[0235] In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence No. 19) is used in combination therapy (co-administered) with inhibitors of BTLA and / or CD160. In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence No. 19) is used in combination therapy (co-administered) with anti-CD47 / SIRPA agents (eg, anti-CD47, anti-SIRPA, high affinity CD47 binding agents, high affinity SIRPA binding agents, etc.). In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence No. 19) is used in combination therapy (co-administered) with inhibitors of TIM3 and / or CEACAM1.

[0184]

[0236] In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence No. 19) is fused with another protein (ie, "fusion partner", "second polypeptide"). In some embodiments, the second polypeptide (the fusion partner of the IL-18 variant polypeptide of interest) is other than the target molecule bound by the IL-18 variant polypeptide portion of the fusion protein (e.g., IL-18R specifically binds to a target molecule of a variant other than IL-18R that binds to IL-18R; or a variant other than IL-18BP that binds to IL-18BP).

[0185]

[0237] Thus, in some embodiments, a subject IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) ( For example, SEQ ID NO: 19) is polyspecific (eg, bispecific). The term "multispecific" or "bispecific" refers to at least one region (e.g., a ligand or Fab of a first antibody) that is specific for a first target, and one region that is specific for a second target. It is commonly used to refer to an agent (eg, a ligand or an antibody) that recognizes two or more different antigens by having at least one second region (eg, a ligand or a Fab of a second antibody). Bispecific agents specifically bind to two targets and are therefore a type of multispecific agent.

[0186]

[0238] In some embodiments, a subject IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., SEQ ID NO: 19) is multispecific (e.g., bispecific) in which the first region of the polypeptide comprises the IL-18 variant polypeptide sequence of interest (i.e., the first region contains the IL-18 variant polypeptide sequence of interest). variant polypeptide), the second region specifically binds another target molecule (eg, an antigen). For example, in some cases, IL-18 polypeptides (e.g., stabilized IL-18, such as stabilized DR IL-18 variants or stabilized D2D IL-18 variants) (e.g., sequences No. 19) is fused to a second polypeptide that specifically binds to a target molecule other than the target molecule bound by the IL-18 variant polypeptide.

[0187]

[0239] Any one of the agents discussed above in the context of co-administration may be administered to a subject IL-18 polypeptide (e.g., stabilized IL-18, e.g. stabilized DR IL-18 variant or stabilized (eg, SEQ ID NO: 19). The term "co-administration" as used herein is meant to include such conjugated compounds. For example, when drug 1 is co-administered with drug 2, the term is meant to encompass embodiments in which drug 1 and drug 2 are not conjugated to each other, and embodiments in which drug 1 and drug 2 are conjugated to each other. is also meant to include (eg, drug 1 and drug 2 are both proteins and drug 1 is fused to drug 2).

[0188]

[0240] In some cases, a multispecific IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., The second region of SEQ ID NO: 19) contains a checkpoint inhibitor. In some cases, the second region of the multispecific IL-18 variant polypeptide includes PD-L1, PD1, CTLA4, TIM3, TIGIT, LAG3, B7H3, B7H4, VISTA, BTLA, CD47, SIRP alpha, CD48 , CD155, CD160, TREM2, IDO1, adenosine 2A receptor, aryl hydrocarbon receptor, KIR, and LILRB2.

[0189]

[0241] In some cases, a multispecific IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., The second region of SEQ ID NO: 19) contains an immune agonist. In some cases, the second region of the multispecific IL-18 variant polypeptide agonizes one or more proteins selected from ICOS, GITR, 41BB, OX40, and CD40. of a multispecific IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., SEQ ID NO: 19). Further examples of immune agonists that can be used as (or can be used as part of) region 2 include, but are not limited to, tumor necrosis factor receptor superfamily (TNFRSF) proteins (e.g., GITR, 41BB, OX40, agents (e.g., antibodies or their antigen-binding regions) that agonize immunoglobulin superfamily (IgSF) proteins (e.g., CD28, ICOS, CD226, NKG2D); agents that agonize TLRs (e.g., TLR2, TLR4, TLR5, TLR7, TLR9); agents that agonize nucleic acid sensors (e.g., STING, cGAS, RIG-I (DDX58)); inflammasome activation factors; T cell engagers (e.g. multispecific agents that cross-link CD3 and / or CD28 with tumor antigens, e.g. BiTE); cytokines or cytokine variants (e.g. IL-2, IL-7, IL-10, IL- 12, IL-15, IL-21, IL-23, IL-27, IL-33, TNF, TL1A, IFNA, IFNB, IFNG); etc.

[0190]

[0242] In some cases, a multispecific IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., The second region of SEQ ID NO: 19) is a cancer cell opsonizer. In some cases, the second region of the multispecific IL-18 variant polypeptide is CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD47, SIRPA, CD52, CD56, CD70, One or more selected from CD96, CD97, CD99, CD123, CD279(PD-1), CD274(PD-L1), EGFR, 17-1A, HER2, CD117, C-Met, PTHR2, and HAVCR2(TIM3) Target multiple proteins. In some cases, a multispecific IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., The second region of SEQ ID NO: 19) includes CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD47, SIRPA, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD -1), an opsonizing agent that targets one or more proteins selected from CD274 (PD-L1), EGFR, 17-1A, HER2, CD117, C-Met, PTHR2, and HAVCR2 (TIM3). be.

[0191]

[0243] For example, in some cases, a multispecific IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) ( For example, the second region of SEQ ID NO: 19) may contain an ectodomain, e.g. polypeptide). In some cases, the second region of the multispecific IL-18 variant polypeptide includes CTLA-4, Lag-3, BTLA, Tim-3, CD244, CD40, CD40L, CD47, SIRPA, PD-1, and PD-L1.

[0192]

[0244] In some embodiments, the IL-18 variant polypeptide has increased biological activity compared to wild-type IL-18. In some embodiments, the IL-18 variant does not contain cysteine ​​residues compared to those that naturally occur in wild-type IL-18. In some embodiments, the IL-18 variant polypeptide comprises an amino acid sequence without pegylated amino acids.

[0193]

[0245] In some embodiments, the subject IL-18 variant polypeptide (eg, stabilized IL-18) includes a linker (eg, a linker polypeptide). For example, in some embodiments, a subject IL-18 variant polypeptide and a fusion partner are separated by a linker (eg, a linker polypeptide). Linker polypeptides can have any of a variety of amino acid sequences. The proteins are joined by a linker polypeptide and may be flexible (eg, a flexible linker polypeptide), although other chemical bonds are not excluded. Suitable linkers include polypeptides between about 6 and about 40 amino acids in length, or between about 6 and about 25 amino acids in length. These linkers can be produced by using synthetic, linker-encoding oligonucleotides that join the proteins. Peptide linkers with some degree of flexibility may be used. The linking peptides can have virtually any amino acid sequence, bearing in mind that in some cases the linker will normally have a sequence resulting in a flexible peptide. The use of small amino acids such as glycine and alanine is of use in creating flexible peptides. Creation of such sequences is routine to those skilled in the art. A variety of different linkers are commercially available and are considered suitable for use.

[0194]

[0246] In some embodiments, the IL-18 variant polypeptide (e.g., stabilized IL-18) is used in immune cells, e.g., tumor-infiltrating lymphocytes (TILs), CAR-T, TCR-T cells (engineered transduced by a TCR, e.g., a TCR that has been engineered to bind a target antigen with increased affinity compared to the native TCR), a CAR-NK cell, or an engineered T-cell receptor. Co-administered with other T or NK cells. In other embodiments, the IL-18 variant polypeptide is co-administered with an oncolytic virus.

[0195]

[0247] In some embodiments, a nucleic acid encoding an IL-18 variant polypeptide (e.g., stabilized IL-18) is used in engineered ("altered") immune cells, e.g., CAR-T, TCR- T cells, or CAR-NK cells, or T or NK cells transduced by engineered T cell receptors or tumor-infiltrating lymphocytes (TILs). In this example, the engineered cells (eg, engineered T cells, engineered NK cells, engineered TILs) will secrete the IL-18 variant polypeptide. The ability to secrete IL-18 variant peptides can be controlled in a contextual manner (eg, activated within the tumor microenvironment), eg, by synthetic NOTCH receptors.

[0196]

[0248] In some embodiments, a nucleic acid encoding an IL-18 variant polypeptide (eg, stabilized IL-18) is contained within an oncolytic virus. In this example, a cell infected by an oncolytic virus will secrete an IL-18 variant polypeptide.

[0197]

[0249] In some embodiments, an IL-18 variant polypeptide (eg, stabilized IL-18) is administered to a cell, tissue, organ, system, or subject to treat a disease or disorder. In some embodiments, human IL-18 variant polypeptides are administered to a cell, tissue, organ, system, or subject. In some embodiments, the nucleic acid (e.g., DNA, cDNA, mRNA, etc.) encoding at least one human IL-18 variant polypeptide (e.g., stabilized IL-18) is present in a cell, tissue, organ, etc. system, or administered to a subject.

[0198]

[0250] In some embodiments, compositions of the invention are administered to murine cells, tissues, organs, systems or subjects to treat or prevent a disease or disorder. In some embodiments, a murine IL-18 variant polypeptide, or fragment thereof, is administered to a cell, tissue, organ, system, or subject (eg, a human cell, tissue, organ, system, or subject). In some embodiments, a nucleic acid (eg, DNA, cDNA, mRNA, etc.) encoding at least one murine IL-18 variant polypeptide is administered to a cell, tissue, organ, system, or subject. As described elsewhere herein, examples of murine IL-18 variant polypeptides (in this case, DR IL-18 variants) include, but are not limited to, SEQ ID NOs: 60-72. Also, as described elsewhere herein, examples of murine IL-18 variants (in this case the D2D IL-18 variant that binds to IL-18BP but have reduced binding to IL-18R) include , including, but not limited to, SEQ ID NOS: 126-190.

[0199]

[0251] In some embodiments, the methods provide an isolated nucleic acid molecule encoding one or more IL-18 variant polypeptides described herein (e.g., stabilized IL-18) to a subject. , cells, or tissues. Increasing the level of IL-18 signaling, including by using IL-18 variant polypeptides (e.g., stabilized IL-18), can be achieved in a wide variety of ways, including those disclosed herein. , as well as methods known in the art or developed in the future. That is, based on the disclosure provided herein, one skilled in the art will appreciate that an increase in the level or activity of IL-18 signaling occurs in a biological sample obtained from a subject. Assessing the level of nucleic acid (e.g., mRNA) encoding the fragment, the level of IL-18 or IL-18 variant polypeptide or polypeptide fragment, and / or the level of IL-18 or IL-18 variant polypeptide or fragment activity It will be appreciated that this can be easily evaluated using the following methods:

[0200]

[0252] One skilled in the art will appreciate that, based on the disclosure provided herein, the compositions of the present disclosure (IL-18 variant polypeptides, e.g., stabilized IL-18) can be administered in whole (e.g., systemic) or in part (e.g., will find use in subjects that are or will be treated for diseases or disorders that would benefit from increased IL-18 signaling activity (locally, in cells, tissues, organs). . Based on the teachings provided herein, those skilled in the art will recognize that diseases and disorders treatable by the compositions and methods described herein are those in which increased IL-18 signaling is associated with biological, physiological, and clinical or any disease or disorder that would facilitate a positive outcome of treatment.

[0201]

[0253] In some embodiments, the method comprises at least one IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant). ) (eg, SEQ ID NO: 19) to a subject in need thereof; and administering to the subject a composition comprising an additional agent. In one such embodiment, the additional agent comprises, but is not limited to, modified T cells, chimeric antigen receptor T cells (CAR-T), armed CAR-T cells, chimeric antigen receptor NK cells ( at least one selected from the group comprising: CAR-NK), TCR-T cells, tumor-infiltrating lymphocytes (TILs), viruses, antigens, vaccines, antibodies, immune checkpoint inhibitors, small molecules, chemotherapeutic agents, and stem cells. Including immunotherapeutic agents, including: In some embodiments, at least one IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g. , SEQ ID NO: 19) are used in methods of increasing the activity of the immune system before, during, or after infection by bacteria, viruses, or other pathogens. In some embodiments, compositions comprising at least one IL-18 variant polypeptide improve the number and / or activity of immune cells in vitro, in vivo, or ex vivo, e.g., T cells, NK cells, and / or or used in a method of increasing the number and / or activity of myeloid cells.

[0202]

[0254] In some embodiments, the additional therapeutic agent includes an inhibitor of one or more cytokines. In some embodiments, the inhibitor of one or more cytokines is a chemical compound, protein, peptide, peptidomimetic, antibody, ribozyme, small Includes molecular chemical compounds, or antisense nucleic acid molecules (eg, siRNA, miRNA, etc.). In some embodiments, the inhibitor inhibits IL-17, IL-5, or IL-3 expression, activity, or both. In some embodiments, administration of a cytokine inhibitor reduces toxicity. In some embodiments, the administration of a cytokine inhibitor comprises the administration of an administered IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a D2D IL-18 variant). ) (eg, SEQ ID NO: 19).

[0203]

[0255] As used herein, the term "pharmaceutically acceptable carrier" refers to a suitable IL-18 polypeptide (e.g., stabilized IL-18, e.g. stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., SEQ ID NO: 19), and after combination, the IL-18 polypeptide (e.g., stabilized IL-18, e.g. stabilized DR IL-18). or a stabilized D2D IL-18 variant) (eg, SEQ ID NO: 19) to a subject.

[0204] Production of IL-18 variants SUMO protease

[0256] Compositions and methods are provided for creating a polypeptide of interest (e.g., an inactive protein) by using a SUMO (small ubiquitin-like modifier) ​​protease that cleaves the SUMO tag of the polypeptide of interest. . A SUMO tag may be placed at the N-terminus of the protein of interest, and a SUMO protease (eg, ULP1) may provide for scarless removal of the SUMO tag via a cleavage reaction. In some cases, cleavage will occur intracellularly (eg, within bacterial cells, yeast cells); in other cases, cleavage will occur in vitro, cell-free.

[0205]

[0257] For example, in some cases, a fusion protein (comprising the protein of interest fused at its N-terminus to a SUMO tag) is introduced into a bacterial cell (e.g., via a nucleic acid encoding the fusion protein) and SUMO The protease will also be introduced into the same cell (in such a case both proteins are said to have been introduced exogenously) and the cleavage reaction will therefore occur within the cell. In some cases, the protease is encoded by a nucleic acid that is integrated into the genome of the cell; in some cases, the nucleic acid will not be integrated (eg, it may be a plasmid). The SUMO protease may be expressed from a constitutive promoter or may be operably linked to (under the control of) an inducible promoter, such as the rhamnose inducible promoter. Any convenient inducible promoter may be used. As such, in some such cases, contacting the fusion protein with a SUMO protease within a cell (eg, a bacterial cell) may include inducing expression of the SUMO protease.

[0206]

[0258] In some cases, the fusion protein and SUMO protease are encoded by the same nucleic acid (eg, a plasmid). In some such cases, both proteins are operably linked to the same promoter (e.g., they can be translated from bicistronic mRNAs), and in other cases, the two proteins are linked to separate promoters. operably coupled.

[0207]

[0259] In some cases, the fusion protein is contacted with SUMO protease in an in vitro environment, cell-free. For example, the fusion protein can be purified / isolated and then contacted with purified SUMO protease (readily available).

[0208]

[0260] If the polypeptide of interest is an IL-18 polypeptide (e.g., wild-type IL-18, stabilized IL-18 variant, DR IL-18 variant, D2D IL-18 variant, stabilized DR IL-18 variant) , stabilized D2D IL-18 variants) (e.g., SEQ ID NO: 19), such proteins are not fully active when the N-terminal amino acid is methionine (e.g., human wild-type The IL-18 protein is normally cleaved by caspase 1 to expose the N-terminal tyrosine and yield the active mature form). Accordingly, the methods of the present disclosure can be used to produce active IL-18 polypeptides. In such cases, the SUMO (small ubiquitin-like modifier) ​​tag promotes the production of large quantities of the fusion protein (IL-18+SUMO tag), followed by removal of the SUMO tag and activation of the N-terminus. IL-18 proteins (eg, those with tyrosine, but not methionine) can be exposed. The SUMO tag can be removed by contacting the fusion protein with a SUMO protease (eg, yeast ULP1) that cleaves the tag to expose the natural N-terminal amino acid (Tyr in the case of human IL-18). In some cases, the contacting step is performed within a cell, such as a bacterial cell. In some such cases, the active protein produced can then be purified, eg, from a cell lysate (see below for further details).

[0209]

[0261] Any convenient SUMO tag may be used, one example of which is set forth as SEQ ID NO:26. In some cases, it is desirable to include an additional tag on top of the SUMO tag (eg, a 6XHis tag), eg, for subsequent purification (see below). SEQ ID NO: 27 provides one non-limiting example of such a tagged SUMO tag.

[0210] Purification step

[0262] In some embodiments, the subject "method of making" / "producing" further comprises purifying the polypeptide of interest after the SUMO tag has been removed (e.g., an IL-18 polypeptide, e.g. (eg, SEQ ID NO: 19). In some such cases, cleavage (SUMO tag removal) occurs in vitro, cell-free, and purification may include removal of the SUMO tag and SUMO protease. For example, in some cases, SUMO proteases and / or SUMO tags may be tagged (e.g., His-tagged), which in some cases can be used after cleavage, e.g., for purification of the polypeptide of interest. Immobilized metal affinity chromatography (IMAC), such as a nickel column, can be used to facilitate removal of these components.

[0211]

[0263] In some cases, cleavage (SUMO tag removal) occurs in cells (eg, bacterial cells discussed above) and the polypeptide of interest is purified from the cell lysate. In some cases, the polypeptide of interest is secreted into the medium (eg, in some cases when using yeast cells) and then purified from the medium. Any convenient step or series of steps can be used to purify the protein from, for example, a bacterial lysate or a medium in which the protein was secreted. In some cases (e.g., the polypeptide of interest is an IL-18 polypeptide, e.g., a stabilized IL-18 variant, a DR IL-18 variant, a D2D IL-18 variant, a stabilized DR IL-18 variant) In some cases, such as stabilized D2D IL-18 variants (e.g., SEQ ID NO: 19), purification can be performed by ion-exchange chromatography (e.g., Capto Q), IMAC (e.g., remaining his-tagged removed SUMO, uncleaved proteins, and / or proteases), multimodal chromatography (e.g., Capto MMC chromatography - Capto MMC mediates the capture and purification of proteins from bulk supplies by packed bed chromatography. hydrophobic interaction chromatography (HIC) (e.g., phenyl Sepharose HIC in some cases). In some cases, fast Q chromatography is also performed. In some such cases, ultrafiltration (UF) and diafiltration (DF) steps are performed before each chromatography step. See Figure 48 for an example of one possible purification process.

[0212]

[0264] It will be understood by those skilled in the art that the invention, including the methods detailed herein and armed with this disclosure, is not limited to the treatment of diseases or disorders once established. In particular, the symptoms of the disease or disorder need not be manifest to the point of harm to the subject, and indeed the disease or disorder need not be detected in the subject before treatment is administered. That is, significant pathology from a disease or disorder does not need to have occurred before the present invention can provide benefit. Accordingly, the invention, as more fully described herein, includes methods of preventing diseases and disorders in a subject, and as discussed elsewhere herein, activators of IL-18 activity are , may be administered to a subject prior to the onset of the disease or disorder, thereby preventing the onset of the disease or disorder.

[0213] Pharmaceutical compositions of the present disclosure

[0265] Polypeptides, polypeptide fragments, IL-18 polypeptides (e.g., stabilized IL-18, e.g. stabilized DR IL-18 variants or stabilized D2D IL-18) as described elsewhere herein. 18 variants, etc.) (eg, SEQ ID NO: 19) can be formulated and administered to a subject as described herein. By way of non-limiting example, IL-18 polypeptides (e.g., stabilized IL-18, e.g. stabilized DR IL-18 variants or stabilized D2D IL-18 variant, etc.) (eg, SEQ ID NO: 19) can be formulated and administered to a subject in any convenient manner, eg, as described herein.

[0214]

[0266] The present disclosure describes active ingredients (IL-18 polypeptides, e.g., stabilized IL-18, e.g., stabilized DR IL-18 variants or stabilized D2D IL-18 variants, etc.) (e.g., SEQ ID NO: 19) encompasses the preparation and use of pharmaceutical compositions, including compositions useful for the treatment or prevention of diseases or disorders disclosed herein. Such pharmaceutical compositions may consist only of the active ingredient, in a form suitable for administration to a subject, or may consist of the active ingredient and one or more pharmaceutically acceptable carriers, one It may also contain one or more additional ingredients, or some combination thereof. The active ingredient may be present in the pharmaceutical composition in the form of a physiologically acceptable ester or salt, for example in combination with a physiologically acceptable cation or anion, as is well known in the art.

[0215]

[0267] As used herein, the term "pharmaceutically acceptable carrier" refers to a suitable IL-18 polypeptide (e.g., stabilized IL-18, e.g. stabilized DR IL-18 variant or stabilized D2D IL-18 variant, etc.) (eg, SEQ ID NO: 19) and which, after combination, can be used for administration to a subject.

[0216]

[0268] In some embodiments, the pharmaceutical compositions contain large, slowly metabolized macromolecules, such as proteins, polysaccharides such as chitosan, polylactic acid, polyglycolic acid, and copolymers (e.g., latex-functionalized Sepharose™, agarose). , cellulose, etc.), polymeric amino acids, amino acid copolymers, and lipid aggregates (eg, oil droplets or liposomes).

[0217]

[0269] subject methods (e.g., IL-18 polypeptides, e.g., wild-type IL-18, stabilized IL-18, DR IL-18, D2D IL-18, stabilized DR IL-18, stabilized D2D IL-18, etc.) (e.g., SEQ ID NO: 19) may be between about 0.1 ng and 100 mg per kg (e.g., 1 ng to 100 mg, 100 ng to 100 mg, 1 μg to 100 mg per kg). , 100μg~100mg, 1mg~100mg, 25mg~100mg, 50mg~100mg, 1ng~80mg, 100ng~80mg, 1μg~80, 100μg~80mg, 1mg~80mg, 25mg~80mg, 50mg~80mg, 1ng~50mg, 100ng ~50mg, 1μg~50mg, 100μg~50mg, 1mg~50mg, 25mg~50mg, 50mg~50mg, 1ng~50mg, 100ng~50mg, 1μg~50mg, 100μg~50mg, 1mg~50mg, or 25mg~50mg) dosage can be administered to deliver.

[0218]

[0270] In various embodiments, pharmaceutical compositions useful in the methods of the invention can be administered systemically, parenterally, subcutaneously, intraperitoneally, or topically, in oral, inhaled formulations, including, for example, solid or aerosol formulations. and may be administered topically or by other similar formulations or intraocularly. In addition to suitable therapeutic compositions, such pharmaceutical compositions may contain pharmaceutically acceptable carriers and other ingredients known to enhance and facilitate drug administration. Other possible formulations, such as nanoparticles, liposomes, other preparations containing active ingredients, and immunologically based systems can also be used for the administration of suitable modulators thereof according to the methods of the invention.

[0219]

[0271] The carrier can carry the agent of interest (eg, IL-18 variant polypeptide) in a variety of ways, including covalent attachment, either directly or through a linker group, and non-covalent association. Suitable covalent carriers include proteins such as albumin, peptides, and polysaccharides such as aminodextran, each of which has multiple sites of attachment of moieties. The carrier can also be used to bind an IL-18 polypeptide (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stable (e.g., SEQ ID NO: 19). The nature of the carrier may be either soluble or insoluble for the purposes of the present invention.

[0220]

[0272] Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed and include buffering agents such as phosphoric acid, citric acid, and other organic acids; ascorbic acid and methionine. antioxidants, including; preservatives (e.g. octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkylparabens, such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, e.g. , glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol ; salt-forming counterions such as sodium; metal complexes (eg Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycols (PEG). Preparations used for in vivo administration must be sterile. This is easily accomplished by filtration through a sterile filter membrane.

[0221]

[0273] The active ingredient can be present in colloidal drug delivery systems (e.g. , liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in microemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, edited by Osol, A. (1980).

[0222]

[0274] The compositions can be prepared as injectables, either as aqueous solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. The preparation may be emulsified or encapsulated in liposomes or microparticles, such as polylactide, polyglycolide or copolymers, for enhanced adjuvant effect, as discussed above. Langer, Science 249:1527, 1990 and Hanes, Advanced Drug Delivery Reviews 28:97-119, 1997. The agents of the invention may be administered in the form of depot injection or implant preparations which may be formulated in such a way as to allow sustained or pulsatile release of the active ingredient. Pharmaceutical compositions are typically sterile, substantially isotonic, and formulated in full compliance with all Good Manufacturing Practices (GMP) of the United States Food and Drug Administration.

[0223]

[0275] As used herein, the term "physiologically acceptable" ester or salt refers to an active ingredient that is compatible with any other ingredients of the pharmaceutical composition that are not deleterious to the subject to whom the composition is administered. means the ester or salt form of

[0224]

[0276] Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such methods of preparation involve bringing the active ingredient into association with the carrier or one or more other accessory ingredients and then, if necessary or desirable, shaping the product into the desired unit or multiple dosage units. or include packaging steps.

[0225]

[0277] Although the description of pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions that are suitable for prescription administration to humans, it is understood that such compositions are generally suitable for administration to animals of all kinds. As will be understood by those skilled in the art. Modifications of pharmaceutical compositions suitable for human administration to make the composition suitable for administration to a variety of animals are well understood, and our veterinary pharmacologists will It can be designed and implemented simply by routine experimentation.

[0226]

[0278] Pharmaceutical compositions useful in the methods of the invention include oral, rectal, intravaginal, parenteral, topical, intrapulmonary, intranasal, buccal, intravenous, transdermal, intralesional, subcutaneous, intramuscular, and ophthalmic. , intraspinal and other known routes of administration, and may be prepared, packaged, or sold in formulations suitable for intraspinal and other known routes of administration. Other formulations considered include nanoparticles, liposomal preparations, other preparations containing active ingredients, and immunologically based formulations.

[0227]

[0279] Pharmaceutical compositions of the invention may be prepared, packaged, or sold in bulk as a single unit dose or as multiple single unit doses. As used herein, a "unit dose" is an individual amount of a pharmaceutical composition containing a predetermined amount of active ingredient. The amount of active ingredient will usually be equal to the dose of active ingredient administered to a subject, or a convenient fraction of such dose, such as one-half or one-third of such dose.

[0228]

[0280] The relative amounts of the active ingredient, pharmaceutically acceptable carrier, and any additional ingredients in the pharmaceutical compositions of the present invention will vary and will vary depending on the identity, size, and condition of the subject being treated. Depends on the route of administration. By way of example, the composition may contain between 0.1% and 100% (w / w) of active ingredient.

[0229]

[0281] In addition to the active ingredients, the pharmaceutical compositions of the invention may further comprise one or more further pharmaceutically active agents.

[0230]

[0282] Controlled or sustained release formulations of the pharmaceutical compositions of the invention can be made using conventional techniques.

[0231]

[0283] Formulations of the pharmaceutical compositions of the invention suitable for oral administration include, but are not limited to, tablets, hard or soft capsules, cachets, troches, or intracavity tablets, each containing a predetermined amount of the active ingredient. may be prepared, packaged, or sold in the form of discrete solid dosage units. Other formulations suitable for oral administration include, but are not limited to, powder or granule formulations, aqueous or oily suspensions, aqueous or oily solutions, or emulsions.

[0232]

[0284] Pharmaceutically acceptable excipients used in the manufacture of pharmaceutical compositions include, but are not limited to, inert diluents, granulating and disintegrants, binders, and lubricants. Known dispersants include, but are not limited to, potato starch and sodium starch glycolate. Known surfactants include, but are not limited to, sodium lauryl sulfate. Known diluents include, but are not limited to, calcium carbonate, sodium carbonate, lactose, microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, and sodium phosphate. Known granulating and disintegrants include, but are not limited to, corn starch and alginic acid. Known binders include, but are not limited to, gelatin, acacia, pregelatinized corn starch, polyvinylpyrrolidone, and hydroxypropyl methylcellulose. Known leveling agents include, but are not limited to, magnesium stearate, stearic acid, silica, and talc.

[0233]

[0285] Liquid formulations of the pharmaceutical compositions of the invention can be prepared, packaged, and sold either in liquid form or in the form of a dry product intended for reconstitution with water or another suitable vehicle before use.

[0234]

[0286] Liquid suspensions may be prepared using conventional methods to effect suspension of the active ingredient in an aqueous or oily vehicle. Aqueous vehicles include, for example, water and isotonic saline. Oily vehicles include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as peanut, olive, sesame or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. Liquid suspensions may contain one or more suspending, dispersing or wetting agents, emulsifying agents, demulcents, preservatives, buffering agents, salts, flavoring, coloring, and sweetening agents. Additional ingredients may further be included. The oily suspensions may further contain a thickening agent.

[0235]

[0287] Known suspending agents include, but are not limited to, sorbitol syrup, hydrogenated edible fats, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, and 15-hydroxypropylmethylcellulose. Known dispersants or wetting agents include, but are not limited to, naturally occurring phosphatides such as lecithin, alkylene oxides with fatty acids, long chain aliphatic alcohols, partial esters derived from fatty acids and hexitols, or Condensation products with fatty acids and partial esters derived from hexitol anhydride (eg, polyoxyethylene stearate, heptadecaethylene oxycetanol, polyoxyethylene sorbitol monooleate, and polyoxyethylene sorbitan monooleate, respectively). Known emulsifiers include, but are not limited to, lecithin and acacia. Known preservatives include, but are not limited to, methyl, ethyl, or n-propyl-para-hydroxybenzoate, ascorbic acid, and sorbic acid. Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin. Known thickening agents for oily suspensions include, for example, beeswax, hard paraffin and cetyl alcohol.

[0236]

[0288] Liquid solutions of active ingredients in aqueous or oily solvents may be prepared in substantially the same way as liquid suspensions, the main difference being that the active ingredients are dissolved rather than suspended in the solvent. It is. Liquid solutions of pharmaceutical compositions of the invention may contain each of the ingredients described for liquid suspensions, with suspending agents not necessarily aiding in solubilization of the active ingredient in the solvent. Aqueous solvents include, for example, water and isotonic saline. Oily solvents include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as peanut, olive, sesame or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin.

[0237]

[0289] Powder and granule formulations of the pharmaceutical preparations of the invention may be prepared using known methods. Such formulations may be administered directly to a subject, for example by addition of an aqueous or oily vehicle thereto to form tablets, fill capsules, or form an aqueous or oily suspension or solution. can be used to prepare Each of these formulations may further include one or more dispersing or wetting agents, suspending agents, and preservatives. Additional excipients, such as fillers and sweetening, flavoring or coloring agents, may also be included in these formulations.

[0238]

[0290] Pharmaceutical compositions of the invention may also be prepared, packaged, or sold in the form of oil-in-water or water-in-oil emulsions. The oil phase may be a vegetable oil, such as olive or peanut oil, a mineral oil, such as liquid paraffin, or a combination thereof. Such compositions include one or more emulsifiers, such as naturally occurring gums such as gum acacia or gum tragacanth, naturally occurring phosphatides such as soybean or lecithin phosphatide, fatty acids and anhydrous hexitols such as sorbitan monooles. It may further include esters or partial esters derived from combinations of ates, as well as condensation products of such partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. These emulsions may also contain additional ingredients including, for example, sweetening or flavoring agents.

[0239]

[0291] Methods of infiltrating or coating a material with a chemical composition are known in the art, including, but not limited to, methods of depositing or bonding a chemical composition to a surface, into the structure of the material during the synthesis of the material. and chemical compositions (i.e., e.g. by physiologically degradable substances), and methods of absorbing aqueous or oily solutions or suspensions into absorbent materials, with or without a subsequent drying step. .

[0240]

[0292] As used herein, "parenteral administration" of a pharmaceutical composition refers to administration characterized by a physical wound in the tissue of a subject, and any route of administration of a pharmaceutical composition through a tissue wound. include. Thus, parenteral administration of the pharmaceutical composition may include, but is not limited to, by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a non-surgical wound that penetrates tissue. Including the administration of a substance. In particular, parenteral administration is contemplated to include, but is not limited to, dermal, subcutaneous, intraperitoneal, intravenous, intramuscular, intracisternal injection, and renal dialysis infusion techniques. In some cases, the IL-18 polypeptide of interest (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant) (e.g., sequence No. 19) is administered subcutaneously.

[0241]

[0293] Formulations of pharmaceutical compositions suitable for parenteral administration include the active ingredient in combination with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus or continuous administration. Formulations for injection may be prepared, packaged, or sold in unit dosage form, eg, in ampoules or in multi-dose containers with a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained release or biodegradable formulations. Such formulations may further contain one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In some embodiments of formulations for parenteral administration, the active ingredient is added for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition. Provided in dry (ie, powder or granule) form.

[0242]

[0294] Pharmaceutical compositions can be prepared, packaged, or sold in the form of sterile injectable aqueous or oleaginous suspensions or solutions. This suspension or solution may be formulated according to known techniques and may contain, in addition to the active ingredient, additional ingredients such as dispersing agents, wetting agents, or suspending agents as described herein. Such sterile injectable preparations may be prepared using nontoxic parenterally acceptable diluents or solvents, such as water or 1,3-butanediol. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other useful parenterally administrable formulations include those containing the active ingredient in microcrystalline form, in liposome preparations, or as a component of a biodegradable polymer system. Compositions for sustained release or incorporation may include pharmaceutically acceptable polymers or hydrophobic substances, such as emulsions, ion exchange resins, sparingly soluble polymers, or sparingly soluble salts.

[0243]

[0295] Formulations suitable for topical administration include, but are not limited to, liquid or semi-liquid preparations such as liniments, lotions, oil-in-water or water-in-oil emulsions, such as creams, ointments or pastes, and solutions or suspensions. Contains liquid. Topically administrable formulations may contain, for example, from about 1% to about 10% (w / w) active ingredient, although the concentration of active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further include one or more additional ingredients described herein.

[0244]

[0296] Pharmaceutical compositions of the invention can be prepared, packaged, or sold in formulations suitable for intrapulmonary administration via the buccal cavity. Such formulations may include dry particles containing the active ingredient and having a diameter ranging from about 0.5 to about 7 nanometers, preferably from about 1 to about 6 nanometers. Such compositions are conveniently prepared using a device containing a dry powder reservoir into which a stream of propellant can be directed and the powder dispersed, or in a self-propelling solvent / powder dispensing container, e.g. a closed container. in the form of a dry powder for administration using a device containing the active ingredient dissolved or suspended in a low-boiling propellant. Preferably, such a powder comprises particles in which at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% by number of the particles have a diameter less than 7 nanometers. More preferably, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions preferably include a solid fine powder diluent, such as sugar, and are conveniently presented in unit dosage form.

[0245]

[0297] Low-boiling propellants typically include liquid propellants that have a boiling point below 18.3° C. at atmospheric pressure. Typically, the propellant may constitute 50-99.9% (w / w) of the composition and the active ingredient may constitute 0.1-20% (w / w) of the composition. The propellant comprises further components, such as liquid non-ionic or solid anionic surfactants or solid diluents (preferably having a particle size of the same order of magnitude as the particles containing the active ingredient).

[0246]

[0298] Pharmaceutical compositions of the invention formulated for intrapulmonary delivery may also provide the active ingredient in the form of droplets of a solution or suspension. Such formulations may be prepared, packaged, or sold as aqueous or dilute alcoholic solutions or suspensions, optionally sterile, containing the active ingredient, and which may be conveniently administered using any inhalation or nebulization device. can be done. Such formulations may further contain one or more additional ingredients including, but not limited to, flavoring agents such as sodium saccharin, volatile oils, buffering agents, surfactants, or preservatives such as methyl oxybenzoate. . The droplets provided by this route of administration preferably have an average diameter in the range of about 0.1 to about 200 nanometers. Formulations described herein that are useful for intrapulmonary delivery are also useful for intranasal administration of pharmaceutical compositions of the invention. Another formulation suitable for intranasal administration is a coarse powder containing the active ingredient and having average particles of about 0.2 to 500 micrometers.

[0247]

[0299] Such formulations are administered in such a way that the snuff is taken up by rapid inhalation through the nasal cavity from a container of powder held near the nostrils. Formulations suitable for nasal administration include, for example, a minimum of about 0.1% (w / w) to a maximum of 100% (w / w) of the active ingredient, and further include one or more of the additional ingredients described herein. obtain.

[0248]

[0300] Pharmaceutical compositions of the invention can be prepared, packaged, or sold in formulations suitable for buccal administration. Such formulations may, for example, be in the form of tablets or intracavitary tablets made using conventional methods, containing, for example, 0.1-20% (w / w) active ingredient, orally dissolvable or degradable. and a balance that optionally includes one or more of the additional ingredients described herein. Alternatively, formulations suitable for buccal administration may include powdered or aerosolized or micronized solutions or suspensions containing the active ingredient. Such powdered, aerosolized, or aerosolized formulations, when dispersed, preferably have an average particle size or droplet size in the range of about 0.1 to about 200 nanometers, and preferably have an average particle size or droplet size in the range of about 0.1 to about 200 nanometers; It may further include one or more of additional ingredients.

[0249]

[0301] Pharmaceutical compositions of the invention may be prepared, packaged, or sold in formulations suitable for eye drops. Such formulations may be in the form of, eg, eye drops, comprising, eg, a 0.1-1.0% (w / w) solution or suspension of the active ingredient in an aqueous or oily liquid carrier. Such droplets may further include one or more of buffering agents, salts, or other additional components described herein. Other eye drop formulations that are useful include those containing the active ingredients in microcrystalline form or in liposome preparations.

[0250]

[0302] As used herein, "further ingredients" includes, but is not limited to: excipients; surfactants; dispersants; inert diluents; granulating and disintegrants; binders; leveling agents. sweeteners; flavoring agents; coloring agents; preservatives; physiologically degradable compositions, such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, analgesics buffering agents; salts; thickeners; fillers; emulsifiers; antioxidants; antibodies; antimicrobial agents; stabilizers; and pharmaceutically acceptable polymers or hydrophobic substances. Other "additional ingredients" that may be included in the pharmaceutical compositions of the invention are known in the art and are, for example, Genaro, ed., 1985, Remington's Pharmaceutical Sciences, Mack, incorporated herein by reference. Published by Publishing Co., Easton, Pa.

[0251] Exemplary formulation

[0303] In some embodiments, the formulation comprises an active ingredient comprising an IL-18 polypeptide, one or more buffering agents to adjust pH, one or more stabilizers, one or more solvents, a surfactant, agents, anti-oxidation reagents, and stabilizers. In some embodiments, the formulation of the IL-18 polypeptide comprises a combination of L-histidine (His), L-histidine hydrogen chloride (His-HCl), sucrose, polysorbate 80, L-methionine, and the disodium salt of EDTA. Contains one or more.

[0252]

[0304] An experimentally arrived at IL-18 polypeptide (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18 variant, etc.) (e.g., SEQ ID NO: 19). One example of a suitable formulation is (1) an IL-18 polypeptide (e.g., wild type IL-18, stabilized IL-18, DR IL-18, D2D IL-18, stabilized DR IL-18). , stabilized D2D IL-18) (e.g., SEQ ID NO: 19); (2) a buffer that maintains the pH between 6.2 and 6.8 (e.g., 6.5 in some cases) (e.g., 8~ (12mM, e.g. 10mM His / His-HCl); (3) sugars (e.g. 6-10%; in some cases 8% sucrose); (4) chelating agents (e.g. 0.05-1.5mM, e.g. (5) agents that prevent oxidation (e.g. 4-6mM, e.g. 5mM L-methionine in some cases); and (6) agents that prevent protein adsorption (e.g. 0.1mM EDTA); , 0.01-0.03% w / v, for example 0.02% PS80).

[0253]

[0305] Thus, in some cases, the formulation: (1) IL-18 polypeptide (e.g., wild-type IL-18, stabilized IL-18, DR IL-18, D2D IL-18, stabilized DR IL-18, stabilized D2D IL-18) (e.g., SEQ ID NO: 19); (2) 10 mM His / His-HCl; (3) approximately 8% sucrose; (4) approximately 0.1 mM Contains EDTA; (5) approximately 5 mM L-methionine; and (6) approximately 0.02% (w / v) PS80.

[0254]

[0306] In some embodiments of the above (e.g., where the formulation is administered subcutaneously), IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18, DR IL-18, D2D IL-18, -18, stabilized DR IL-18, stabilized D2D IL-18, etc.) (e.g., SEQ ID NO: 19) is 10-100 mg / ml (e.g., 10-90, 10-75, 10-60 , 10~50, 10~40, 10~30, 25~100, 25~90, 25~75, 25~60, 25~50, 25~40, 25~30, 30~100, 30~90, 30 ~75, 30~60, 30~50, 30~40, 40~100, 40~90, 40~75, 40~60, 40~50, 50~100, 50~90, 50~75, or 50~ 60 mg / ml). In some embodiments of the above (e.g., where the formulation is administered subcutaneously), IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18, DR IL-18, D2D IL-18, -18, stabilized DR IL-18, stabilized D2D IL-18, etc.) (eg, SEQ ID NO: 19) will be present at a concentration in the range of 50-60 mg / ml. In some embodiments of the above (e.g., where the formulation is administered subcutaneously), IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18, DR IL-18, D2D IL-18, -18, stabilized DR IL-18, stabilized D2D IL-18, etc.) (eg, SEQ ID NO: 19) will be present at a concentration in the range of 20-30 mg / ml.

[0255]

[0307] In some embodiments, the pharmaceutical product is formulated in batches. In some embodiments, the batch is 1.5L. In other embodiments, the batch is 10.5L. A batch can include, for example, the IL-18 polypeptide of SEQ ID NO: 19, L-histidine, L-histidine hydrogen chloride, sucrose, polysorbate 80, L-methionine, the disodium salt of EDTA, and water for injection. In some embodiments, the batch comprises: between 40g and 50g of SEQ ID NO: 19; between 1.00g and 2.00g of L-histidine; between 0.25g and 1.00g of L-histidine hydrogen chloride; 100.00g and 150.00g of L-histidine; between 0.01 g and 0.60 g of polysorbate 80; between 1 g and 1.5 g of L-methionine; between 0.005 g and 0.1 g of the disodium salt of EDTA; and enough for about 1.5 L Contains water. In some embodiments, the batch comprises about 45 g of SEQ ID NO: 19; about 1.91 g of L-histidine; about 0.57 g of L-histidine hydrogen chloride; about 120.0 g of sucrose; about 0.30 g of polysorbate 80; g of L-methionine; about 0.06 g of the disodium salt of EDTA; and enough water to about 1.5 L. In some embodiments, a 10.5L batch includes: between 300g and 350g SEQ ID NO: 19; between 10.00g and 15.00g L-Histidine; between 3.50g and 4.50g L-Histidine Hydrogen Chloride; sucrose between 1.5g and 2.5g; L-methionine between 7.00g and 8.00g; disodium salt of EDTA between 0.1g and 0.6g; and about 10.5L Contains sufficient amount of water. In some embodiments, a 10.5L batch includes about 315g SEQ ID NO: 19, about 13.34g L-histidine; about 3.99g L-histidine hydrogen chloride, about 840.0g sucrose; about 2.1g polysorbate 80. ; about 7.88 g L-methionine; about 0.42 g disodium salt of EDTA; and enough water to about 1.5 L.

[0256]

[0308] Formulations of the present disclosure can be maintained at a pH that helps stabilize or maintain the activity of the compounds or polypeptides disclosed herein, for example. The pH of the formulations of the present disclosure can range from about 3 to about 12, for example. The pH of the composition is, for example, about 3 to about 4, about 4 to about 5, about 5 to about 6, about 6 to about 7, about 7 to about 8, about 8 to about 9, about 9 to about 10, It can range from about 10 to about 11, or from about 11 to about 12 pH units. The pH of the composition can be, for example, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12 pH units. The pH of the composition can be, for example, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9 pH units. The pH of the composition can be, for example, up to 5, up to 6, up to 7, up to 8, up to 9, up to 10, up to 11, or up to 12 pH units.

[0257]

[0309] The formulations disclosed herein can have a pH of about 5.5 to about 8. For example, formulations of the present disclosure may be about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, It may have a pH of about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, or about 8.0. In some embodiments, the pH is 6.5±0.6, 6.5±0.5, 6.5±0.4, 6.5±0.3, 6.5±0.2, 6.5±0.1, about 6.5, or 6.5. In some embodiments, the pH is 6.2±0.6, 6.2±0.5, 6.2±0.4, 6.2±0.3, 6.2±0.2, 6.2±0.1, about 6.2, or 6.2. In some embodiments, the pH is 6.8±0.6, 6.8±0.5, 6.8±0.4, 6.8±0.3, 6.8±0.2, 6.8±0.1, about 6.8, or 6.8. In some embodiments, the pH is 7.4±0.6, 7.4±0.5, 7.4±0.4, 7.4±0.3, 7.4±0.2, 7.4±0.1, about 7.4, or 7.4. In some embodiments, the pH is about 6.2 to about 6.8. If the pH is outside the range desired by the formulation, the pH can be adjusted by using sufficient pharmaceutically acceptable acids and bases.

[0258]

[0310] In some embodiments, the formulations disclosed herein can include a buffering agent. In some embodiments, buffering agents contribute to maintaining a stable pH and helping to stabilize the compounds or polypeptides disclosed herein. In some embodiments, the buffer system includes at least one buffering agent having buffer ranges that overlap all or part of the pH range of 5.5 to 7.4. In some embodiments, the buffer has a pKa of about 6.5±0.5, or 6.2±0.5.

[0259] administration

[0311] An IL-18 polypeptide (e.g., wild type IL-18, stabilized IL-18 variant, DR IL-18 variant, D2D IL-18 variant, stabilized DR IL-18 variants, stabilized D2D IL-18 variants, etc.) (e.g., SEQ ID NO: 19) are in amounts ranging from 0.001 mg to about 10 mg per kilogram of animal body weight (mpk). . In some embodiments, the IL-18 polypeptide (e.g., wild-type IL-18, stabilized IL-18 variant, DR IL-18 variant, D2D IL-18 variant, stabilized DR IL-18 variant, stabilized D2D IL-18 variant, etc.) (e.g., SEQ ID NO: 19) is 0.01~4mpk (e.g., 0.01~3.5, 0.01~3.3, 0.01~3, 0.01~1.5, 0.01~2, 0.01~ 1.5, 0.01~1, 0.01~0.5, 0.01~0.35, 0.025~4, 0.025~3.5, 0.025~3.3, 0.025~3, 0.025~1.5, 0.025~2, 0.025~1.5, 0.025~1, 0.025~0.5, 0.025~0.35, 0.05~4, 0.05~3.5, 0.05~3.3, 0.05~3, 0.05~1.5, 0.05~2, 0.05~1.5, 0.05~1, 0.05~0.5, 0.05~0.35, 0.1~4, 0.1~ 3.5, 0.1~3.3, 0.1~3, 0.1~1.5, 0.1~2, 0.1~1.5, 0.1~1, 0.1~0.5, 0.1~0.35, 0.25~4, 0.25~3.5, 0.25~3.3, 0.25~3, 0.25~1.5, 0.25~2, 0.25~1.5, 0.25~1, 0.25~0.5, 0.25~0.35, 0.5~4, 0.5~3.5, 0.5~3.3, 0.5~3, 0.5~1.5, 0.5~2, 0.5~ 1.5, or 0.5 to 1 mpk). In some embodiments, the IL-18 polypeptide (e.g., wild-type IL-18, stabilized IL-18 variant, DR IL-18 variant, D2D IL-18 variant, stabilized DR IL-18 variant, stabilized D2D IL-18 variant, etc.) (e.g. SEQ ID NO: 19) is 0.05~3.5mpk (e.g. 0.05~3.3, 0.05~3, 0.05~1.5, 0.05~2, 0.05~1.5, 0.05 ~1, 0.05~0.5, 0.05~0.35, 0.1~3.5, 0.1~3.3, 0.1~3, 0.1~1.5, 0.1~2, 0.1~1.5, 0.1~1, 0.1~0.5, 0.1~0.35, 0.25~3.5 , 0.25~3.3, 0.25~3, 0.25~1.5, 0.25~2, 0.25~1.5, 0.25~1, 0.25~0.5, 0.25~0.35, 0.5~3.5, 0.5~3.3, 0.5~3, 0.5~1.5, 0.5 ~2, 0.5-1.5, or 0.5-1mpk). In some cases, compounds may be administered to animals several times a day, or less frequently, such as once a day, once a week, once every two weeks, once a month, or more frequently. It may be administered less frequently, such as once every few months or once a year or less.

[0260]

[0312] However, as mentioned above, in some cases it is delivered once a week or less.

[0261] Method of administration Frequency of administration

[0313] Those skilled in the art will appreciate that the IL-18 proteins discussed herein can be administered acutely (e.g., over a short period of time) or chronically (e.g., over an extended period of time, such as over several months or a year). you will understand. Those skilled in the art will understand that they can be administered alone or in any combination with other agents. Furthermore, the IL-18 proteins described herein may be administered alone or in any combination in a temporal sense, where they are administered simultaneously and / or before and / or after each other. Good too. One skilled in the art will be able to use IL-18 protein compositions to treat a disease or disorder in a subject in need thereof based on the disclosure provided herein, and that such proteins alone or It will be appreciated that it may be used in any combination with other agents or with other agents that affect the therapeutic outcome.

[0262]

[0314] Surprisingly, as demonstrated in the Examples below, IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants) , stabilized DR IL-18 variants, stabilized D2D IL-18 variants, etc.) (e.g. SEQ ID NO: 19) may in some cases be administered too frequently, e.g. once per week. In higher amounts, it can be harmful (eg, can cause toxicity ~ anemia). For example, the following example shows that twice weekly administration of DR-18 in primates (monkeys) reduced hemoglobin in a dose-dependent manner compared to saline-treated monkeys. In contrast, weekly administration did not result in a decrease in hemoglobin levels compared to saline treatment.

[0263]

[0315] Thus, in some embodiments, IL-18 polypeptides (e.g., wild type IL-18, stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants, stabilized DR IL-18 -18 variant, stabilized D2D IL-18 variant, etc.) (e.g. SEQ ID NO: 19) no more than once per week (1 dose per week) (e.g. no more than once every two weeks, no more than once per month) administered to individuals at a frequency of In some cases, IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants, stabilized DR IL-18 variants) , stabilized D2D IL-18 variants, etc.) once per week to once every 6 months (e.g., once per week to once every 4 months, once per week to once every 2 months, or It is administered to individuals at a frequency ranging from once per week to once per month). In some cases, IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants, stabilized DR IL-18 variants) , stabilized D2D IL-18 variant, etc.) (eg, SEQ ID NO: 19) is administered to an individual at a frequency ranging from once per week to once per month.

[0264]

[0316] In some cases, IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants, stabilized DR IL-18 variants) , stabilized D2D IL-18 variant, etc.) (eg, SEQ ID NO: 19) is administered to an individual about once per week. In some cases, IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants, stabilized DR IL-18 variants) , a stabilized D2D IL-18 variant, etc.) (eg, SEQ ID NO: 19) is administered to an individual about once every two weeks. In some cases, IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants, stabilized DR IL-18 variants) , a stabilized D2D IL-18 variant, etc.) (eg, SEQ ID NO: 19) is administered to an individual about once per month. In some cases, IL-18 polypeptides (e.g., wild-type IL-18, stabilized IL-18 variants, DR IL-18 variants, D2D IL-18 variants, stabilized DR IL-18 variants) , stabilized D2D IL-18 variants, etc.) is administered to an individual no more frequently than once per week.

[0265] disease

[0317] In some embodiments, the methods of the present disclosure are directed to tumors or cancerous tumors that are deficient in surface expression of MHC class I; Useful in the treatment or prevention of tumors with mutations in antigen-bearing complexes, such as tapasin.

[0266]

[0318] Metabolic diseases and disorders include a variety of metabolic and endocrine-related diseases and disorders. The following are non-limiting examples of metabolic and endocrine-related diseases and disorders that may be treated or prevented by the methods and compositions of the present invention: obesity, diabetes, prediabetes, type II diabetes, juvenile onset adult diabetes. (MODY), hyperglycemia, metabolic syndrome, dyslipidemia, hypertriglyceridemia, and hypercholesterolemia.

[0267]

[0319] Non-limiting examples of other diseases and disorders that may be treated or prevented using the compositions and methods of the invention include viral infections, bacterial infections, parasitic infections, and low immune activity. In some embodiments, the viral infection is at least one of a poxvirus, smallpox virus, molluscum contagiosum, an HPV infection, and a wart caused by a virus. In some embodiments, the infection is a systemic infection. In some embodiments, the viral infection is a vaccinia virus infection. In some embodiments, the viral infection is a systemic vaccinia virus infection. In some embodiments, the bacterial infection is sepsis. In some embodiments, low immune activity is neutropenia, which can be caused, for example, by chemotherapy.

[0268]

[0320] Non-limiting examples of other diseases and disorders that can be treated or prevented using the compositions and methods of the invention include macular degeneration. For example, in some cases the disease or disorder is wet macular degeneration, and in some cases the disease or disorder is wet age-related macular degeneration. In some such cases, IL-18 variant polypeptides (eg, stabilized IL-18) can be used as anti-angiogenic agents. For example, a subject IL-18 variant polypeptide (eg, stabilized IL-18) can in some cases attenuate choroidal neovascularization.

[0269]

[0321] In some embodiments, an IL-18 polypeptide (e.g., a stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., SEQ ID NO: 19) are useful in the treatment or prevention of diseases or disorders. In various embodiments, the disease or disorder is cancer or a metabolic disease or disorder, including obesity and diabetes (eg, the subject methods can result in a reduction in body fat). Thus, in some embodiments, the composition comprises at least one IL-18 polypeptide (e.g., stabilized IL-18, e.g., stabilized DR IL-18 variant or stabilized D2D IL-18). 18 variants, etc.) (eg, SEQ ID NO: 19). In other embodiments, at least one IL-18 polypeptide (e.g., stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., A method of administering SEQ ID NO: 19) is practiced to treat a disease or disorder, such as, but not limited to, cancer or a metabolic disease or disorder.

[0270]

[0322] The following are non-limiting examples of cancers that may be treated or prevented by the methods and compositions of the present disclosure: acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, appendiceal carcinoma, basal cell carcinoma. Cancer, bile duct cancer, bladder cancer, bone cancer, brain and spinal cord tumors, brainstem glioma, brain tumor, breast cancer, bronchial tumor, Burkitt's lymphoma, carcinoid tumor, central nervous system atypical teratoma / rhabdoid tumor, central nervous system Nervous system embryonoma, central nervous system lymphoma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, cerebral astrocytoma / malignant glioma, cervical cancer, pediatric optic pathway tumor, chordoma, chronic lymphoid Leukemia, chronic myeloid leukemia, chronic myeloproliferative diseases, colon cancer, colorectal cancer, craniopharyngioma, skin cancer, cutaneous T-cell lymphoma, endometrial cancer, ependymoblastoma, ependymomas, esophagus Ewing tumor, extracranial cancer, extragonadal germ cell tumor, extrahepatic bile duct cancer, extrahepatic cancer, eye cancer, mycosis fungoides, gallbladder cancer, gastric (stomach) Cancer, gastrointestinal cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (gist), germ cell tumor, gestational cancer, gestational trophoblastic tumor, glioblastoma, glioma, hairy cell leukemia , head and neck cancer, hepatocellular (liver) cancer, histiocytosis, Hodgkin's lymphoma, hypopharyngeal cancer, hypothalamic and optic pathway glioma, hypothalamic tumor, intraocular (eye) cancer, intraocular melanoma , pancreatic islet cell tumor, Kaposi's sarcoma, kidney (kidney cell) cancer, Langerhans cell carcinoma, Langerhans cell histiocytosis, pharyngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, lung cancer, lymphoma, macroglobulinemia malignant fibrous histiocytoma (histiocvtoma) of bone and osteosarcoma, medulloblastoma, medulloepithelioma, melanoma, Merkel cell carcinoma, mesothelioma, occult primary metastatic squamous neck cancer , mouth cancer, multiple endocrine tumor syndrome, multiple myeloma, fungal disease, myelodysplastic syndrome, myelodysplastic / myeloproliferative disease, myelogenous leukemia, myeloid leukemia), myeloma, myeloproliferative diseases, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, cavity cancer), oropharyngeal cancer, osteosarcoma and malignant fibrous histiocytoma, osteosarcoma and malignant fibrous histiocytoma of bone, ovary, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignancy degree tumors, pancreatic cancer, papillomatosis, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, intermediate pineal parenchymal tumor, pineoblastoma and supratentorial primitive Neuroectodermal tumors, pituitary tumors, plasma cell tumors, plasma cell tumors / multiple myeloma, pleuropulmonary blastoma, primary central nervous system cancer, primary central nervous system lymphoma, prostate cancer, rectal cancer , renal cell (kidney) cancer, renal pelvis and ureteral cancer, respiratory tract cancer containing the nut gene on chromosome 15, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Sézary syndrome, skin cancer (melanoma), skin cancer (non-melanoma), skin cancer, small cell lung cancer, small intestine cancer, soft tissue cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer, stomach (stomach) (gastric) cancer, supratentorial primitive neuroectodermal tumor, supratentorial primitive neuroectodermal tumor and pineoblastoma, T-cell lymphoma, testicular cancer, pharyngeal cancer, thymoma and thymus. cancer, thymic cancer, transitional cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter, chorionic tumor, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, visual pathway and hypothalamic glioma, vulvar , Wandenström hypergammaglobulinemia, and Wilms tumor.

[0271]

[0323] In some non-limiting examples, a cancer is defined by its molecular characteristics rather than by its histological tissue of origin. For example, tumors with high tumor mutational burden (TMB), tumors with microsatellite instability (MSI), tumors with defective or reduced surface expression of MHC class I (e.g., lack of beta-2 microglobulin or tapasin) due to loss of IL-18BP), or tumors that express high levels of IL-18BP. In some cases, these molecular features are determined by next generation sequencing (eg, TMB / MSI). In some cases, these molecular characteristics are determined by immunohistochemistry, immunofluorescence, or flow cytometry. Accordingly, non-limiting examples of cancers that may be treated or prevented by the methods and compositions of the present disclosure include solid tumor cancers, liquid cancers, hematological cancers, teratomas, sarcomas, and cancers.

[0272]

[0324] In some embodiments, the compositions and methods of the present disclosure are useful for treating tumors or cancers that are resistant to immune checkpoint inhibitors (ICIs). Examples of immune checkpoint inhibitors include, but are not limited to, anti-PD1 agents such as anti-PD1 antibodies (e.g., nivolumab), anti-PD-L1 agents such as anti-PD-L1 antibodies, anti-CTLA4 (e.g., ipilimumab), Anti-TIM3, anti-TIGIT, anti-LAG3, anti-B7H3, anti-B7H4, anti-VISTA, anti-BTLA, anti-CD47, anti-SIRP alpha, anti-CD48, anti-CD155, anti-CD160, anti-TREM2, anti-IDO1, anti-adenosine 2A receptor, anti- Contains aryl hydrocarbon receptor, anti-KIR, and anti-LILRB2. Examples of immune checkpoint inhibitor targets include, but are not limited to, PD-L1, PD1, CTLA4, TIM3, TIGIT, LAG3, B7H3, B7H4, VISTA, BTLA, CD47, SIRP alpha, CD48, CD155, CD160, Includes TREM2, IDO1, adenosine 2A receptor, aryl hydrocarbon receptor, KIR, and LILRB2.

[0273]

[0325] Thus, examples of immune checkpoint inhibitors include proteins such as: PD-L1, PD1, CTLA4, TIM3, TIGIT, LAG3, B7H3, B7H4, VISTA, BTLA, CD47, SIRP alpha, CD48, CD155, CD160, TREM2 , IDO1, adenosine 2A receptor, aryl hydrocarbon receptor, KIR, and LILRB2. In some cases, the stabilized IL-18 variant polypeptide (e.g., DR-IL-18 variant, D2D-IL-18 variant) (e.g., SEQ ID NO: 19) of interest is an immune checkpoint inhibitor ( For example, PD-L1, PD1, CTLA4, TIM3, TIGIT, LAG3, B7H3, B7H4, VISTA, BTLA, CD47, SIRP alpha, CD48, CD155, CD160, TREM2, IDO1, adenosine 2A receptor, aryl hydrocarbon receptor, KIR, LILRB2, or any combination thereof).

[0274]

[0326] In some embodiments, the compositions and methods of the present disclosure are useful in cancers associated with high levels of IL-18BP (e.g., circulating or expressed by tumors) or in which IL-18R is invasive. Useful in treating cancers associated with tumors expressed on T cells or NK cells.

[0275]

[0327] Accordingly, the present invention provides therapeutically effective amounts of IL-18 variant polypeptides to cells, tissues, organs, or subjects in need thereof for the treatment of a disease or disorder, or its associated signs, symptoms, or conditions. Prevention of disease or disorder and Regarding treatment. In one embodiment, the invention provides for administering a therapeutically effective amount of an IL-18 variant polypeptide (e.g., a stable The present invention provides methods for administering a recombinant IL-18 variant polypeptide, an active IL-18 variant polypeptide fragment (eg, an IL-18 variant peptide, etc.). In one embodiment, the invention provides for administering a therapeutically effective amount of an IL-18 variant to the cells, tissues or organs of a subject having, suspected of having, or at risk of having a disease or disorder described herein. Methods of administering polypeptides (eg, stabilized IL-18), recombinant IL-18 variant polypeptides, active IL-18 variant polypeptide fragments (eg, IL-18 variant peptides, etc.) are provided.

[0276] kit

[0328] The invention also relates to kits useful in the methods of the invention. Such kits can contain, for example, an IL-18 polypeptide (e.g., a stabilized IL-18, such as a stabilized DR IL-18 variant or a stabilized D2D IL-18 variant) (e.g., SEQ ID NO: 19) and / or materials for quantitatively analyzing IL-18 variant polypeptides or IL-18 variant nucleic acids, and / or materials for evaluating the activity of IL-18 variant polypeptides or IL-18 variant nucleic acids. , and / or various combinations of ingredients useful in any of the methods described elsewhere herein, including instructional materials. For example, in some embodiments, a kit includes components useful for quantifying IL-18 variant nucleic acids in a biological sample. In another embodiment, the kit includes components useful for quantifying IL-18 variant polypeptides in biological samples. In further embodiments, the kit includes components useful for assessing the activity (eg, enzymatic activity, ligand binding activity, etc.) of an IL-18 variant polypeptide in a biological sample.

[0277]

[0329] In a further embodiment, the kit comprises instructional materials, components of an assay for monitoring the effectiveness of a treatment administered to a subject in need of treatment, and IL-18 in a biological sample obtained from the subject. Includes a component for determining whether the level of signaling is modulated during or after administration of the treatment. In various embodiments, to determine whether the level of IL-18 signaling is modulated in a biological sample obtained from a subject, the level of IL-18 signaling is compared to a positive control, a negative control, a historical the level of at least one comparator included in the kit, such as a historical control, a historical standard, or the level of another reference molecule in a biological sample. In certain embodiments, the ratio of IL-18 signaling and a reference molecule is determined to aid in monitoring treatment.

Example

[0278]

[0330] The invention will be further explained in detail with reference to the following experimental examples. These examples are provided for illustrative purposes only and are not intended to be limiting unless otherwise specified. Therefore, this invention should in no way be construed as limited to the following examples, but rather as encompassing any and all variations that become apparent as a result of the teachings provided herein. Should.

[0279]

[0331] Without further elaboration, it is believed that one skilled in the art, using the foregoing description and the following illustrative examples, can make and use the invention and practice the claimed methods. The following examples are therefore in no way to be construed as limiting the remainder of this disclosure.

[0280] Example 1 IL-18 variant polypeptide

[0332] IL-18 is an inflammatory cytokine that can stimulate T, NK, and myeloid cells. Given its ability to stimulate anti-tumor immune cells, it has been proposed as an immunotherapeutic agent for cancer. As shown herein, the therapeutic efficacy of recombinant IL-18 treatment can be greatly limited by upregulation of its natural endogenous soluble inhibitor IL-18BP. The present disclosure is based in part on the development of variants of both human and murine IL-18 that exhibit minimal binding to IL-18BP. Cytokine variants exhibit altered relative preferences for receptors (IL-18Rα and IL-18BP) by hundreds of thousands to over a million-fold. These variants have potent antitumor activity in preclinical tumor models both as monotherapy and in combination with immune checkpoint inhibitors such as anti-PD-1. As a further application, IL-18 also has a well-established anti-obesity role and it is shown herein that administration of the variant significantly reduces body fat composition compared to WT IL-18 treatment. Therefore, the new variant has indications in endocrinology / metabolism / obesity in addition to tumor immunotherapy.

[0281]

[0333] Also described herein is a further set of IL-18 variants that act as IL-18BP antagonists by binding exclusively to IL-18BP and having absent or greatly reduced binding to IL-18Rα. It is envisioned that these proteins can be used to enhance the activity of endogenous IL-18 by neutralizing IL-18BP.

[0282]

[0334] The materials and methods used in these experiments are described here.

[0283] Protein expression and purification

[0335] Human IL-18, mouse IL-18 (amino acids 1-157) and their variants were assembled as gBlocks (Integrated DNA Technologies, IDT) and N-terminally SUMO-tagged and C-terminally conjugated in E. coli BL21(DE3) Rosetta strain. Cloned into pET28a-smt vector for expression of hexahistidine-tagged protein. Protein expression was induced using 0.5mM IPTG for 20 hours at 16°C. After initial purification of the fusion protein using Ni chelating resin, the SUMO tag was cleaved using SUMO protease. Proteins were then separated from the aggregates by sequential ammonium sulfate cleavage in which the aggregates were precipitated with 20% ammonium sulfate and the target protein was precipitated with 70% ammonium sulfate. The protein pellet was resuspended and reapplied to Ni chelating resin to remove the SUMO tag and subjected to an endotoxin removal wash with 0.1% Triton X-114. Finally, the eluted proteins were buffer exchanged into PBS by a PD-10 column (GE Healthcare). Protein samples were tested for monodispersity by size exclusion chromatography using FPLC (Bio-Rad) and SEC650 columns (Bio-Rad).

[0284]

[0336] Human IL-18Rα extracellular domain (amino acids 19 to 329), IL-18Rβ extracellular domain (amino acids 15 to 356), and IL-18BP (amino acids 31 to 194) were secreted and purified using a baculovirus expression system. Briefly, all construct sequences were cloned into the pAcBN-BH3 vector (BD Biosciences) with an N-terminal gp67 signal peptide and a C-terminal AviTag™ and hexahistidine tag. Plasmid constructs were transfected into Spodoptera frugiperda (Sf9) insect cells cultured at 27°C in SF900II SFM medium (Invitrogen) to establish high titer recombinant virus, which was then amplified. Trichopulsia ni (High-Five) insect cells (Invitrogen) grown in Insect Xpress medium (Lonza) at 27°C were infected with the virus to express recombinant proteins. Three days after infection, proteins were extracted and concentrated by Ni-NTA (QIAGEN) affinity chromatography using a SEC650 sizing column (Bio-Rad) equilibrated in 10mM HEPES (pH 7.5) and 150mM NaCl. It was purified to a homogeneity of over 98%.

[0285]

[0337] Mouse IL-18Rα extracellular domain (amino acids 19-329) and IL-18BP (amino acids 31-194) were produced as secreted proteins using the Expi293 expression system (Thermo Fisher). Briefly, all construct sequences were cloned into the BacMam expression vector pEZT_D_Lux along with the N-terminal H7 signal peptide and the C-terminal AviTag™ and hexahistidine tags. Expi293 cells cultured at 37°C in Expi293 expression medium (Thermo Fisher) were transfected with plasmids using the ExpiFectamine 293 Transfection Kit (Thermo Fisher) according to the manufacturer's instructions. Cells were harvested 3-5 days after transfection. Protein purification procedures were the same as for human proteins.

[0286]

[0338] For biotinylation of proteins, a C-terminal biotin acceptor peptide (AviTag)-GLNDIFEAQKIEWHE was fused to all IL-18 receptor constructs. Biotinylation of proteins was performed using soluble BirA ligase enzyme in 0.1mM bicine (pH 8.3), 10mM ATP, 10mM magnesium acetate, and 0.5mM biotin (Sigma). Protein was purified by size exclusion on a SEC650 column as described above.

[0287] Yeast display of IL-18

[0339] Human and mouse IL-18 gene blocks (IDT) were synthesized, cloned into vector pYAL, and displayed on Saccharomyces cerevisiae strain EBY100. Individual colonies of IL-18 yeast were grown overnight at 30°C in SDCAA liquid medium and induced in SGCAA liquid medium at 20°C for 1 day. IL-18 display levels on yeast were verified by flow cytometry using an anti-cMyc tag antibody (anti-myc-PE; Cell Signaling Technologies). Receptor staining with biotinylated IL-18Rα (with or without IL-18Rβ) or biotinylated IL-18BP was performed on ice in PBS supplemented with 0.5% BSA and 2mM EDTA (PBE). All analyzes were performed on a Sony SA3800 flow cytometer.

[0288] Construction and selection of human IL-18 library

[0340] For the first human decoy-resistant IL-18 library, the structure of the hIL-18 / hIL-18Rα / hIL-18Rβ complex (Protein Data Bank (PDB ID) code 3OW4) was 3F62), 14 hIL-18Rα and hIL-18BP contact residues in hIL-18 (Table 1) were identified from homologous positions. A library randomizing these residues was constructed using assembly PCR with degenerate primers listed in Table 2. The library is approximately 1.96×10 11 had a theoretical diversity of unique protein sequences. The PCR product was further amplified using primers with homology to the pYAL vector and co-electroporated into EBY100 yeast along with linearized pYAL. The resulting library is 2.5×10 8 It contained several transformants. For the second V2.0 human decoy-resistant IL-18 library, 11 hIL-18Rα and hIL-18BP contact residues in hIL-18 were selected and randomized, resulting in 3.44 × 10 9 (described in Figure 7A). A library randomizing these residues was constructed using assembly PCR with degenerate primers and co-electroporated into EBY100 yeast with pYAL. The resulting library is 6×10 8 The transformants had a diversity of

[0289]

[0341]

[0290]

table 1

[0291]

[0342]

[0292] [Table 2]

[0293]

[0343] For both libraries, transformed yeast were harvested and expanded in liquid synthetic dextrose casamino acid (SDCAA) medium at 30 °C and by dilution 1:10 in liquid synthetic galactose casamino acid (SGCAA) medium. The cells were induced and cultured at 20°C for 24 hours. An appropriate number of induced yeasts were used in each round to ensure at least 10-fold coverage of the expected diversity of the library at each step, and at least 10 8 of cells were secured. All selection steps were performed at 4°C using PBE buffer (PBS containing 0.5% BSA and 2mM EDTA). For first generation libraries, the selection reagents for each round are listed in Table 3. For round 1, yeast were counterselected using anti-Cy5 / AlexaFluor 647 microbeads (Miltenyi) and LS MACS columns (Miltenyi) to remove non-specific bead binders. Positive selection was performed by labeling yeast with 1 μM biotinylated hIL-18Rα for 1 h at 4°C followed by magnetic selection using SA / AlexaFluor 647 microbeads and a LS MACS column. For round 2, using the same positive selection as round 1, counterselection was performed with 1 μM biotinylated IL-18BP. For rounds 3-5, incubate yeast with 100 nM (rounds 3-4) or 10 nM (round 5) biotinylated IL-18Rα and 250 nM preformed biotin-capped hIL-18BP / SA-PE tetramers. The selection was made by: After completion of binding, yeast were washed and labeled with SA AlexaFluor 647 to detect IL-18Rα. Display levels were determined by staining with AlexaFluor 488-conjugated anti-cMyc (Cell Signaling Technologies) and 1% display normalized IL-18Rα binders (of IL-18BP non-binders) from the top. , isolated using FACS using a Sony SA3800 cell sorter. After each round of selection, the recovered yeast were expanded in SDCAA medium overnight at 30°C and then induced by 1:10 dilution in SGCAA medium for 24 hours at 20°C.

[0294]

[0344] The V2.0 human DR-IL-18 library was selected in a similar manner, but the specific selection steps are detailed in Figure 7B.

[0295] Construction and selection of mouse IL-18 library

[0345] Construction and selection procedures are similar to human IL-18, with the following changes. Library construction was informed by the mouse IL-18 / receptor complex structure modeled in silico (predicted by Phyer2.0). Thirteen positions were selected for randomization using the primers listed in Table 4 (Table 3). 4 × 10 by simultaneous electroporation with pYAL 8 A library of transformants was obtained. The selection reagents used for each round are listed in Table 5.

[0296]

[0346]

[0297] [Table 3]

[0298]

[0347]

[0299] [Table 4-1]

[0300] [Table 4-2]

[0301]

[0348]

[0302] [Table 5]

[0303] surface plasmon resonance

[0349] Experiments were performed using a Biacore T100 and run at 25°C. Biotinylated IL-18Rα or IL-18BP was immobilized on a Biacore biotin capture chip (Series S CAP sensor chip, GE Healthcare) to obtain an Rmax of approximately 50RU (IL-18Rα) or approximately 10RU (IL-18BP). . Measurements were performed using serial dilutions of IL-18 variants in HEPES-buffered saline-P+ buffer (10mM HEPES pH7.4, 150mM NaCl, 0.005% surfactant P20). The surface was regenerated by three 60 sec injections of regeneration buffer (3 / 4 (v / v) 8M guanidine hydrochloride and 1 / 4 (v / v) 1M sodium hydroxide). Experiments were performed simultaneously in multiple channels for increased observation. All data were analyzed using Biacore T100 evaluation software version 2.0 using a 1:1 Langmuir binding model.

[0304] cell line

[0350] HEK-Blue IL-18 sensor cells (InvivoGen) were grown in complete medium (10% heat-inactivated FBS) supplemented with 100 μg / mL normocin, 30 μg / mL blasticidin, 180 μg / mL zeocin, and 200 μg / mL hygromycin. , DMEM containing 2 mM L-glutamine, 50 U / mL penicillin, and 50 μg / mL streptomycin). YUMMER1.7 melanoma cells were cultured and prepared as previously described (Wang et al., 2017, Pigment Cell Melanoma Res., 30(4):428-435).

[0305] HEK-Blue cytokine activity assay

[0351] For measurements of cytokine activity, 50,000 HEK-Blue IL-18 sensor cells per well of a flat-bottomed 96-well plate were incubated with successively decreasing concentrations of recombinant human IL-18 in a total volume of 200 μL of complete medium. Incubated with 37℃ and 5%CO 2 After 20–24 h of incubation, 30 μL of cell culture supernatant was mixed with 170 μL of QUANTI-Blue detection medium (InvivoGen) until a color change from pink to blue was detectable (0.5–24 h). 4 hours), 37°C and 5% CO 2 Incubated with Levels of alkaline phosphatase were quantified using a spectrophotometer at a wavelength of 655 nm. Cytokine activity was determined by calculating the relative absorbance value (percentage of the maximum absorbance value measured at 655 nm) for each cytokine in the assay.

[0306]

[0352] For IL-18BP blocking experiments, a fixed concentration of recombinant human IL-18 was preincubated with successively decreasing concentrations of recombinant human IL-18BP for 1 h at 4 °C. Subsequently, the protein mixture was added to HEK-Blue IL-18 sensor cells and the assay was performed as described.

[0307] mouse

[0353] C57BL / 6 wild-type mice (6-9 weeks old) from Jackson Laboratory were used for in vivo mouse experiments. Experimental groups were matched by weight, sex, and age. All animal experiments were performed in accordance with approval from the Yale Institutional Animal Care and Use Committee.

[0308] In vivo pharmacodynamic and pharmacokinetic studies

[0354] Mice (n=9 per group) received daily intraperitoneal (i.p.) injections of 1 mg / kg of recombinant IL-18 (WT or variant SEQ ID NO: 61), or PBS as a vehicle control. On days 1, 4, and 7 of the experiment, three mice per group were sacrificed 5 h after injection for blood collection by cardiac puncture, followed by plasma or leukocyte analysis (mouse IL -18BP ELISA, Luminex-based multiplex immunoassay for mouse cytokine analysis, and immunophenotyping by flow cytometry) were performed. Throughout the 7-day experiment, body temperature was monitored daily using a Rodent thermometer BIO-TK8851 (Bioseb) and a RET3 rectal probe for mice (Braintree Scientific Inc.). Body weight was monitored daily.

[0309] Plasma preparation from whole blood

[0355] Plasma preparation from whole blood was performed using EDTA-coated Microtainer Plasma Separator Tubes (BD) according to the manufacturer's instructions. Plasma samples were frozen once at -20°C and then used for analytical assays. ELISA for IFN-γ and IL-18BP

[0356] To measure the levels of human IFN-γ in cell culture supernatants, use the Human IFN-γ ELISA MAX Deluxe Set (with a sensitivity of 4 pg / mL and a detection range of 7.8–500 pg / mL) according to the manufacturer's instructions. BioLegend) was used. A Quantikine Human IL-18BP immunoassay (R&D Systems) was used for quantification of human IL-18BP in cell culture supernatants with a sensitivity of 7.52 pg / mL and a detection range of 26.6 to 1,700 pg / mL. Mouse IL-18BP levels in plasma were quantified using a mouse IL-18BP ELISA kit (R&D Systems) with a sensitivity of 0.156 ng / mL and a detection range of 0.156-10 ng / mL. All assays including sample preparation were performed according to the manufacturer's instructions.

[0310] Luminex-based multiplexed immunoassay for mouse cytokine analysis

[0357] Luminex-based Bio-Plex Pro multiplex immunoassay (Bio-Rad) was used to quantify levels of various mouse cytokines in plasma, including IFN-γ and IL-12. Rad) was conducted. Cytokines of interest were analyzed using Bio-Plex Pro Mouse Cytokine Standard 23-Plex (Group I) reconstituted in DMEM according to the manufacturer's instructions.

[0311] Immunophenotyping by flow cytometry

[0358] For leukocyte analysis, 100 μL of whole blood was collected into an EDTA-coated Microtainer Plasma Separator Tube (BD) containing an additional 50 μL of heparin solution and mixed by inversion several times. Red blood cell lysis was performed by adding ACK Lysing Buffer (VWR) and incubating for 3-5 minutes at room temperature. After addition of MACS buffer (2mM EDTA, 2% FBS in PBS), leukocytes were collected by centrifugation (5 min, 400xg, 4°C) of the supernatant and aspiration. Leukocytes were washed once with cold MACS buffer and recollected as described. Cell pellets were resuspended in 200 μL MACS buffer containing 10% (v / v) rat serum (STEMCELL Technologies Inc.) and specific fluorescently labeled antibodies and stained for subsequent flow cytometry analysis. did. Staining was performed for 30 min at 4°C using the following antibodies: αCD4-AF700 (BioLegend), αCD8-APC (BioLegend), B220-APC-Cy7 (BioLegend), CD11b-PB (BioLegend), NK1. 1-PE (BioLegend), NKp46-PE (BioLegend), and CD69-FITC (BioLegend). Leukocytes were then washed twice with MACS buffer as described above. Finally, cells were resuspended in 100 μL of MACS buffer and samples were acquired using a flow cytometer (Sony SA3800). Aliquots of 10 μL were taken and cell counts were performed using an Invitrogen Countess II Automated Cell Counter (Thermo Fisher Scientific). FlowJo v10.3 software was used for data analysis and cells were gated for leukocytes and single events using forward and side scatter.

[0312] Tumor treatment experiment

[0359] 0.5×10 6 YUMMER1.7 cells were implanted subcutaneously into C57BL / 6J mice. Treatment was started 7 days after implantation, when the tumor weighed approximately 50 mg. Mice were treated with 1) vehicle (saline), 2) anti-PD1 (rat clone RMP1-14, Bio X Cell, West Lebanon, New Hampshire, US), 3) wild type IL-18, 4) SEQ ID NOs: 61, 5 ) wild type IL-18+anti-PD-1, and 6) SEQ ID NO: 61 IL-18+anti-PD1. Anti-PD-1, wild-type IL-18, and SEQ ID NO: 61 IL-18 were administered by intraperitoneal injection twice weekly at 8 mg / kg, 0.32 mg / kg, and 0.32 mg / kg, respectively. Mice were monitored for signs of clinical toxicity and tumor growth was followed twice weekly using caliper measurements. Mice were euthanized when tumor diameter reached or exceeded 1.5 cm in its largest dimension; this was considered the endpoint for survival analysis.

[0313]

[0360] The B2m-deficient YUMMER1.7 study was performed in a similar fashion with slight modifications. Tumors grew slower than the parental strain, so 1.0 × 10 6 cells were engrafted. Treatment consisted of saline, anti-PD1+anti-CTLA4, and SEQ ID NO: 61, given at the same schedule and dose as in the above study.

[0314]

[0361] The results of the experiment are described here.

[0315] IL-18 axis as a target for cancer immunotherapy

[0362] To identify potential signaling nodes for immunotherapeutic intervention, single-cell RNAseq data from tumor-infiltrating lymphocytes were analyzed for expression of cytokine pathway components (Singer et al., 2016, Cell, 166:1500 ~1511, e1509). The receptor subunits of IL-18 - IL-18Rα (i.e., IL-18R1) and IL-18Rβ (i.e., IL-18RAP) - and IL-18 itself are upregulated in both activated and dysfunctional lymphocyte programs. regulated (Figure 1A). Further analysis of the Immune Genome (ImmGen) database revealed that the expression of both IL-18 receptor subunits was significantly increased by CD4 and CD4 including PD-1, Tim3, Lag3, and TIGIT after chronic antigen exposure as shown in Figure 1B. It was shown to correlate with the expression of T cell "exhaustion" markers in CD8 cells. These expression characteristics suggested that the IL-18 pathway could be used to selectively stimulate activated and dysfunctional / exhausted T cells within tumors as an immunotherapeutic paradigm. IL-18 is a Th1 cytokine that was first called "interferon-gamma-inducing factor" (IGIF) for its ability to robustly stimulate the release of interferon-gamma (IFN-γ) by T and NK cells. Feedback inhibition of IL-18 sterically inhibits the ability of IL-18 to bind to and activate its receptor. -Achieved by γ-driven induction (Figure 2A). Without wishing to be bound by any particular theory, this mechanism is very similar to the induction of PD-L1 by IFN-γ, which suggests that IL-18BP acts as a "soluble immune checkpoint". This suggests that it may work. Consistent with this hypothesis, IL-18BP was found to be upregulated in several types of cancer in the TCGA and Oncomine databases, most notably breast cancer, gastric cancer, and brain tumors (Fig. 2B). Furthermore, IL-18BP expression strongly correlates with the expression of the important immune checkpoint PD-1 in tumors (r=0.65 and 0.78 in gastric cancer and breast cancer, respectively, Figure 2C), which suggests that IL-18BP Our results suggest that it may also contribute to immune evasion and lymphocyte exhaustion.

[0316]

[0363] Recombinant IL-18 was administered to cancer patients in multiple clinical trials. It was found to be well tolerated at doses as high as 2 mg / kg, with robust pharmacodynamic outputs including expansion of activated CD69+ natural killer (NK) cells and a dramatic increase in serum IFN-γ levels. showed that. However, a phase II trial in melanoma patients was discontinued due to lack of efficacy. Examination of the reported pharmacodynamic results from these clinical trials shows that the efficacy of rIL-18 is attenuated with repeated administration, leading to peripheral NK cell activation / expansion and cytokine release (IFN-γ and GM-CSF). This indicates that rapid-onset resistance is observed for (including). The attenuating efficacy of rIL-18 coincides with a large increase in serum levels of IL-18BP, two orders of magnitude higher than pre-treatment levels, often exceeding 100 ng / mL. Without wishing to be bound by any particular theory, it is believed that IL-18BP limits the efficacy of rIL-18 therapy and that IL-18 variants that are not affected by IL-18BP inhibition are effective tumor immunotherapies. It was hypothesized that this could be the case. Furthermore, inhibitors of IL-18BP are likely to be effective for tumor immunotherapy.

[0317] Engineering IL-18 variants that are resistant to IL-18BP inhibition (human DR-IL-18 variants)

[0364] Directed evolution using yeast surface display was used to obtain variants of IL-18 that can signal through IL-18Rα / IL-18Rf3 but are not susceptible to inhibition by IL-18BP. We first analyzed the structure of the ternary signaling complex of human IL-18:IL-18Rα:IL-18Rf3 (PDB=3OW4), showing that the IL- Eighteen residues were identified (Figure 3A). hIL-18: Since the structure of hIL-18BP has not been determined, a related complex of IL-18 and a viral (ectromelia virus) ortholog of IL-18BP was used (PDB=3F62). A combinatorial library (see Table 1) that randomized this set of residues to a defined set of alternatives was created using degenerate oligonucleotide primers and assembly PCR. This library was electroporated into yeast together with the N-terminal yeast display vector pYAL to produce 2.5 × 10 8 A library containing several transformants was obtained. Using this library, directed evolution was achieved by sequential selection rounds using magnetic and fluorescent cell sorting (FACS) with recombinant hIL-18Rα and counterselection with hIL-18BP, as summarized in Figure 3B. was carried out. After five rounds of selection, an apparent majority of library clones completely swapped their relative preference to hIL-18BP and hIL...

Claims

1. A modified interleukin-18 (IL-18) polypeptide, comprising: (i) at least one mutation in at least one of the following positions relative to wild-type (WT) IL-18 as set forth in SEQ ID NO: 30: Y1, L5, K8, M51, K53, S55, Q56, P57, G59, M60, E77, Q103, S105, D110, N111, M113, V153, and N155; and (ii) mutations at amino acid positions C38 and C68 relative to SEQ ID NO: 30 and exhibiting substantially reduced binding to human IL-18 binding protein (IL-18BP) as compared to WT human IL-18.

2. (i) the mutation at C38 is C38S and the mutation at C68 is C68D, C68S, C68G, C68A, or C68N; or (ii) The modified IL-18 polypeptide of claim 1, wherein the mutation at position C38 is C38S and the mutation at position C68 is C68D, C68G, C68A, or C68N.

3. The DR IL-18 variant has the following seven mutations relative to SEQ ID NO:30: (1) M51E, M51R, M51K, M51T, M51D, or M51N; (2) K53G, K53S, K53T, or K53R; (3) Q56G, Q56R, Q56L, Q56E, Q56A, Q56V, or Q56K; (4) D110S, D110N, D110G, D110K, D110H, D110Q, or D110E; (5) N111G, N111R, N111S, N111D, N111H, or N111Y; (6) P57A, P57L, P57G, or P57K; and (7) M60L, M60R, M60K, or M60Q 3. The modified IL-18 polypeptide of claim 1 or 2, comprising at least five of the following:

4. 4. The modified IL-18 polypeptide of claim 3, wherein the DR IL-18 variant further comprises the mutation S105D, S105A, S105N, S105R, S105D, or S105K relative to SEQ ID NO:

30.

5. 5. The modified IL-18 polypeptide of claim 4, wherein the DR IL-18 variant comprises an amino acid sequence set forth in any one of SEQ ID NOs: 19, 6, 16, 17, and 21, or consists of an amino acid sequence set forth in any one of SEQ ID NOs: 19, 6, 16, 17, and 21.

6. 6. The modified IL-18 polypeptide of any one of claims 1 to 5, wherein the DR IL-18 variant comprises an amino acid sequence having 85% or more sequence identity, which may be 90% or more, 92% or more, 95% or more, 97% or more, 98% or more or 98.5% or more, to the amino acid sequence set forth in SEQ ID NO: 19 or consists of an amino acid sequence having 85% or more sequence identity, which may be 90% or more, 92% or more, 95% or more, 97% or more, 98% or more or 98.5% or more, to the amino acid sequence set forth in SEQ ID NO:

19.

7. 5. The modified IL-18 polypeptide of claim 4, wherein the DR IL-18 variant comprises or consists of the amino acid sequence set forth in SEQ ID NO:

19.

8. A stabilized human modified IL-18 polypeptide, comprising: (i) an amino acid sequence having 90% or more sequence identity to an IL-18 variant amino acid sequence set forth in any one of SEQ ID NOs: 6, 87-91, and 16-21; and (ii) a modified IL-18 polypeptide comprising mutations at amino acid positions C38 and C68 relative to SEQ ID NO:30, which exhibits binding affinity to interleukin-18 receptor (IL-18R) equivalent to wild-type (WT) human IL-18, and which exhibits substantially reduced binding to IL-18BP as compared to WT human IL-18.

9. A modified IL-18 polypeptide that is a decoy-to-decoy (D2D) IL-18, which binds preferentially to IL-18 binding protein (IL-18BP) over IL-18 receptor (IL-18R), comprising: A modified IL-18 polypeptide comprising mutations at amino acid positions C38 and C68 relative to SEQ ID NO:30, and exhibiting improved stability compared to wild-type IL-18, a corresponding modified IL-18 polypeptide not comprising the mutations at C38 and C68, or both.

10. The modified IL-18 polypeptide comprises: (i) WTIL-18 does not contain any unnatural cysteine ​​residues; (ii) does not contain pegylated amino acids; (iii) contains cysteine ​​residues at positions C76 and C127; or (iv) any combination of (i) to (iii); A modified IL-18 polypeptide according to any one of claims 1 to 9.

11. A pharmaceutical composition comprising a modified IL-18 polypeptide according to any one of claims 1 to 10, and a pharma- ceutically acceptable excipient.

12. A nucleic acid comprising a nucleotide sequence encoding the modified IL-18 polypeptide of any one of claims 1 to 10.

13. A cell comprising the nucleic acid of claim 12.

14. 14. The cell of claim 13, which is a chimeric antigen receptor T cell (CAR-T cell), an engineered TCR-T cell, a chimeric antigen receptor NK cell (CAR-NK cell), or a tumor infiltrating lymphocyte (TIL), expressing an encoded modified IL-18 polypeptide.

15. An oncolytic virus comprising the nucleic acid described in claim 12.

16. A pharmaceutical composition for use in the treatment of cancer, a metabolic disease or an infectious disease, comprising a modified IL-18 polypeptide according to any one of claims 1 to 10, a nucleic acid according to claim 12, a cell according to claim 13 or 14, or an oncolytic virus according to claim 15.

17. 17. The pharmaceutical composition of claim 16, wherein the cancer is selected from the group consisting of cancer that is resistant to immune checkpoint inhibitors (ICI), cancer associated with tumors with reduced or absent surface expression of MHC class I, cancer associated with high levels of IL-18BP, cancer with high tumor mutation burden (TMB), cancer with tumors with microsatellite instability (MSI), and cancer associated with tumors where IL-18R is expressed on infiltrating T cells or NK cells.

18. 1. A method for producing an active polypeptide comprising the steps of: contacting an exogenously provided fusion protein with an exogenously provided SUMO (small ubiquitin-like modifier) ​​protease in a bacterial cell, wherein the fusion protein comprises a polypeptide of interest fused at its N-terminus to a SUMO tag; 9. A method according to claim 1, wherein within the bacterial cell, a SUMO protease cleaves the fusion protein, thus removing the SUMO tag from the polypeptide of interest, the polypeptide of interest being an IL-18 polypeptide according to any one of claims 1 to 8 that is activated by removal of the SUMO tag.